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ABSTRACT
Alzheim er's disease is a debilitating neurological disorder which has been predicted to 
afflict as m uch as 10 percent of the aged population over 85 years. The disease is 
characterised by the presence of senile plaques and neurofibrillary tangles, and by 
w idespread  neurochem ical alterations throughout the brain. The initial event in 
neurochemical transm ission involves the interaction of neurotransm itters with specific 
receptors. In the majority of cases the modulation of cellular activities by receptor activation 
is controlled by guanine nucleotide binding proteins (G-proteins). G-proteins are located on 
the intracellular membrane and respond to receptor stimulation to m odulate a variety of 
signal transduction pathways. Thus, effective therapies targeted at the neurochemical 
deficits in Alzheimer's disease requires G-protein function to be m aintained. This thesis 
examined the integrity of G-protein mediated signal transduction activities in Alzheimer's 
disease.
The levels of five G-proteins a  subunits G(x0 /Ga jl, Ga j2 , Ga s L, Ga sS, and the G(3 subunits 
were examined by semiquantative immunoblot analysis. The functional status of G-proteins 
was assessed by measuring the activities of the intrinsic GTPase action associated with G- 
proteins. Additionally, the effector molecule adenylate cyclase was assayed. To determine 
whether G-proteins could be reliably examined in hum an postm ortem  brain material, these 
param eters were examined for the effect of prolonged intervals between death and the 
freezing of brain tissue (postmortem interval). The G-protein levels were not significantly 
altered by prolonged intervals betw een death and the freezing of brain  tissue. At a 
postm ortem  interval of 24 hours however, the basal and stim ulated GTPase activity was 
significantly reduced compared to fresh tissue. In this thesis the investigation of the effect of 
Alzheimer's disease on G-proteins was conducted on control and diseased subjects that were 
closely matched for age and postmortem intervals.
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The distribution of G-protein levels and adenylate cyclase activity was examined in five 
regions (frontal cortex, hippocampus, striatum, cerebellum and pons) of aged control hum an 
brain. In general, the level of Ga o/ Ga jl, and Ga j2 are higher in the frontal cortex and 
hippocam pus compared to the cerebellum pons and striatum. However, Ga s L, Ga s S were 
found to be m ost abundant in the cerebellum. Basal adenylate cyclase activity was not 
heterogeneously distributed although the m agnitude of stimulation of adenylate cyclase by 
fluoroaluminate varied significantly between regions. The pattern of G-protein distribution 
and basal adenylate cyclase activity exhibited an inverse relationship. This suggested that 
the basal activity in hum an brain is influenced by the level of G a i and the ratio of 
G a s L /G a sS species. Within the striatum a third G-protein was detected with the antisera 
to Gas- TWs protein may be the putative G-protein G0 lf.
The effect of partial cholinergic denervation of the septal/h ippocam pal pathw ay on the 
activities of G-proteins was examined in the rat hippocampus. Rats were lesioned at the 
medial septal which induced a significant reduction of choline acetyl transferase activity in 
the hippocampus. There was no significant reduction in the level of G-proteins. Functionally, 
the activity of GTPase and its response to muscarinic and GABAergic activity was preserved 
in lesioned animals. The effector enzyme adenylate cyclase was not significantly altered in 
the hippocam pus of lesioned animals when compared to sham lesioned controls. These 
findings suggests that following partial denervation of the sep tal/h ippocam pus pathway, 
the rem aining hippocampal neurons are capable of an adaptive response to m aintain the 
functional components of the adenylate cyclase signal transduction pathway.
The levels of G-protein a  subunits were found to be robust in Alzheimer's disease. However, 
the level of the G|3 subunit was significantly reduced (by 57%) in the frontal cortex of 
Alzheimer's diseased samples compared to controls but was preserved in the hippocampus. 
The ratio of the G tts  subtypes (G a s L / G a s S) was significantly altered in Alzheimer's disease
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frontal cortex compared to controls. There was no significant alteration in the ratio of 
G asL /G asS measured in Alzheimer's diseased hippocampus when compared to controls. The 
basal adenylate cyclase activity was significantly reduced (by 45%) in Alzheimer's diseased 
frontal cortex compared to control samples but was preserved in the hippocam pus of 
Alzheimer's disease subjects. The basal GTPase activity was reduced by 25% in Alzheimer's 
disease frontal cortex when compared to control levels (P<0.05). The basal GTPase was also 
reduced 27% in the hippocam pus of Alzheimer's disease samples bu t failed to achieve 
statistical significance1 (P=0.Q51). The magnitude of stimulation of GTPase by carbachol and 
baclofen was similar for control and Alzheimer's disease frontal cortex and hippocam pus 
preparations.
These findings indicate that although there is no gross alteration in the level of G-proteins, 
the functional activity of the G-protein controlled adenylate cyclase transduction pathw ay is 
compromised in Alzheimer's disease. This may be due to a breakdow n in the synchrony 
between the inhibitory and stimulatory G-protein regulation of adenylate cyclase activity. 
This is supported by a positive correlation in the levels of the G ai subunits and GTPase 
activity in the control frontal cortex and hippocampus which was not evident in Alzheimer's 
disease. Thus, although in this study the coupling of G-proteins to receptors were found to be 
preserved, the functional responsiveness of G-proteins, as indicated by the GTPase data, is 
altered in Alzheim er's disease. These findings are pertinen t to the developm ent of 




1. Guanine nucleotide binding proteins (G-proteins) and signal transduction.
1.1. The discovery of G-proteins.
The discovery of G-proteins originated in the 1950s w hen Sutherland and co-workers 
described the involvem ent of adenosine triphosphate (ATP) in receptor m odulation of 
glycogen metabolism in the liver (Sutherland & Cori, 1951; Rail et al 1956). They identified 
an enzyme (adenylate cyclase) which catalysed the form ation of cyclic adenosine mono 
phosphate (cAMP) from ATP. Two decades later, Rodbell and co-workers (1971), discovered 
that guanine nucleotides had the capacity to m odulate the receptor stim ulation cAMP 
production by hepatic adenylate cyclase activity. This w as the first indication that a 
protein which binds guanine nucleotides can influence the ability of ligands to m odulate 
cAMP. Greater insight into the role of guanine nucleotides in cell signalling was achieved 
w ith the developm ent of GTP analogues such as guanosine 5’ (p,y-imino) triphosphate  
(Gpp(NH)p), and guanosine 5' (y-thio triphosphate) (GTPyS), which are poorly hydrolysed 
by nucleoside triphosphatases. Specifically, these compounds dem onstrated that in frog and 
avian erythrocytes, the activation of adenylate cyclase by adrenaline is deactivated w ith a 
concomitant hydrolysis of GTP and that the duration of stimulation was enhanced with the 
analogues (Spiegal & Aurbach, 1974). In addition to the effect of GTP on adenylate cyclase 
activity, a modulatory effect of GTP on phototransduction was described for photon activation 
of cyclic GMP phosphodiesterase in the rod cone (Wheeler & Bitensky, 1977) thereby 
indicating that the GTP influence may be a common mechanism employed by diverse cellular 
transduction systems.
Final confirmation that a specific protein was involved in these transduction processes was
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achieved with the purification of GTP binding proteins described for the adenylate cyclase 
system (Kuhn 1980), and for the phototransduction system (Godchaux & Zimmerman, 1979). 
The proteins isolated from these systems are now referred to as Ga s (stimulatory) and Gai 
(inhibitory) for the adenylate cyclase system and GaT (transducin) for the phototransduction 
system. G-proteins exhibit considerable similarities in that they are composed of three 
subunits designated a , P and y. The a  subunit is believed to confer specificity of the G-protein 
w ith respect to both the receptor with which it interacts, and the effector system  that the 
specific G-protein modulates. GTP hydrolysis is achieved by an intrinsic enzymatic activity 
of the Ga  subunit. The GTPase activity has been attributed to a conserved region common to 
all Ga  subunits which is homologous to the GTP binding site of elongation factor TU (Masters 
et al., 1986). The P and y  subunits, which exist predom inantly as a dimer, were originally 
thought to constitute a common pool which can interact with all Ga  subunits (Gilman, 1987). 
However, recent evidence suggests that a higher degree of selectivity exists betw een the 
interaction of G a and the Py complex (Pronin & Gautam, 1992).
Several effector systems, in addition to adenylate cyclase and cGMP phosphodiesterase, 
have now been shown to be controlled via receptor activation of G-proteins. These include:- 
activation of phopholipase C (Smrcka et al., 1991; Taylor et al., 1991) activation of 
phospholipase A2 and phospholipase D (reviewed by Cockcroft, 1992; and Cockcroft & 
Thomas, 1992); modulation of voltage-gated ion channels via pertussis sensitive G-proteins 
(Hescheler e t al., 1987; Kleuss et al., 1991). G-proteins are also im plicated in cellular 
differentiation. This activity was suggested by the localisation of G ao  w ith  grow th 
activating phosphoprotein (GAP 43) in PC12 cells (Strittmatter et al., 1990 & 1991), the 
altered expression of G-proteins during differentiation (Watkins et al., 1992) and  by the 
m odulation of differentiation in cells treated with antisense oligonucleotides to G as and G ai 
(Watkins et al., 1992., Wang, H.Y. et al., 1992).
To date, at least 30 genes encoding G a subunits have been identified although the specific
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function and mode of action of many remain unclear. The development of techniques, such as 
antisense oligonucleotide (Wang H.Y. et al., 1992; Kleuss et al., 1991), should greatly assist in 
defining the roles of specific G-proteins in cellular activity.
1 .2 . The GTPase cycle of G-protein activation and deactivation.
The early observations that GTP can stim ulate adenylate cyclase activity (Rodbell et al., 
1971) and that prolonged activation required continual addition of GTP or the addition of a 
non-hyrolysable analogue Gpp(NH)p (Spiegel & Aurbach, 1974) suggested tha t GTP 
hydrolysis acts as a temporal control mechanism. This was confirmed by Cassel & Selinger 
(1976), who demonstrated with eythrocytes that the release of ^2pi from [y-^P] GTP occurred 
with high affinity under basal unstimulated conditions. In this system, the turnover of GTP 
was significantly enhanced by the addition of catecholineamines Cassel & Selinger (1976). 
Detailed examinations of the mechanisms involved in the regulation of cell transduction can 
be examined in reconstitution systems (reviewed by Cerione, 1991). This approach overcomes 
the difficulties associated with studies of biological preparations which invariably contain 
numerous G-proteins, receptors and effector molecules at varying concentrations.
Several investigators dem onstrated that the addition of GTP analogues to reconstituted 
systems induced a dissociation of the apy heterotrimer, resulting in a free GTP bound a  subunit 
(N orthup et al., 1983; Fung, 1983., Codina et al., 1984); this effect w as maximal in  the 
presence of receptor agonist (Fung, 1983). It was suggested that receptor occupancy by agonists 
induce dissociation of the GDP bound to a  subunit which facilitates GTP binding and that the 
dissociation of GDP is the rate limiting step (Ferguson et al., 1986). Brandt & Ross (1986) 
however, conducted elegant experiments in vesicles reconstituted with purified p-adrenergic 
receptors and G aS which demonstrated similar rates of GTP binding and GDP dissociation. 
They proposed that receptor binding induced an 'open* conformation of the a  subunit which 
can m ore readily  exchange GTP for GDP. The dissociation of the GTP bound  G-
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protein/receptor complex occurs at a faster rate than GTP hydrolysis (Guy et al., 1990; Brant 
& Ross, 1986). This mechanism enables one receptor to activate more than one G-protein with 
a resulting increase in GTP turnover without increasing the rate of hydrolysis by the G-protein 
(Guy et al., 1990; Brant & Ross, 1986).
The process of receptor regulation of GTP binding and hydrolysis requires low concentrations of 
magnesium ions (Brant & Ross, 1986; Hilf &! Jakobs, 1989). Although the role of magnesium is 
no t entirely clear, it has been suggested that it chelates nucleotides and the resulting 
nucleotide-metal ion complex represents an active nucleotide triphosphate species. Receptor 
activation of G-proteins is also influenced by the relative stoichiom etry of the a  and Py 
subunits. It has been estimated that for rhodopsin catalysed fluorescence of transducin (GaT)/ 
which distinguishes between the GTP and GDP bound G(xT/ approximately half the total Ga T 
complexes could be activated at ratios of Pyx to GaT "*1:150 and greater than 80% of GaT-GDP 
activated at ratios of pyr to GaT -1:20 (Osawa et al., 1990). Reconstituted receptor, G as and 
adenylate cyclase systems, rather than being silent, have a basal intrinsic GTPase activity 
which is inhibited with the addition of Py subunits and gives an enhanced signal to noise 
ratio on receptor activation of the system (Cerione, 1991). This has also been observed with 
membranes preparations (Katada et al.J1984a)and G as *n solution (Northup et al, 1983).
Gilman, (1987) proposed a model to describe a cyclic cascade of G-protein regulated signal 
transduction. The process is initiated by receptor activation which induces the activation and 
dissociation of the G-protein heterotrimer. The 'off switch is the hydrolysis of GTP resulting 
in the reformation of the receptor G-protein complex. In biological systems this process is 
occurring at a basal intrinsic rate governed by the ratio of Kdiss G D P /K ^ t GTP. On receptor 
binding, the equilibrium is shifted in favour of the activation process. D iagram  I illustrates 
the key points of the cascade of events believed to occur for the activation of the stimulatory 
G as and the inhibitory action of Gai on adenylate cyclase activity. In addition, this diagram  
highlights the complexity of G-protein mediated signal transduction pathw ays. Recently is
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has been dem onstrated that G-proteins which operate via independent receptors, such as 
adenosine and (5-adrenoceptors, have the capacity to cross-talk and cross-regulate (Hadcock 
et al., 1990). Furthermore, the recombinant forms of G as (large and small) have different 
rates of GTP hydrolysis due to differences in GDP dissociation rates, yet the Kcat (hyrolytic 
cycle per m inute per molecule) were similar for both G as proteins (Graziano et al., 1989). 
Similarly, recom binant Ga i subtypes expressed different dissociation rates of GDP in 
com parison to G ao  although the Kcat were com parable (Linder et al., 1990). These 
observations underline the intricate nature of G-protein regulated signal transduction.
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Diagram I: The regulation of adenylate cyclase activity by the GTPase cycle.
This diagram  illustrates the molecular cascade which occurs on receptor activation and results 
in the activation of specific effector molecules which, in this case, is adenylate cyclase. The 
m ain events are shown in the left hand side of the diagram with each major stage annotated. 
The inclusion of a second receptor-linked pathway on the right hand side serves to illustrate 
the ability of different systems to interact. Although this diagram implies that this cascade 
occurs only on agonist binding to receptor, in fact this cycle is continuous with a significant 
basal activity of all stages such as GTP hydrolysis and adenylate cyclase activity. Agonist 
binding shifts the equilibrium to the right inducing an enhanced flow through the cycle.
(1) The unoccupied receptor is considered to be in a high affinity state and associated with 
the heterotrim er G-protein complex which is considered the dorm ant inactive configuration. 
Agonist binding induces an alteration in the conformation of the receptor and possibly the G a 
subunit, which lowers the energy barrier for GDP dissociation and GTP binding. The GTP 
bound G-protein complex dissociates from the receptor with a concomitant shift in the receptor 
affinity from a high to a low affinity state. (2) The GTP bound G a subunit dissociates from 
the py dimer. At this stage the Ga  is regarded as the active form and the free py is available 
to interact w ith GDP-bound G a subunits possibly from another pathway. Additionally, the 
py dim er may interact directly with the effector molecule. (3) The active GTP bound free Ga  
subunit can interact with adenylate cyclase to stimulate cyclic AMP production, as is the case 
for G a s /or inhibit, as with Gai. (4) The activation of adenylate cyclase is terminated by the 
intrinsic hydrolysis of GTP to GDP. This induces dissociation of the GDP-bound G a subunit 
and its reassociation w ith the py dimer. (5) The GDP-bound heterotrim er can reassociate 
w ith the receptor, thereby completing the cyclic process.
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1.3. Heterogeneity of the a subunits of G-proteins.
The application of cloning and sequencing techniques has identified m ultiple G-protein a  
subunits in the eucaryotic organism (reviewed by Bimbaumer et al, 1990; Simon et al., 1991). 
To date as many as thirty cDNA clones encoding a  subunits have been reported, although the 
precise characterisations of receptor-effector interaction of m any of the protein products 
awaits their isolation and purification. Of the a  subunits that have been characterised, 
there is sufficient heterogeneity at their sequence, effector function and their capacity to act 
as substrates for ADP-ribosylation by bacterial toxins to allow G-proteins to be classified into 
one of four broad categories. These are: pertussis toxin sensitive, cholera toxin sensitive, 
pertussis toxin insensitive and the G12 class of a  subunits. Some of the m em bers of these 
categories have sufficient similarities to permit their being grouped into a separate subclass. 
As m ore inform ation is acquired regarding the individual G-proteins, this classification 
system m ay yet prove to be inadequate and may have to be revised.
1.3.1 The Gao subunits.
The G ao protein (termed "o" for other since its function was unknown), originally isolated 
from bovine brain, has a molecular weight of 39 KDal (Stemweis & Robishaw, 1984). cDNA 
encoding two forms of mammalian Goo and human chromosomal gene encoding Goo have been 
isolated (Strathmann et al., 1990; Tsukamoto et al., 1991). The two protein products which 
have now been identified (Mullaney & Milligan, 1990; Asano et al., 1992) are substrates for 
pertussis toxin ADP-ribosylation which results in the inactivation of the protein. The 
proteins are thought to arise from a single gene by alternate splicing (Strathmann et al., 1990; 
Tsukamoto et al., 1991). G ao is located mainly in neuronal and endocrine tissue, although a 
significant level of Gtto is located in the heart (Asano et al., 1988). Recently Asano et al. 
(1992), examined the distribution of the two forms of Gao/ referred to as G aoA  and  GaoB. 
GaoA was located mainly in neural tissue whereas Ga oB is located in brain, pituitary gland,
17
adipose tissue, lung and testes.
The identification of the function of the Goo protein has proved elusive. It has been suggested 
that G ao  can m odulate the phosphatidylinositol via phospholipase C (M oriarty et al., 
1990). There is however strong evidence which suggests that its prim e activity is associated 
with the regulation of ion channels. These include four distinct types of potassium  channels in 
cell free m em brane patches of hippocampal pyram idal neurons (VanDongen et al., 1988); 
inhibition of voltage dependent calcium channels in neuroblastom a x gliom a hybrids 
(Hescheler e t al., 1987; Bergamaschi et al., 1992) and in rat pituitary GH3  cells (Kleuss et 
al., 1991). In the latter study, Kleuss et al. (1991) demonstrated that both species of G ao are 
capable of inhibiting calcium channel activity. M embrane depolarisation which induces 
changes in the affinity of muscarinic receptors is mediated by a pertussis sensitive G-protein, 
suggested to be G ao (Cohen-Armon & Sokolovsky, 1991). Recently G ao has been shown to be 
associated with growth activating polypeptide (GAP 43) in neuronal growth cone membranes 
(Strittmatter et al., 1990 &1991).
1.3.2. The G ai subunits.
This subclass of G-proteins were first described by Hilderbrant et al, (1982) who observed that 
pertussis toxin treatment of liver preparations blocked the inhibitory regulation of adenylate 
cyclase; they defined this protein as the inhibitory G-protein, Gai- Subsequent purification 
and molecular cloning studies have shown that a G ai family of proteins exist which is 
comprised of three highly related proteins: G a il/ Gai2 and G ai3 (Milligan & Klee, 1985; 
Jones & Reed, 1987; Itoh et al., 1988). These proteins have molecular weights of 41 KDal, 40 
KDal and 39 KDal respectively. They exhibit a similar amino acid sequence, (G ail and Gai3 
share 95% homology) and they are respectively 8 8 % and 85% identical to Gai2 (Jones & Reed, 
1987). G a il and Gai2 are present in all tissue but most abundant in brain (Asano et al., 1989); 
whereas Gai3 is undetectable in mammalian brain (Kanaho et al., 1989), although a recent
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report identified low levels of Gai3 in brain myelin (Berti-Mattera et al., 1992).
A lthough the Ga i nom enclature implies that all three Ga i proteins are capable of an 
inhibitory effect on adenylate cyclase, Ga i2 is the only member which has been demonstrated 
to exhibit this function (Simonds et al., 1989; McKenzie et al., 1990; Bushfield et al., 1990a). 
The mechanism by which Ga i achieves its inhibitory influence is still to be clearly defined. 
K a ta d a  et al. (1984a) suggested that the inhibition of adenylate cyclase involves the 
interaction of the free py subunit with Gas; whereas other studies in G ai2  deficient cell lines 
suggest the inhibition is achieved by a direct action of Gai on adenylate cyclase (Hildebrandt 
et al., 1982). Recently, Taussig et al. (1993b) reported that G a il  is inhibitory to type V 
adenylate cyclase bu t only weakly inhibitory for type 1 adenylate cyclase. There is also 
evidence that members of the Ga i family can regulate the activity of phospholipase C 
(Bizzarri., 1990). Since G ao Is also a substrate for pertussis toxin, its involvem ent in this 
activity cannot be discounted.
The high degree of hom ology betw een the different G ai species has h indered  their 
assignm ent to specific cellular activities, although the developm ent of m ore selective 
techniques is however beginning to delineate some of their roles. For instance, Ga i3 has been 
im plicated in controlling epithelial sodium  channels by activating phospholipase A2  
(Cantiello et al., 1990), whilst Gai2 is reported to be involved in cellular differentiation 
(W atkins et al., 1992).
1.3.3 Transducin (GaT) subunits.
Transducin or Ga T is a 39 KDal protein which is sensitive to pertussis toxin and communicates 
the signal from light activated rhodopsin to cyclic GMP phosphodiesterase (reviewed by 
Liebman et al., 1987). The carboxy-terminal region of Ga T contains the binding site for 
rhodopsin (Hamm et al., 1988) which is also thought to correspond to the region on G as which
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interacts with P-adrenergic receptors (Sullivan et al 1987). Two types of G aT have been 
cloned: the GaT-r is composed of 350 amino acids and located in rod cells; Ga T-c is 354 amino 
acids long and located in cone cells (Liebman et al., 1986). These Ga T members share 80% 
homology at their amino acid level and are closely related at the carboxy-teminal to G«i 
proteins. Mechanistically, the G aT protein, like all other G-proteins, exists as a trim er 
composed of afty subunits which on activation go through the GTPase cycle of activation and 
deactivation (Fung et al., 1983). Indeed, as discussed in relation to the GTPase cycle, the 
transducin-rhodopsin system has been intensely studied and has contributed greatly to the 
current understanding of the interactions involved in G-protein controlled signal transduction.
1.3.4. The Gas subunits.
Two G as subunits with distinct molecular weights of 45 KDal (Gas$ for small) and 52 KDal 
(G ash for large) were originally purified from from rabbit liver (Northup et al., 1983). Both 
G tts proteins are substrates for ADP-ribosylation by cholera toxin which results in their 
constitutive activation (Bimbaumer et al., 1990). Molecular cloning has identified four forms 
of G as cDNAs which arise from an alternative splicing reaction (Bray et al., 1986). The G as 
splice variants comprise of a pair of shorter and a pair of longer molecules which differ by a 
block of 14 amino acids encoded on exon 3. Each pair are formed by two polypeptides that 
differ by the presence and absence of a single serine residue at the insertion-deletion junction 
(Kozasa et al., 1988; Robishaw et al., 1986; Bray et al., 1986).
The stimulation of adenylate cyclase by G as has been unequivocally dem onstrated by the 
ability to reconstitute hormonal, fluoroaluminate and GTP sensitivity of adenylate cyclase in 
cyc'S49 cells which are deficient i n G tts (Codina et al., 1984), and by their ability to 
activate the purified catalytic unit of adenylate cyclase (Tang et al., et al., 1991). Patch 
clamp studies have also shown that G as can regulate the activity of cardiac and skeletal L- 
type calcium channels (Yatani et al., 1987). This activity can be achieved by three of the four
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splice variants which are also equally functional in stimulating adenylate cyclase (Mattera 
et al., 1989). Additionally, Gots has been shown to activate a novel calcium transporter in 
Xenopus oocytes (M urphy & McDermott, 1992). Thus, Gtts appears to be involved in  the 
regulation of multiple effector systems.
Recently an additional member of the G as subclass has been described as predom inantly 
localised in olfactory neurons and was therefore term ed G aolf (Jones & Reed, 1989). A 
detailed biochemical investigation of the three G as proteins, G aolf G asL anc* GasS/ was 
conducted by expressing their respective cDNAs in cyc 'k in ' S49 cells which lack Ga s 
proteins (Jones et al., 1990). The data revealed that Gaolf *s 8 8 % homologous to G as at the 
amino acid sequence level, has a molecular weight of 47 KDal and is a substrate for cholera 
toxin. Functionally, Ga olf can couple to (3-adrenergic receptors to stimulate adenylate cyclase, 
although the efficacy of the coupling is poor in comparison to the large and small Gas.
1.3.5. The Gaq subunits.
The involvement of G-proteins (termed Gap) in the signal transduction mechanisms m ediating 
agonist stim ulation of phosphoinositol hydrolysis has been suggested for some time. The 
evidence for the involvement of G-proteins in this process is based on the observations that 
phospholipase C stimulation is dependent on GTP; agonist stimulation of phospholipase C 
results in enhanced high affinity GTPase; and agonist stim ulation of phospholipase C is 
enhanced by non-hydrolysable GTP analogues and fluoroaluminate. Additionally, while this 
activity can be inhibited in some instances by pertussis toxin, (for example in  neutrophils), 
other tissues exhibited a refractory response to pertussis toxin (reviewed by Cockcroft & 
Thomas, 1992b). Recently, molecular cloning has identified a pertussis toxin insensitive class 
of G-proteins which are now believed to be coupled to phospholipase C and are term ed G aq
(Smrcka et al., 1991; Wilkie et al., 1991; Taylor et al., 1991). The G aq family comprise of at
least five G-proteins, Gaq/ Ga l l /  Ga l 4 , Ga l 5  and Ga l 6  (Wilkie et al., 1991) which lack the
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cysteine residue at their carboxy-terminal required for ADP-ribosylation. The G aq and G a l l  
share 8 8 % homology at the amino acid sequence level while G a l4  and G a l5  are 81% and 58% 
identical to G ttq  respectively (Wilkie et al., 1991).
The Gttq and Ga i l  proteins have similar molecular weights of 42 KDal which, in combination 
with their high degree of homology and their insensitivity to pertussis toxin, hindered their 
assignm ent to specific receptors and phospholipase C subtypes (of which five have been 
identified). However, it has been shown that Gaq protein(s) isolated from liver can couple to 
brain purified phospholipase p i isotype, but not phospholipase yl and a l  isotypes (Taylor et 
al., 1991). G aq  can also enhance the maximal activity and  calcium  dependence of 
phospholipase C isolated from bovine brain (Smrcka et al., 1991). The G aq  / G a l l  are 
expressed in a w ide variety of tissue (Wilkie et al., 1991), whereas Ga l 4 / Ga l 5  and Ga l 6  
have a more restricted tissue distribution (Wilkie et al., 1991). Recently, M illigan (1993) 
reported that G aq was heterogeneously distribution in regions of rat brain whereas the levels 
of Ga l l  was more uniformly expressed throughout rat brain.
1.3.6. The Gaz (or Gax) subunit
The G az protein was first cloned from rat brain (Matsuoka et al., 1988) and subsequently from 
hum an retina (Fong et al., 1988) and hum an brain (Matsuoka et al., 1990). The protein has a 
molecular weight of 40 KDal and is located primarily in neuronal tissue (Casey et al., 1990). 
G az has a similar amino acid sequence to Gai but is divergent in the cysteine residue, which is 
the site for ADP-ribosylation, and at the GTP binding domain. Biochemical investigation of 
the recom binant Gttz dem onstrated a 100  fold reduction in the GTPase activity of G az 
compared to Goo/ Gai and Gas (Casey et al., 1990). The divergence of the GTP binding domain 
of G az  rnay represent a structural modification which could potentially  enhance the 
activation time of this G-protein. To date the function of G az  is unknow n however its 
interesting kinetic profile and its predom inantly neuronal location have provided excellent
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incentives for its continued investigation.
1.3.7. The Gai2 and Gtt13 subunits.
Very little is known about the G a l 2 and G a l3 proteins. The clones for these proteins were 
isolated alongside the Gttq clones (Strathmann et al., 1989). Their mRNA is ubiquitously 
expressed yet their function remains unknown.
1.4. The role of the Py subunit complex in signal transduction.
The early observation by Sternwies, (1986) that purified G a subunits fail to associate with 
phospholipid vesicles unless Py subunits were present, led to the suggestion that the Py dimer 
may serve to anchor the G a protein to the membrane. This proposal is supported by the
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findings of Milligan & Unson, (1989) who showed that agonist activation of G-proteins 
(resulting in dissociation of the aPy complex) can result in the removal of the Ga  subunit from 
the plasma membrane. It has also been shown, however, that a subset of G a proteins namely 
G ao/ G a il/ Gai2, Gai3, and G az undergo co-translational N-myrystolyation (Mumby et al.,
1990). This modification could assist membrane association of G-proteins (Mumby et al., 
1990; Jones et al., 1990b). On the other hand, G as and m utants of Gai2 are not myristicated 
(Jones et al., 1990; Gallego et al., 1992) yet can associate with the plasma membrane. Thus, 
although Py dimers are required for the association of the heterotrimer with the receptor on 
the internal plane of the plasma membrane (Stemweis, 1986), the a  subunit is also influential 
in this activity. It is now emerging that the Py dimer plays a more dom inant role in various 
G-protein controlled signal transduction pathways: Py can interact directly to m odulate the 
activity of phospholipase A2 in phototransduction (Jelsema & Axelrod, 1987), phospholipase 
C-p2 in transfected COS-1 cells (Camps et al., 1992; Katz et al., 1992) and adenylate cyclase 
(Tang & Gilman, 1991; Taussig et al., 1993a). Considerable attention is now being focused on 
the Py dimers to clarify their roles in the mechanisms of signal transduction.
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To date four p subunits have been identified (pi, P2, P3 and p4) which share more than 80%
am ino acid sequence homology (reviewed by Q apham  & Neer, 1993). p i, P2 and P3 are
ubiquitously expressed whereas P4 is abundant in brain and lung but expressed at low levels in 
other tissue (Simon et al., 1991). The literature commonly refers to two classes of P subunits, 
P3 5  and P3 6  due to their molecular weights of 35 KDal and 36 KDal respectfully. The P35  anci 
P36, which can be separated by electrophoresis, probably contain a mixture of the four p 
subunits. Similarly, the Gas subtypes may contain products of the additional Gas genes.
Six species of the y subunit have now been identified h o w e v e r  th e ir  fu n c tio n a l a n d  
b iochem ical characteristics rem ains to be estab lished . T hree y-pro tein  iso ty p es  have  
been  described. G^i is located only in photoreceptors, G ^2 is differentially expressed in all 
tissue and Gy3 is present in brain and testis only (Simon et al., 1991). The carboxy terminal of 
both G y i and Gy2 contain a Cys-Ali-Ali-Xaa motif (Ali, aliphatic am ino acid; Xaa, any 
amino acid) which is similar to the ras oncoprotein. The C-terminal of the ras oncoprotein 
and the G y pro tein  undergoes a post-translational m odification w hich involves the 
prenylation of the cystein residue (Spiegal et al., 1991; Fukada et al., 1990). This process is 
thought to be critical for membrane association but not for the assembly of, or the stability of 
the aPy heterotrimer. The multiplicity of the y and P subunits have the potential to greatly 
increase the divergence of G-protein receptor coupling. Indeed, it has recently been shown 
that p and y subunits interact in a selective m anner (Pronin l & Gautam, 1992) which could 
generate heterogeneous pools of Py dimers.
1.5. The adenylate cyclase system.
The hormonal regulation of intracellar cyclic AMP levels via G-protein control of adenylate 
cyclase activity is one of the most thoroughly investigated signal transduction systems. The 
enzyme is under the dual regulation of the stimulatory G-protein, G as and the inhibitory
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action of G ai (reviewed by Gilman 1987). Additionally, in some tissue adenylate cyclase 
activity was found to be regulated by intracellular free calcium levels (reviewed by Cooper & 
Brooker, 1993). Subsequent protein purification and amino acid sequencing has allowed the 
cloning of several forms of adenylate cyclase. These proteins have been classified into two 
groups, the calmodulin-sensitive and the calmodulin-insensitive adenylate cyclase.
To date six adenylate cyclase enzymes have been cloned and partially characterised. Type I 
(Tang et al., 1991) and type III (Bakalyar & Reed, 1990) are calmodulin sensitive. Type II 
(Feinstein et al., 1991), type IV (Gao & Gilman 1991), type V and type VI (Katsushika et al.,
1992) are insensitive to calcium/calmodulin. Tissue distribution studies of the various mRNA 
has established that type I is restricted to neural tissue; type II and type IV are broadly 
distributed, although type II is most abundant in brain; type III is restricted to olfactory 
neurons; and that type V and type VI are widely expressed, although type VI mRNA is most 
abundant in brain (Xia et al., 1991 & 1993). Monoclonal antibodies have recently been 
produced and have been used to identify three antigens with molecular weights of 160 kDal, 
150 kDal and 115 kDal (Mollner et al 1991). It has yet to be confirmed that these proteins are 
adenylate cyclase isotypes. These antibodies should prove to be useful tools in establishing 
the relative concentration of the adenylate cyclase subtypes in various tissue, the functional 
significance of differential expression and the mechanisms involved in their control.
1.6. The identification of receptors coupled to G-proteins.
It has been suggested that as many as 80% of the known hormones and neurotransm itters 
m ediate their cellular activities th rough G-proteins via in terac tions w ith  receptors 
(Birnbaumer et al., 1990). The assignment of a receptor population to the G-protein coupled 
group is prim arily based on several observations; the GTP m odulation of pharmacological 
ligand-binding characteristics, the alteration of high affinity GTPase activity and known G- 
protein controlled effectors by specific agonists, and, in some instances, on the ability of the
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bacterial toxins, pertussis or cholera, to interfere w ith the agonist stim ulation of effector 
molecules. It is clear that within a single cell there exist m any different G-proteins and 
receptor populations, many of which contain numerous subtypes. Additionally, there is now 
evidence for cross-talk between different receptor mediated signaling pathw ays (Hadcock et 
al., 1990). Thus, the assignment of a specific G-protein to a particular receptor, which is 
based on current empirical evidence, will in most cases need to be reassessed as more specific 
receptor and G-protein probes are developed. Table 1 gives examples of different receptor 
types, the G-protein to which they are coupled, and the effector system  w hich they 
modulate. The reader is referred to mainly to reviews which provide detailed information on 
the variations in the coupling of receptors and G-proteins in different tissues.
The molecular basis for receptor interaction with G-proteins has been examined in relation to 
several receptor types, m ost notably the photoreceptor rhodopsin, the m uscarinic and 
adrenergic receptor classes (reviewed by Bonner 1989 & 1992; Lefkowitz and Caron 1988). 
From the deduced amino acid sequence of many G-protein coupled receptors, the most striking 
feature is that each contains seven stretches of 20-28 hydrophobic amino acids which, based 
on the rhodopsin template, are likely to represent membrane spanning regions. Of these 
regions, the third cytoplasmic domain, which connects the fifth and sixth transm em brane 
domain, has been proposed as the receptor/G-protein coupling site and also confers selectivity 
of the receptors for specific G-proteins. This was dem onstrated by introducing deletion 
mutations of the third cytoplasmic domain of the ^2-adrenoceptor which rem oved its ability 
to stim ulate adenylate cyclase (Dixon et al 1987; Strader et al 1987). Further evidence was 
obtained from the observations that chimeric a 2-adrenoceptor (inhibitory to adenylate 
cyclase), containing part of the fifth and the complete sixth dom ains from  the (52- 
adrenoceptor, could stimulate the activity of adenylate cyclase (Kobilka et al 1988). Similar 
studies conducted on the muscarinic receptors subtypes also concluded that the third domain 
was responsible for G-protein interaction. More specifically, the first 16-21 amino acids of the 
third dom ain of the cloned m2 and m3  receptors (expressed in Xenopus oocytes) confer the
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selectivity of these subtypes for the phosphoinositol and the adenylate cyclase pathw ays 
respectively (Bonner, 1992). Although these data strongly implicates the third cytoplasmic 
dom ain as being the main site for G-protein interaction, the efficiency of chimeric receptors in 
producing an effector response is generally less than the wild type molecules. Thus it is 
equally likely that the regions distal to the th ird  cytoplasmic dom ain can also have a 
significant influence on the specificity and efficacy of receptor G-protein coupling.
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TABLE 1. Examples of receptor modulated transduction system of neuronal tissue that are 
controlled by G-proteins.
Type of receptor Effector
system
G-protein References
Muscarinic Ml type 
(Ml, M3) phosphoinositol Gaq, (1), (3)
Muscarinic M2 type 
(M2, M4) K+ channels Gao,Gai, (1), (4)
adenylate cyclase Gao, Gai, Gaq (1), (4),(6)
metabotropic glutamate 
mGluRl, mGluR5 phosphoinositol Gao? (5)
adenylate cyclase G ai? (5), (2)
mGluR2, mGluR3, mGluR4 adenylate cyclase G ai? (5), (2)
Som atostatin adenylate cyclase G ai (1)
calcium channels Gao? (1)
Opioid
8 adenylate cyclase, Gai2 (1), (7)
K. channels Gai2 (1), (7)
K Ca. channels Gai, Gao? (1), (7)
P adenylate cyclase, 
K. channels Gai, Gao? (1), (7)
Adrenergic a -ty p e  
a l phosphoinositol Gaq (6), (9), (10)
al adenylate cyclase Gai (6), (9), (10)
Ca, K channels Gai? Gao? (6), (9), (10)
Adrenergic (3-type
Pi adenylate cyclase Gas (6), (9), (10)
(32 adenylate cyclase Gas (6), (9), (10)
Dopamine
D1 adenylate cyclase Gas (1)
D2 potassium channels G ai/G ao (1)
adenylate cyclase Gai (1)
GABAB Ca channels, K. channels G ai/G ao (1), (8)
adenylate cyclase G ai/G ao (1)
Serotonin (5HT) 
S -la adenylate cyclase G ai/G ao ( 1 )
K channels G ai/G ao ( 1 )
S-lc phosphoinositol Gaq ( 1 )
S-2 adenylate cyclase Gas ( 1 )
Ca channels Gao ( 1 )
Adenosine
Al adenylate cyclase Gai ( 1 )
A2 adenylate cyclase Gas ( 1 )
VIP adenylate cyclase Gas ( 1 )
Neuropeptide Y adenylate cyclase Gas ( 1 )
Ca, K channels Gao? ( 1 )
References:
(1) Birnbaumer et al., (1990), (2) Itano et al., (1991), (3) Mullaney et al., 1993, (4) Baumgold, 
(1992), (5) Shoepp& Conn, 1993, (6) Milligan,(1993a), (7) Childers, (1991), (8) Holz et al., 
(1989) , (9) Hadcock & Malbon, 1993, (10) Summers & McMartin (1993)
28
1.7. Disease induced alteration of G-protein mediated signal transduction.
There is now a growing body of evidence that indicates that alterations in  G-proteins are 
associated with a variety of clinical conditions. Perhaps the earliest examples of targeting 
G-proteins was revealed by the action bacterial toxins, produced by the causative organisms 
of cholera (cholera toxin) and whooping cough (pertussis toxin). Pertussis toxin selectively 
blocks G-protein function while cholera toxin results in over-expression of the second 
messengers cAMP by constitutively activating G as proteins (Birnbaumer et al., 1990). A recent 
report identified sequences in the hum an cytomeglovirus, a herpesvirus, tha t were highly 
homologous to the seven membrane spanning peptides of the rhodopsin like G-protein coupled 
receptor (Chee et al., 1990). This raises the interesting possibility that viral transform ation 
of the host cell may be achieved via a transduction system.
More reliable information on the plastic response of G-proteins to disease has been reported 
for other conditions. G-proteins have been implicated in cardiovascular disease, the first 
evidence of which was the observed reduction in the contractile response to p adrenergic 
agonists (Bristow et al., 1982). This response was attributed to dow n regulation of the p i- 
adrenoceptor (Fowler et al., 1986; Bristow et al., 1986). Investigations of signal transduction 
components in diseased hearts reported alteration in the level of pertussis toxin binding and 
concomitant changes in the activities of adenylate cyclase (Feldman et al., 1988). Similarly, 
m odifications of selective G a subunits (G ai2 and Gai3) in the heart of spontaneously 
hypertensive rats has recently been reported (Anand-Strivastava, 1992).
The m ost closely-studied clinical disorder of G-proteins is probably A lbright hereditary 
osteodystrophy, an uncommon genetic disorder that is characterised by skeletal defects. 
Affected members are classified as exhibiting either pseudohypoparathyroidism  (PHP) or 
pseudopseudohypoparathyroidism  (PPHP) depending on whether or not they are resistant to 
parathyroid hormone, thyroid hormone and gonadotrophins respectively. In both cases, it
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has been dem onstrated that Ga s  mRNA levels are reduced by approxim ately 50% when 
compared with controls in all tissue examined (Levine et al.j 1988). In chemically induced 
hypothyroidism  of the rat, there is a decreased responsiveness to agents which stimulate 
adenylate cyclase, whereas the inhibitory response is enhanced. In this condition the effect 
is due to increased am ounts of God and Gj3 proteins (Milligan et al., 1987) although the 
mechanisms responsible for the altered G-protein levels are unclear. Regarding Albright 
hereditary osteodystrophy, examination of genomic DNA by polym erase chain reaction 
identified m utations of the G as gene from. The mutations in PHP patients consisted a single 
base substitution (Glycine to Cysteine) at the donor splice junction at exon 10, and a frame shift 
m utation created by a single base deletion within exon 10 in both PHP and PPHP (Weinstein 
e t al., 1990). It was proposed that this frameshift m utation resulted in an abnorm ally 
truncated Gas/ whereas the substitution mutation could alter the steady state level of the G as 
mRNA. W hile the genetic bases for full phenotypic expression are still unclear, this 
syndrome is a clear example of a genetic abnormality of a G-protein.
Mutations of Gtts isolated from thyroid (Lyons et al., 1990) and pituitary adenom as (Landis et 
al., 1989; Valler et al., 1987) have also been reported. These proteins contain a substitution of 
either of two conserved amino acids which result in the inhibition of GTPase activity, 
producing a constitutively active G as protein, termed gsp (Masters et al.,1989; Landis et 
al.,1989). Lyons et al. (1990) also described a mutation of the G ai subunit (gsp 2) which, in a 
similar fashion to Gas/ w ^s subsequently shown to constitutively inhibit the activity of 
adenylate cyclase (Wong et al., 1991). These are further examples of genetic m utations of G- 
proteins that have, in this case, potential oncogenisity.
Alterations in G-protein mediated signal transduction have also been described in diabetes. 
This was first dem onstrated by Gawler et al. (1987), where streptozocin induced type I 
diabetes in rat resulting in a marked reduction in the level of Ga i together w ith a functional 
loss in the inhibitory effect on adenylate cyclase and a marked reduction in basal adenylate
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cyclase in hepatocytes. This effect was found to be partially reversed in diabetic animals 
which were administered sufficient insulin to normalise their blood glucose levels.
The disease conditions described above represent examples where alterations in G-protein 
levels w ith concomitant functional changes have been closely examined. It is likely that 
im proved technologies will lead to the identification of additional pathological conditions 
where G-proteins may be implicated. Indeed, alterations in G-protein levels have been 
reported  in  obesity (Begin-Heick, 1990), bipolar affective disorder (Young et al., 1991), 
olivopontocerebellar atrophy (Kish et al.,1993) and it has been suggested that an altered 
equilibrium of the GTPase cycle occurs in brain ischemia (Takenaka et al., 1991).
1.8. Drug induced alteration of G-protein mediated signal transduction.
Investigation into the mechanisms of cell tolerance to long term opioid exposure has revealed 
complex changes in both receptor and G-protein subtypes. Opioid receptors have been 
classified into three subtypes, mu (p), delta (8 )and kappa (k ) based on pharmacological and 
ligand binding studies all of which are coupled to G-proteins (reviewed by Childers, 1991). 
Studies performed on different preparations of cells with neural origin have show n that 
opioids can m odulate a variety of cellular activities. These include the inhibition of 
adenylate cyclase activity (Attali & Vogel, 1989), and inhibition of calcium  currents 
(Hescheler et al., 1987). Of these cellular responses, the adenylate cyclase system  has 
received most attention and it has been proposed that modifications in this neurochemical 
pathw ay underlie the development of opioid tolerance.
In NG108 neuroblastoma cell line, the 8  subclass has an inhibitory input on the adenylate 
cyclase pathw ay which is m ediated through God (McKenzie et al., 1988). In this cell line, 
long term  exposure to the opiate receptor agonists altered basal and stim ulated GTPase 
activity without altering the level of G-proteins G ao an<* G ai (Lang & Costa, 1989). Attali &
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Vogel, (1989) showed that the G ail level was significantly reduced in rat spinal cord-dorsal 
root ganglion co-cultures following chronic long term opiate exposure. Nestler et al. (1989), on 
the other hand, showed that chronic morphine administration resulted in an increased level 
of both G ai and G ao of the dopamergic neurons of the ventral tegmental area such as the 
nucleus accumbens and in associated target neurons of the locus coeruleus. The complexity of 
the G -protein alterations following chronic opioid treatm ent is also illustrated  by the 
selective changes in different G a subunits which have been observed in cultured neurons 
derived from rat cortex (Eriksson et al., 1992). In this cell culture system k receptor agonist 
exposure increased G as mRNA and Gai2 mRNA; 8  agonists had no effect on either Gtts 
mRNA, G a il mRNA or Gai2 mRNA, while [i agonists decreased the level of G as  m RNA, 
G a il mRNA and Gai2 mRNA. Reductions in the pertussis toxin sensitive G-protein levels 
G a i and G ao following chronic cocaine adm inistration in rats have also been observed 
(Nestler et al, 1990;j Striplin and Kalivas, 1992). Thus, m odulating the levels of selective G- 
proteins may underline the augmentation of motor stimulant effects and possible behavioral 
augmentation induced by these psychoactive drugs.
Lithium, which stabilises the mood fluctuations of manic depression, is believed to exert its 
therapeutic  effect at the post-receptor G-protein level (Avissar et al., 1988). The 
biochemical basis of lithium action is unclear There is evidence which suggests that lithium 
can exert an inhibitory influence on adenylate cyclase action (Colin et al 1991), while 
inhibition of the phosphoinositol system has also been suggested (Berridge et al., 1982). 
Lithium has an inhibitory effect on the coupling of muscarinic receptors and p-adrenoceptors 
to G-proteins which is reversed by magnesium (Avissar et al., 1991). Since m agnesium  is 
required for G-protein activation, lithium therefore has the potential to m odulate both the 
adenylate cyclase and the inositol pathways. It has been dem onstrated that chronic lithium 
treatm ent of rat resulted in an increased expression in the cortex of type I and  type II 
adenylate cyclase, decreased G ail/ whilst Gao G as and Gp remained unchanged (Colin et al.,
1991).
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The effect of exposure of adrenergic agonist on receptors, associated G-proteins and adenylate 
cyclase action, is probably the m ost extensively studied and best characterised system 
(reviewed by Hadcock & Malbon, 1993). The ai-adrenergic receptors mediate the regulation 
of phospholipase C, p i-adrenerg ic  activation stim ulates adenylate cyclase w hile <X2~ 
adrenergic has an inhibitory input on adenylate cyclase (reviewed by Summers and McMartin 
1993). Short term  and long term exposure of a variety of cells to adrenergic agonists are 
believed to induce distinct cellular transduction adaptations.
Acute, short term  agonist exposure results in a desensitisation of many adrenergic receptors 
where phosphorylation of the receptor plays a prominent role in this adaptation. The short 
term  response appears to be largely independent of changes in the steady state levels of G- 
protein and receptor mRNA (Hausdorff et al., 1990). Chronic long-term agonist exposure, on 
the other hand, induced adaptive changes in the transduction pathw ays by altering the 
steady state level and expression of G-proteins and receptors. The persistent activation of p- 
adrenergic receptors induced an increase in G a il mRNA and protein expression, and a 
reduction in G as mRNA, although the G as protein levels were unaltered (Hadcock et al., 
1990). The alterations were also achieved by the persistent activation of adenylate cyclase 
by forskolin (Hadcock et al., 1990).
Thus, the investigations described above have demonstrate that drug  exposure can induce 
alterations in a variety of signalling pathways which, in some instances, involves adaptive 
changes at the G-protein level.
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2. Neurochemical and pathological features associated with the neurodegenerative 
disorder of Alzheimer's disease.
2.1 Methodological considerations in hum an brain research.
The investigations of hum an neurological disorders, in general, adop t one of three 
approaches: (1) use of animal models in which specific neuronal damage has been induced; (2 ) 
use of fresh biopsy material and (3) use of postmortem tissue obtained at autopsy. Each of 
these strategies has restrictions (reviewed by Dodd et al., 1988). While anim al models can 
allow for the control of genetic, environmental and dietary factors, and are a source of fresh 
tissue, it is difficult, if not impossible, to accurately induce the complex neuroanatomical and 
neuropathologic changes associated w ith disorders such as A lzheim er's disease. Thus, 
although animal models have generated valuable data concerning adaptive changes as a 
consequence of disruption of specific neural circuits, extrapolation of these data from animal to 
hum an conditions m ust be interpreted with caution. Fresh biopsy material is no t widely 
available since, in  general, neurosurgery is not perform ed in patients suffering from 
intractable neurological conditions. W here biopsy m aterial is available the quantity  of 
tissue is usually inadequate for a comprehensive functional neurochemical analysis. Thus, the 
majority of studies of human brain disorders are performed on postmortem tissue. Postmortem 
material is not the ideal tissue source for conducting functional biochemical analysis since the 
interval between death and the freezing of brain tissue, and the agonal status of the patients 
are bu t two factors which may influence the quality of the data generated for a  particular 
param eter. However, valuable information has been obtained from studies conducted on 
hum an postm ortem  m aterial particularly where the stability of various receptors and 
enzymes has been established.
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2.1.1 The effect of the interval between death and brain freezing (postmortem interval) and
agonal state on various enzymes and receptors.
Several studies have exam ined the effect of postm ortem  delay in terval on various 
neurochemical aspects of brain function. W hitehouse et al. (1984) used rat as a model to 
examine neurotransm itter binding over a range of postm ortem  delay. The design of their 
experiment was such that the temperature changes in the rat postm ortem  closely resembled 
the cooling curve profile of hum an brains. In addition to following the cooling curve to 4°C 
(mortuary storage temperature), rat heads were m aintained at room tem perature (22°C) for 
extended postmortem delay intervals. Under both sets of conditions there was a significant 
reduction in agonist binding to muscarinic receptors (N-methylscolpolamine), although the 
extent of the decrease was more marked at 22°C. At 22°C a statistically significant reduction 
(43%) in muscarinic ligand binding, compared to fresh tissue, was observed at a 6  hours 
postm ortem  interval; at 4°C  the ligand binding was stable until a 24 hours postm ortem  
interval where a 23% reduction in binding achieved statistical significance. Kinetic analysis 
showed that Bm ax was reduced w ithout significant changes in Kd, suggesting a loss of 
muscarinic ligand binding sites rather than an alteration in receptor affinity. Similarly, the 
binding of a 2 -adrenergic agonist (p-aminoclonidine) was significantly reduced at 22°C at 48 
hours postmortem interval but not significantly reduced in brains cooled to 4°C. Scatchard 
analysis revealed a single binding site for p-aminoclonidine in fresh tissue , whereas tissue 
w ith a 48 hour postm ortem  delay interval displayed both high and low affinity binding 
sites. Reduced binding was also observed for dopamine agonist while benzodiazepine binding 
was increased due to an increase in Kd. None of the agonist binding profiles were effected by 
freezer storage times.
In a more recent study, Syapin et al. (1987) compared postmortem delay effect on the binding 
of various agonist and enzymatic activity of two strains of rat. W ith regards to receptor 
binding, their results in general agree with the findings reported by W hitehouse et al (1984):
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a statistically significant reduction in muscarinic ligand binding (quinuclidinyl benzilate) 
occurred at 48 hours, a rapid reduction in opioid ligand binding (2-D-alanine-5-D-leucine 
enkephalin) was evident at 6  hours, while benzodiazepine binding (GABAa agonist) was 
unaffected by prolonged postmortem delay intervals. Ligand binding to muscarinic, opioid 
and benzodiazepine receptors was unaffected by postmortem interval of brains kept at 4°C. 
They also observed that a t 4°C and 25°C the N a+, K+-activated ATPase and low affinity
2  j 1  i
Ca dependent-ATPase activity were stable, while Mg dependent, oubain sensitive- 
ATPase activity was significantly reduced at 24 and 48 hours but significantly elevated at 72 
hours. The postm ortem  interval effect on enzymatic activities and receptor binding was 
similar for both rat strains, although an increase in diazepam  binding was observed with 
brains from Sprague-Dawley rats which was not evident in the N /N ih  strain. Postmortem 
interval would appear to have a selective effect on receptor binding which in some cases is 
influenced by the animal strain. The apparent stability of ATPase activity (w ith the 
exception of the Mg^+ dependent species) agreed with an earlier study by Nicol et al. (1981). 
The activities of adenylate cyclase activity and low affinity GTPase is stable at postm ortem  
intervals up  to 10  hours, however, a decrease in adenylate cyclase activity occurred in 
homogenates preparations but not in washed membranes (Nicol et al., 1981).
The selective vulnerability of proteins to postmortem interval may be due to alterations in 
the optimal membrane lipid environment specific to different m embrane associated proteins. 
It has been shown that both mono and diacylglycerol kinase activities are reduced in brains 
stored at 4°C and 23°C for 24 hours in comparison to fresh tissue (Farooqui & Horroks, 1991). 
The decay profiles of both enzymes exhibited a sharp fall in activity when stored for up to 8  
hours after death, thereafter a gradual decline in activity continued until 24 hours (Farooqui 
& Horroks, 1991). A further indication that membrane lipid metabolism is altered between 
dea th  and  au topsy  is the reported  increase in the  basal ra te  of hydro lysis of 
phophatidylinositol in rat cortex which had been stored for 4 hours after death (Candy et al 
1984). The effect of postmortem delay interval on membrane lipid composition, which may
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subsequently alter the functional activities of membrane associated proteins, m ay also be 
compounded by the influence of the mode of death (agonal status) of the patient.
Agonal state can be divided into two broad groups; where death occurs relatively quickly such 
as cardiac failure, and prolonged death for example bronchopneumonia where death  occurs 
after periods of prolonged, severe illness. A number of neurochemical differences have been 
identified between the two categories. Brains from patients who have suffered a protracted 
death  have reduced activities of phosphofructokinase and glutam ate decarboxylase, 
elevated tryptophan and reduced pH (Perry et al., 1982). Perry (In Dodd et al 1988) also 
observed that in the patients with a long terminal phase, a postm ortem  delay induced 
reduction in glutamate decarboxylase is more pronounced than in brains from the rapid death 
category. Prem ortem  hypoxia has also been shown to influence the stability of selected 
mRNA (reviewed by Barton et al., 1993) and may therefore be a significant contributing factor 
the the degradation of selected mRNA species that is frequently encountered in  postmortem 
studies (Ross et al.,il992). Recently it has been shown that the basal binding of the glutamate 
receptor subtype N-m ethyl-D-aspartate ligand MK-801 is significantly reduced  in slow 
death cases (Piggott et al., 1992). Thus agonal status may influence the outcome of receptor 
binding studies.
Extensive neurochemical analysis of hum an brain disorders therefore necessitates the use of 
hum an postmortem material. The period between death and autopsy, together w ith possible 
differences in the mode of death of the cases examined, will impose restrictions on the type of 
analysis that can be performed to generate reliable data. These factors can be m inimised by 
closely m atching , where possible, the control and diseased groups. W hile this will not 
com pletely  elim inate the poten tial variab ility  encountered  by  these  factors, by 
acknowledging their contribution the interpretation of data should be more secure.
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2.1.2. Effect of aging on various enzymes and receptors.
M ost of the current knowledge of Alzheimer’s disease originates from  histological and 
biochemical investigations conducted on postmortem material of diseased and age m atched 
control samples. In addition to the potential variations introduced by postmortem and agonal 
status as described above, the aging process introduces another complicating factor in studies 
of age-related neurodegenerative disorders. There is evidence of deficits in pre- and 
postsynaptic neurochemical markers with aging (reviewed by Decker, 1987). Thus the aging 
effect may, in some instances, prevent accurate neurochemical analysis.
A dysfunction of the cholinergic processes, one of the m ost consistent neurochem ical 
abnormalities associated with Alzheimer's disease, has stim ulated num erous studies of the 
effect of aging on the status of the cholinergic neurons. Although the nature and severity of 
aging effect on the cholinergic processes remain in dispute, on balance the more recent studies 
suggest that these neurons are susceptible to aging induced alterations. A ge-related 
decrements in choline acetlytransferase activity (Arujo et al., 1990), depolarisation induced 
acetyl choline release (Araujo 1990) and muscarinic receptor binding (Vannucchi & Goldman- 
Rakic, 1991) has been described. Zawia et al. (1992) recently reported that ibotenate lesion of 
the  nucleus basilis induced  reductions in cortical choline acety ltransferase  and  
acety lcho linesterase  activ ity . The m agnitude of reduced  acety ltran sferase  and  
acetylcholinesterase activity was significantly greater in aged com pared to young rats. 
Zawia et al. (1992) suggested that the basal forebrain cholinergic system is more susceptible 
to neurotoxic damage.
An aging effect has also been described for a variety of biochemical activities in the brain. 
For example, alterations in aging brains compared to young brains have been reported for:- 
lipid composition in various regions of aging brains (Soderberg et al., 1990); changes in 
subcellular distribution of opioid receptors and G-proteins (Bern et al., 1991); brain protein
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oxidation (Smith et al., 1991); mitochondrial function (Bowling et al., 1993); and eukaryotic 
initiation factor 2 activity (Kimball et al., 1992). The diversity of these age related changes 
may be of particular consequence to the central nervous system since neurons, unlike most other 
cells types, do not have the capacity to divide. Thus, in order for neurons to survive the aging 
effect, they m ust express a complex adaptive response to m aintain their general house­
keeping biochemical activities in addition to their highly specialised roles.
2.2 Neuropathological features of Alzheimer's disease.
Alzheim er's disease has, historically, been subdivided into two, categories; early onset 
which affects patients less than 50-65 years of age, and late onset which develops from 
approxim ately 65 years. Additionally there are other dem entias affecting the population 
such as, vascular dem entia and m ulti-infarct dem entia. Confirm ation of the clinical 
diagnosis of Alzheimer’s type dementia is achieved only on neuropathological examination 
by the presence of the characteristic senile plaque, cerebrovascular am yloidosis and 
neurofibrillary tangles which were first described by Alzheim er in 1907 (review ed by 
H enderson & Finch, 1989). Over the last decade there has been significant advancem ent in 
our knowledge of the neuroanatomical distribution and molecular composition of these lesions.
2.2.1 Amyloidogenesis in Alzheimer's disease.
The classical senile plaque is composed of a proteinous core of P am yloid surrounded by 
dystrophic neurites and glia cells . The term  amyloid is used to describe tissue protein 
precipitates which have a predom inant (3 sheet secondary structure that confers a high 
affinity for the histochemical dye congo red, although a variety of histological staining 
techniques are now employed to examine the density and morphological appearances of 
p laques (Khachaturian, 1985). In A lzheim er's disease, p laques are  p resen t in  high 
concentrations in various neuroanatomical locations but occur predom inantly in the cortical
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and hippocam pal regions (Braak & Braak, 1991). I. Amyloid plaques are not, however, 
restricted to Alzheimer’s diseased brains; they are present in normal aged brains although at 
a significantly lower density than diseased brains, and in aged Downs syndrome (trisomy 21) 
subjects (Masters et al., 1985). Plaques, visualised histologically, are roughly spherical in 
appearance and can vary in diameter from a few pm to 200pm. Modified histological staining 
methods, which employ more sensitive silver staining and immunological techniques (Ikeda 
et al., 1988), have identified an amorphous or diffuse, noncongophilic plaque (Yaipaguchi et 
al., 1989). It has been suggested by some authors that the diffuse plaque are the earliest 
lesion of Alzheim er's disease and that they m ature into the senile or neuritic plaque 
(Yamaguchi et al., 1989). Others believe, however, that the diffuse plaque is a harmless 
accompaniment of the aging process (Masliah et al., 1990a).
Significant progress has been made in unravelling the biochemical and molecular nature of 
the major amyloid protein associated with plaques which should aid attempts to understand 
the process of amyloid deposition in the brain and explain the neurological significance of 
this event. The major protein component of the amyloid fibril is a 4.2 KDal protein, now 
referred to as PA4 protein. It was first isolated from brain by Glenner & Wong, (1984). The 
pA4 protein was originally reported as being derived from an integral m em brane amyloid 
precursor protein (APP) containing 695 amino acids (Kang et al., 1987). The APP protein 
consists of a large amino-terminal extracellular domain, followed by a m embrane spanning 
region containing the PA4 fragment, and a short carboxy-terminal intracellular dom ain. 
Three other isoforms of APP have since been identified (APP 593, APP 751, APP 750) which 
contain an additional exon encoding a sequence homologous to the N-terminal Kunitz protease 
inhibitor domain (Kitaguchi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988).
The precursor protein can undergo several post translational modifications such as N-and O- 
glycosylation (Weidemann et al., 1989), phosphorylation (Gandy et al., 1988) and proteolysis 
(W eidemann et al., 1989; Buxbaum et al., 1990). The physiological role of APP, and the
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detailed mechanisms involved in the processing of APP are at present extremely active areas 
of Alzheimer’s disease research. A variety of proposals have been pu t forward to account for 
a role of the APP molecule in neurodegeneration. Bauxbaum et al. (1990) suggested that 
abnorm al phosphorylation of APP is central to its abnormal processing leading to PA4 
deposition. Koo et al. (1990) demonstrated that APP undergoes fast axonal transport. APP 
protein fragments have also been reported to potentiate the neurotoxicity by nerve growth 
factors to! cultures (Yanker et al., 1990), and increase the sensitivity of neurons to glutamate 
toxicity (Mattson et al., 1992). Taken together, the majority of evidence w ould now indicate 
that abnormal processing of APP, leading to the deposition of pA4 is deleterious to neurons.
Downs syndrome patients, in which there is trisomy of chromosome 21 , develop pathological 
features which are similar to Alzheimer's disease . Thus it was proposed that abnormal 
expression of a gene on this chromosome is central to the pathology. This hypothesis was 
fuelled by the discovery that the APP gene was located on chromosome 21 (Goldgaber et al., 
1987; Tanzi et al., 1987) and by the identification of a mutation on chromosome 21 which was 
close to the APP gene (St George Hyslop et al., 1987). However, the m utation identified on 
chromosome 21, and the APP gene were found not to be co-inherited (St George Hyslop et al., 
1990) which eliminated the possibility that Alzheimer's disease is genetically homogeneous. 
Recent studies of two separate families with kindred of early onset A lzheim er's disease 
dem onstrated m utations of the APP gene (Goate et al., 1991; Chartier-Harlin et al., 1991). 
Similar substitution mutations produce abnormal PA4 accumulation in transfected cells (Citron 
et al., 1992) which supports a genetic basis for amyloidogenesis in familial Alzheimer's 
disease. Tanzi & Hyman, (1991) also speculated that APP m utations could alter the stability 
of the mRNA and thus influence the normal translational control of the APP gene. Additional 
genetic loci have recently been implicated in Alzheimer’s disease. A second FAD locus has 
recently been m apped to chromosome 14 (Schellenberg et al., 1992) w hile the gene for 
apolipoprotein E on chromosome 19 is suggested to be involved in late-onset Alzheimer's 
disease (Poirier et al., 1993).
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2.2.2 Neurofibrillary tangles in Alzheimer's disease.
The term  neurofibrillary tangles (NFT) originated from the microscopic appearance of a non­
membrane mass of fibres detected histologically in the cell bodies of neurons. On electron 
microscopy, they consist largely of abnormal filaments with lOnm wide constrictions every 
80nm that are twisted into paired helical structures referred to as paired helical filaments 
(PHF) (Wischik et al., 1988a). Straight filaments ~15nm in diam eter and cytoskeletal 
filaments of normal appearance may also be associated with NFT. Although the NFT lesion 
is present at a higher density in Alzheimers disease, similar structures are also visualised in 
normal aging, Downs syndrome, lateral sclerosis of Guam and pugalistic dementia. Terry et 
al., (1987) also observed that in a substantial minority of Alzheimer's diseased brains (30%), 
tangles were absent in the hippocampus and neocortex. However, in samples where tangles 
are present, the severity of the dementia had a tendency to be greater than those patients 
lacking tangle formations (Terry et al., 1987).
The biochemical composition of NFT has proved difficult to determ ine due to the highly 
insoluble nature of the PHF. Most of the protocols for the isolation of PHF require strong 
protein  denaturents such as SDS and urea and separation of the insoluble fraction by 
centrifugation (review ed by Selkoe, 1989). A lternative approaches have subjected 
preparations to mild proteolytic digestion (Wischik et al., 1988). These techniques have 
invariably led to contamination of the PHF fractions and modification of the isolated PHF 
and therefore the true identity of the PHF and other proteins associated w ith NFT has been 
complex.
To date two proteins, tau and ubiquitin, are the only definite components of PHF. Six isoforms 
have been identified that are thought to arise by alternate splicing of a single pre-mRNA 
(Neve et al., 1986; Kosik et al., 1989). In Alzheim er's disease, tau  is abnorm ally 
phosphorylated (Bancher et al., 1989) which may effect its immunoreactivity and solubility
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(Hanger et al., 1991; Goedert et al., 1992). The abnormal phosphorylation of tau has been 
proposed to arise from altered kinase activity in Alzheimer’s diseased brains (reviewed by 
Saitoh et al., 1991). A strong positive correlation between the level of tau mRNA and APP 
mRNA in normal aged brains has recently been reported (Oyama et al., 1992). It will be 
interesting to see whether such a relationship exists in Alzheimer's diseased brains and also 
if these param eters correlate w ith kinase levels. The significance of the abnorm al 
phosphorylation of tau in Alzheimer's disease is still unclear; however, Brion (1990), has 
suggested that it could alter the normal polymerisation of tubulin and consequently increase 
the am ount of tau not associated with microtubules. This in tu rn  could precipitate PHF 
formation.
Ubiquitin is a small protein (8.5 KDal), highly conserved and abundant in all tissue. The 
association of ubiquitin with NFT has been based largely on immunological evidence. The 
significance of the presence of ubiquitin in NFT is unknown, although brain ubiquitin levels 
are elevated in Alzheimer's disease and correlate with the degree of neurofibrillary changes 
(W ang G.P. et al., 1991). Recently, Bancher e t al. (1991) have show n that abnorm al 
phosphorylation of tau precedes its incorporation into PHF and that ubiquitin association 
occurs secondary to this event. Based on these findings Bancher et al. (1991) suggested the 
presence of ubiquitin could be an attem pt by cells to inhibit protein precipitation. The 
amyloid [3A4 protein is also a minor component of NFT (Yamaguchi et al.,1990b).
Considerable attention has also been devoted to the putative role of alum inium  in 
Alzheim er's pathology. This has been based largely on the identification of alum inium  
silicates a t the core of neuritic plaques (Perl and Brody, 1980; Candy et al., 1986 bu t see 
Landsberg et al.,J 1992) which has led to the postulate that exogeonous alum inium  intake 
potentiates the developm ent of senile plaques. Additionally, m icroprobe studies have 
dem onstrated elevated alum unium  levels associated with NFT (Perl and  Brody, 1980; see 
Good et al., 1993) although other studies failed to detect elevated levels of alum inium  in
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Alzheimer’s diseased brains | (Chafti, 1991). Recently, however, M attson et al. (1993)
concluded that in cultured neurons, alum inium  cannot induce the characteristic features 
associated with the NFT of Alzheimer's disease. Thus, the putative relationship between 
alum inium  and the development of the characteristic Alzheimer's disease pathology remains 
speculative.
2.2.3 Neuronal loss and reactive gliosis in Alzheimers disease.
Neuronal loss in selective brain regions is considered part of the normal aging process. The 
extent to which this phenomena occurs in Alzheimer's disease is, however, debatable. Vogels 
et al. (1990) performed a careful and thorough investigation of the neuron content in the 
N ucleus basilis of Meynert complex (NBMC). Vogels et al. (1990) considered some of the 
factors such as selective neuron loss and shrinkage which m ay have contributed to the 
discrepancies in the literature regarding the extent of neuron loss in Alzheimer’s disease. 
They examined specific anatomical regions of the NBMC in serial section to create a 3- 
dimensional picture of neuron density in these areas. Both large and small neurons were 
counted. An overall neuronal decrease of 15.5% was found, although the density of small 
neurons were increased while the density of large neurons (probably cholinergic) were found to 
be decreased. Vogels et al. (1990) suggested that the inverse alterations in the density of 
small and large neurons in Alzheimer's NBMC was a result of neuronal shrinkage. Similar 
findings were reported by Iraizoz et al, (1990) who conducted a total cell count of the NBMC, 
although a higher neuronal loss compared to Vogel et al, (1990) was observed. In addition, 
Iraizoz et al, (1990) observed an increased nuclear area of remaining neurons suggesting that 
regenerative and degenerative responses co-exist in the NBMC in Alzheimer's disease.
N euronal loss in the frontal and tem poral cortex of Alzheim er’s disease has also been 
confirmed (Terry et al., 1981; Hubbard & Anderson, 1985), and in layers II and III of the 
entorhinal cortex (Hym an et al., 1987). These investigations generally agree that in
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Alzheim er’s disease the larger pyram idal neurons are more m arkedly reduced than the 
smaller intrinsic neurons. The synaptic density of the cortical regions are also reduced 
(Davies et al., 1987). A minimal reduction of 25% to 35% in the synaptic content of the 
temporal and frontal cortices was noted (Davies et al., 1987), although the degree of synaptic 
loss was less marked when correcting synaptic content for cortical atrophy (temporal cortex 
30%; frontal cortex 14%). The marked reduction in the cortical synaptic content particularly 
in layer III of the frontal cortex probably reflects the loss of cholinergic afferents from the 
basal forebrain in addition to intrinsic connections (Scheff et al., 1990). Scheff et al. (1990) 
also observed a negative correlation between synaptic density and synaptic size which may 
suggest a compensatory response. More recently, Masliah et al. (1990b & 1991a) employed 
synaptophysin antibodies to demonstrate a loss of 45% of presynaptic terminals in the frontal 
cortex by both immunohistochemical and Western blotting analysis. The synaptophysin 
antibody may prove a useful marker for synaptic content both in situ and in vitro.
The process of reactive gliosis which results in an increased astrocyte content of grey matter, 
occurs in response to brain traum a (Mathewson & Berry, 1985), and also as a result of aging 
(Beach et al., 1989). Marked gliosis in Alzheimer's disease has been noted by several authors 
(Schechter et al., 1981; Beach et al., 1989). The analysis of astrocyte density  is usually 
perform ed by immunocytochemistry, employing antibodies against glial acidic fibrillary 
protein (GFAP). While some authors have suggested that in the visual cortex there is a 
relationship between the level of gliosis and the severity of the pathological features of 
Alzheimer's disease (neuron and synaptic loss, plaque and tangle accumulation) (Beach et al.,
1989), others found no correlation between gliosis and the severity of pathology observed in 
the hippocam pus (Vijayan et al., 1991).
A lthough gliosis is a well docum ented reaction which is observed in a w ide range of 
conditions affecting the brain, the significance of this phenomenon is not yet fully understood.
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There is evidence that the astrocytes and glia glutamate uptake mechanism can restrict the 
extracellular glutam ate concentration to a sub-toxic concentration (Bouvier et al., 1992; 
Sugiyama et al., 1989; and see Hertz, 1989), while the ability of astrocytes and glia to 
produce growth factors may imply a trophic effect (Araujo & Cotman, 1992).
2.3. Neurochemical features of Alzheimer's disease.
For the last few decades neurochemical investigations of A lzheim er's disease have 
identified a variety of abnormalities associated with the disease (reviewed by Francis et 
al., 1992; Dewar & McCulloch, 1993). Many research groups have pursued a neurochemical 
line of investigation in the hope of identifying a prim ary neurotransm itter lesion similar to 
that of the dopamergic deficit in Parkinson's disease, and thus to enable the developm ent of 
appropriate therapeutic strategies. While the literature describes m odulations in the level 
of several neurotransmitters, receptors and the enzymes involved in the regulation of selected 
neurotransm itters, it is only relatively recently that attention has focussed on the functional 
aspects of neurom odulatory events involving signal transduction. As yet no single neuronal 
lesion has been identified unequivocally as the major factor in Alzheimer’s disease, although 
there is strong evidence to implicate the cholinergic and glutam atergic system s in this 
condition (Palmer & Gershon, 1990).
2.3.1 Cholinergic neurotransmitters and receptors in Alzheimer's disease.
One of the earliest and most consistently reported neurochemical deficiencies in Alzheimer's 
disease is that of significant reductions in various cortical and subcortical regions in the 
activ ity  of the acetylcholine synthesising enzyme, choline acetyltransferase (ChAT) 
(reviewed by Perry, 1986). The severest alterations are reported to occur in the neocortex and 
hippocam pus (Perry, 1986). Losses in other cholinergic markers such as acetyl choline levels 
and acetylcholinesterase (AChE) activity have also been found in  A lzheim er's disease
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(Perry, 1986). The ChAT deficit reported by Perry (1986) was also found to exhibit a 
negative correlation with cognitive decline suggesting a causal relationship betw een the 
neurochemical abnormality and the severity of dementia.
More recent investigations have examined the regulatory events associated w ith acetyl 
choline turnover. Slotkin et al, (1990) examined the ChAT activity and synaptosomal choline 
uptake in rapid autopsy material and found the ratio of choline uptake to ChAT activity to 
be significantly elevated in the cortex of Alzheimer's disease. They interpreted the cortical 
changes as an upregulatory, com pensatory response. Interestingly, the h ippocam pus 
displayed the reverse with a significant reduction in the ratio. Pascaul et al. (1991), on the 
other hand, dem onstrated a significant reduction in the binding sites of a high affinity 
choline uptake marker ([3H] hemocholinium-3) in the frontal cortex and hippocam pus of 
Alzheimer's disease postmortem samples. Pascual et al. (1991) did observe, however, that a 
significant proportion  of the sam ples displayed norm al values and  that the overall 
reductions were not as marked as the ChAT deficit. Pascaul et al (1991) suggested that this 
observation may indicate a compensatory response by the remaining cholinergic neurons.
N um erous studies have examined the status of the cholinergic receptor populations in 
Alzheimer's disease, to establish whether or not regulation of receptors occurs in response to 
cholinergic afferent denervation. The findings of these investigations, however, have been 
contradictory. The muscarinic subclass of receptors, M l have been shown to be preserved 
(Kellar et al., 1987; Rinne et al., 1989), while some investigators found a m oderate decrease 
(Mash et al., 1985; Shimohama et al., 1986) and modest increases have also been observed 
(Danielsson et al., 1988; Probst et al., 1988). Additionally, the level of m l mRNA was shown 
to be increased in Alzheimer's disease (Harrison et al., 1991). While this finding does not 
necessarily imply that the protein level is concomitantly increased, it does support the notion 
of an upregulation in the muscarinic receptors translation efficiency. However in conflict with 
the findings of Harrison et al. (1991), Wang et al. 1992 found a reduction in the m l muscarinic
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recptor message in Alzheimer's disease cortex. The different results between the two groups 
may be due to the particular method employed to isolate the mRNA.
In Alzheimer's disease, the M2 subclass was reported to be decreased in the frontal cortex 
(Araujo et al., 1988; Mash et al.,| 1985), decreased in the hippocam pus (Rinne et al., 1989), 
preserved in the cortex (Kellar et al.,1987; Rinne et al., 1989) and increased in the cortex 
(Nordberg et al., 1992). In Nordberg (1992), found that the M2 receptors were preserved in 
multi infarct dementia. They suggested that misclassification of the patients may be a factor 
which contributes to the conflicting data regarding muscarinic receptors in A lzheim er’s 
disease. O ther factors such as ligand selectivity, lack of anatomical resolution, and  the 
affinity status of receptors could also account for the discrepancies regarding muscarinic 
receptors in Alzheimer's disease.
The literature on the nicotinic receptors in Alzheimer's disease tends to be more consistent 
with most investigations reporting a decrease in receptor density (Kellar et al., 1987;| Nordberg 
et al., 1992). Like most of the major classes of receptors, the nicotinic receptors are now known 
to be a family of proteins for which multiple genes encoding different subtypes have been 
isolated. It rem ains to be established if the subtypes are differentially  altered  as a 
consequence of Alzheimer's disease.
2.3.2 Glutamatergic neurotransmitters and receptors in  Alzheimer's disease.
The excitatory amino acids (EAA) glutam ate and aspartate have received considerable 
attention in studies of neurodegeneration and have been implicated in the pathogenesis of 
cerebral ischemia (reviewed by M eldrum & Garthwaite, 1991). They are also referred to as 
excitotoxins due to their excitatory transmitter action and their toxic effect on cells exposed to 
high concentrations for prolonged periods. There is evidence that glutam ate is a major 
neurotransm itter of pyram idal cells of the cortex and hippocam pus (Palmer et al., 1989).
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Given that there is a significant loss of pyramidal cells in the cortex of Alzheimer's disease 
(Terry et al., 1981; Hubbard & Anderson, 1985; Davies et al., 1987), it is postulated that 
glutamatergic dysfunction is involved. Further studies have examined the glutamatergic 
binding sites in an attempt to substantiate this hypothesis (for reviews see Palmer & Gershon, 
1990; Francis et al., 1993; Dewar & McCulloch 1993).
In Alzheimer’s disease brain, the concentration of glutamate and aspartate has been difficult 
to assess. Glutamate is metabolised in neurons and glia as part of intermediary metabolism, 
which has led to difficulties in segregating the neurotransm itter and metabolic glutam ate 
pools. N onetheless, H ym an et al, (1987) examined the perforant pathw ay  of the 
hippocam pus (which is rich in glutamatergic terminals) and found a marked reduction in L- 
glutam ate content. Evidence that neurotransm itter metabolism is altered in Alzheimer's 
disease was reported by Procter et al. (1988), who observed a reduction in ^H aspartate uptake 
in rapid autopsy material. Reductions in the content of neurons which contain the glutamate 
synthesising enzyme, glutaminase, has been described in Alzheimer's disease (Kowell and 
Beal, 1991), yet the enzyme activity is reported unchanged (Procter et al., 1988). The ligand 
3H-aspartate was considered a marker for glutamatergic terminals and deficits in binding in 
cortical and hippocampal regions has been demonstrated (Chalmers et al.,1990). However, 
recent investigations has questioned the validity of ^H -asparta te  b ind ing  to assess 
glutamatergic binding sites (Browne et al., 199l] Greenamyre et al., 1990).
The glutamate receptors have been classified into two groups. The ionotropic receptors are 
ligand gated integral ion channels. Subclasses of the ionotropic class include N-methyl-D- 
asparta te  (NMDA); a-am ino-3-hydroxy-5-m ethyllisoxazole-4-propionate (AMPA); L-2- 
amino-4-phosphobutyrate (AP4); and Kainate (Sommer & Seeburg, 1992). The metabotropic 
glutam ate receptors are coupled to G-proteins and m odulate a variety of transduction 
pathw ays (Itano et al., 1991). Several subtypes have now been cloned (Schoepp & Conn,
1993).
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The subclasses of the ionotropic receptors have been exam ined in various regions of 
Alzheimer's disease brain. The NMDA subtype exists as a receptor-channel complex and has 
an interesting characteristic in that its activity is allosterically m odulated by glycine, zinc 
and  polyam ines. A derivative of phencyclidine, N -[l-(2-thienyl) cyclohexyl]-3-,4- 
piperidine (TCP) binds to the high affinity NMDA sites. The TCP binding sites were found to 
be significantly reduced in  the frontal cortex (Ninomiya et al., 1990). H ow ever, the 
functional capacity of the remaining complexes has been shown to be preserved in Alzheimer's 
disease (N inom iya et al 1990). In contrast, Procter et al, (1989) reported  th a t the 
noncompetitive NMDA antagonist MK-801 was reduced in the frontal cortex, bu t only in the 
presence of glycine. Chalmers et al, (1990), on the other hand, found a small reduction in 
NMDA sensitive ^H glutamate binding in the frontal cortex which bordered on statistical 
significance; AMPA binding sites were preserved whereas kainate binding was increased, a 
finding which may indicate a compensatory response in selective glutam ate b inding sites. 
Cow burn et al., (1989) reported that the kainate receptor was preserved in A lzheim er's 
disease cortex and hippocampus while quisqualate sensitive glutamate binding (Greenamyre 
et al.,j 1985), AMPA and glutamate metabotropic sites (Dewar et al., 1991) were show n to be 
decreased in the hippocampus. The discrepant findings of investigations of the iontropic 
subtypes may be the result of different ligands and binding conditions. Thus, although there 
exists some confusion regarding the individual glutamatergic receptor subtypes, the evidence, 
in general, suggests that the glutamatergic excitatory amino acid neurons and their receptors 
are compromised in Alzheimer's disease.
2.3.3 Monoaminergic neurotransmitters and receptors in Alzheimer's disease.
Investigations of the m omam inergic system  in Alzheim er's d isease have identified  
alterations in a number of neurochemical systems. Reductions in noradrenaline (Palmer et al., 
1987), dopamine P hydroxylase (Cross et al., 1981) (which synthesises noradrenaline) and the
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noradrenaline metabolite 3-methoxy-4-hydroxyphenolglycol (Crow et al., 1984) have been 
observed in Alzheimer's disease. Investigations of adrenergic receptors have reported the a l  
types to be preserved in the cortex (Cross et al., 1984; Shimohama et al., 1986); decreased in 
frontal cortex (Kalaria and Andorn., 1991; M eana et al., 1992) and preserved in the 
hippocam pus (Meana et al., 1992). A recent autoradiographic study however, described 
reductions of approxim ately 50% in both frontal cortex and hippocam pus (Pascaul et al.,
1992). Data regarding the a l  receptors in Alzheimer's disease are more limited: Shimohama 
et al. (1986) found a decrease in the receptor density and a change in Kq  in the hippocam pus 
and cerebellum with no change in the frontal cortex. Cross et al. (1984), on the other hand, 
found no change in the hippocampus, while Kalaria, (1989) described a small, but significant, 
reduction (25%) in the prefrontal cortex. The discrepancies may be partly explained by group 
size, the different ligands and binding conditions employed, which may be influenced by the 
integrity of the receptor/G-protein coupling
The total number of p  adrenoceptors in Alzheimer's disease were reported to be unchanged in 
the cortex and hippocam pus (Cross et al.,1984). Analysis of the subtypes, however, have 
found a differential alteration. For instance, Shimohama et al. (1987) found a reduction in p i  
in the hippocam pus and an increase in the NBMC and cerebellum. Conversely, the P2 
receptors were reduced in the NBMC, thalam us and cerebellum  bu t increased in the 
hippocam pus (Shimohama et al., 1987). Neither p i  or p 2  were altered in the frontal cortex 
(Shimohama et al., 1987). Kalaria et al. (1989) also found that in the frontal cortex, the 
total P adrenoceptors were preserved, however the p i  subtype was decreased while the P 2  
type was increased. Kalaria et al. (1989) also reported that in the hippocam pus the total p i  
and P2 types were increased. Interestingly, a more recent report examined the laminar binding 
of a variety of ligands to a variety of receptors in the cingulate cortex of Alzheimer's disease 
samples (Vogt et al., 1991). In this study the Alzheimer's disease samples were sub-divided 
on the basis of the severity of neuronal loss. Vogt et al. (1991) reported that P agonist binding 
was elevated only in groups with a marked loss in neurons. Thus, the elevated binding of P
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agonists in Alzheimer's samples may, as suggested by Kalaria et al. (1989) and  Vogt et al. 
(1991), indicate a compensatory change or alternatively reflect gliosis.
Alterations in the serotonergic systems, at various neurochemical levels, has been described in 
A lzheim er's disease. Serotonin (5-hydroxytryptam ine) and  its m onoam ine oxidase 
metabolite 5-hydroxyindoleacetic acid (5-HIAA) have been found to be decreased in the axon 
term inals in Alzheim er's disease (Gottfriesj , 1990). Various stud ies have found 
alterations in the serotonergic binding sites in Alzheimer's disease. Significant reduction of 
5HT binding have been reported for the frontal and tem poral cortex (Cross et al., 1984a; 
Sparks, 1989). Autoradiographic analysis identified specific laminar reductions in the 5HT 
binding sites (Cross et al., 1988). On the other hand Dewar et al, (1990) failed to observe a 
significant change in 5HT sites as assessed by autoradiography.
The dopaminergic system is possibly the least extensively studied monoaminergic system in 
Alzheim er's disease research. A reduction in the level of dopam ine and its metabolite 
homovanillic acid (HVA) in subcortical regions, the amygdala, striatum  b u t no t in cortical 
regions, suggests that the nigrostriatal rather than the mesocortical pathw ay is affected 
(Cortes et al., 1988). In the striatum of Alzheimer's disease, the D2 s recepor subtypes were 
reported to be reduced, wheras the D1 receptor type was found to be preserved (Cross et al., 
| 1984b).
2.3.4. Inhibitory neurotransmitters and neuropeptides in Alzhemer's disease.
The short intrinsic neurons of the cerebral cortex contain the inhibitory transm itter y- 
aminobutyric acid (GABA) which often co-exists with neuropeptides such as somatostatin 
(SRIF) and neuropeptide Y (NPY) (Beal et al., 1986; Chan-Paly et al 1987; Davies et al.,
1990). The neuronal content of both SRIF and NPY has been examined in Alzheimer's disease. 
While some studies report a decrease in SRIF in cortical regions (Davies et al 1990), others
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have found no change (Whitford et al., 1988). Reduction in NPY in the cortex of Alzheimer's 
disease has beem reported (Beal et al., 1986; Davies et al., 1990). Davies et al. (1990) 
concluded, that by allowing for neuronal atrophy, there was a significant reduction of both 
SRIF and NPY containing neurons in addition to a reduced fibre length. These findings are 
supportive of previous reports that SRIF and NPY neurons are depleted in cortical areas in 
Alzheimer’s disease (Kowell & Beal, 1988; Chan-Palay, 1987). Decrements in NPY and SRIF 
binding in the hippocampus and temporal cortex cortex has been observed (Martel et al., 1990; 
Beal et al., 1986). Recently, the high affinity SRIF binding site (SSI) and the low affinity 
site was examined although indirectly. The SSI receptors were reduced in the frontal and 
temporal cortex whereas the non-SSI (presumably the low affinity sites), were preserved in 
the frontal cortex but reduced in the temporal cortex (Krantic et al., 1992). Reductions in the 
binding sites of GABAg has also been described for Alzheimer's disease (Chu et al., 1987)
Sustance P immunoreactive neurons have been reported to be depleted in the cerebral cortex of 
Alzheim er's disease! (Quigley & Kowall, 1991). Morphological changes, sim ilar to those 
described for SRIF neurons, (distorted fibres and reduced perikarya) w ere also observed 
(Quigley & Kowall, 1991). An earlier report found small, non-significant reductions in 
Substance P levels in Alzheimer's disease samples (Sakurada et al., 1990), although the 
analysis w as perform ed on tissue hom ogenates which m ay have m asked  localised 
alterations. A recent report of a protective action of substance P to p-amyloid induced toxicity 
of prim ary neuron cultures (Yanker et al., 1990) has raised the interesting possibility that 
substance P may play an active role in arresting the neurodegenerative processes associated 
w ith  the pathological developm ent in A lzheim er's disease and  m ay be a potential 
therapeutic agent.
Cholecystokinin (CCK), vasoactive intestinal po lypeptide (VIP) and  corticotrophin- 
releasing horm one (CRH) are additional neuropeptides which have been exam ined in 
Alzheimer's disease. Perry et al. (1981) observed a marked loss in CCK immunoreactivity in
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the enterhinal cortex, although modest reductions were reported for the frontal and temporal 
cortex (Mazurek & Beal, 1991) while unchanged CCK levels in the hippocam pus and primary 
sensory cortices have also been reported (Mazurek and Beal, 1991). CRF is reported to be 
reduced in the cerebral cortex (Leake et al 1991) and VIP levels were reported to be unaltered 
in Alzheimer's disease (Ferrier et al., 1983).
Thus, categoric conclusions regard ing  the in tegrity  of inh ib ito ry  and  excitatory 
neurotransm itter systems, can only be achieved w ith the thorough assessm ent of their 
regulatory  biochemical mechanisms together w ith the pharm acological status of their 
receptors.
2.3.5. Transmembrane signalling in Alzheimer's disease.
At the outset of this investigation, limited information was available on the integrity of 
signal transduction mechanisms in Alzheimer's disease, a factor which prom pted this study. 
Probably the first study that addressed the effect of Alzheimer's disease on G-proteins, 
although indirectly, was conducted by Smith et al. (1987). They examined the effect of GTP 
analogues and Mg^+ on the binding of muscarinic ligands to membranes prepared from the 
parietal cortex of Alzheimer's disease and age matched control samples. They found a 
decrease in the ability of Gpp(NH)p to induce the formation of the low affinity state of the 
M l type muscarinic receptor, as determined by carbachol inhibition of parenzipine binding. In 
the study by Smith et al. (1987) however, ligand binding and displacement was performed at 
one concentration of the relevant compound. A postmortem effect was also examined and 
while there were no significant changes in the binding characteristics of rat cortex left for 24 
hours postm ortem. Smith et al. (1987) did observe that the ability of M g^+ to enhance 
carbachol b inding was attenuated at 24 hours postm ortem  com pared to fresh tissue. 
Nonetheless, since the postm ortem  periods were comparable for control and Alzheimer's 
disease groups, the data suggests that the coupling of M l type receptors to G-proteins is
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altered in Alzheimer's disease. Indeed, I Smith et al. (1989) supported their findings by 
demonstrating a significant reduction in the pool of oxotremorine binding sites that can adopt 
the high affinity configuration in the presence of Gpp(NH)p.
Danielsson et al. (1988) examined the activity of adenylate cyclase, its responsiveness to 
various stim ulants and the activity of guanylate cyclase activity in various regions of 
Alzheimer's disease samples. They reported a preservation of muscarinic b inding sites and 
guanylate cyclase activity in the caudate, putam en, thalamus, hippocam pus and  temporal 
cortex. The basal adenylate cyclase was seen to be significantly elevated only in the 
hippocam pus, while vasoactive intestinal polypepide (VIP) and forskolin stim ulation was 
comparable for control and Alzheimer’s disease samples. This study dem onstrated that one of 
the central effector molecules of G-proteins, adenylate cyclase, can be assayed in postmortem 
tissue, and the enzym e is still responsive to receptor dependen t (VIP) and  receptor 
independent (forskolin) stimulation.
At the initiation of this project, the inositol phospholipid signaling system  was also 
beginning to emerge as a neurochemical abnormality associated with Alzheim er's disease. 
Stokes & Hawthorne (1987), measured the content of free myo-inositol and and its products 
phosphoinositol (PI), phosphoinositol mono and di phosphate (PIP and PIP2  respectively) in 
the tem poral cortex and found a significant reduction in PIP levels in Alzheim er's disease. 
Non-significant reductions in the other lipids were also recorded. Stokes and H aw thorne 
(1987) also observed that data variation was considerable and these authors attributed this 
to the large postm ortem  delay. An alteration in this signalling system w as supported by 
Young et al. (1988), who reported a reduction in [^H]inositol binding in Alzheim er’s disease 
cortex.
These studies, therefore, indicated that transmembrane signalling pathw ays are disturbed in 
Alzheimer's disease and that investigations of relevant param eters were possible. However,
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large variations in the data can be expected. Significant progress has since been m ade 
regarding m any different aspects of both the adenylate cyclase and the phosphoinositol 
pathways. These findings shall be examined in more detail in the discussion section of this 
thesis.
2.3.6 Drug treatment in Alzheimer's disease.
In contrast to Parkinsons disease, where dopamine deficiency is the prim ary cause of this 
neurological disorder, Alzheimer's disease appears to be characterised by a m ultiplicity of 
neurochem ical and pathological abnormalities affecting m any brain regions. W hile the 
developm ent of therapeutic agents is a daunting task, (given the complex nature of the 
disease, and  difficulties associated with the delivery of localised doses of agents which may 
poorly transverse the blood brain barrier), pharmacological intervention based on several 
strategies has been pursued (reviewed by Gottfries, 1992; Francis et al., 1992).
The cholinergic system has been the main target for therapeutic intervention. Replacement 
therapy to overcome the deficit has targeted different points in the regulatory mechanism for 
acetyl choline production: at the presynaptic level by supplying acetyl choline precursors; at 
the synaptic level by inhibiting the degradation of acetyl choline; and postsynapticaly by 
supplying analogues that can interact w ith the muscarinic (M l) and nicotinic receptors. 
Various com pounds which meet the above criteria have been examined in clinical trials: for 
exam ple, phosphatidylcholine; physostigm ine and tetrahydroam inoacrid ine (Tacrine); 
arecoline and nicotine which function as acetylcholine precursors, inhibitors of acetylcholine 
degredation, and acetylcholine receptor agonists respectively. Combination drug  treatm ent 
using acetylcholine precursors and inhibitors of acetylcholine degradation are reported to 
enhanced cognitive function of Alzheimer’s disease patients (Eagger et al.j 1991). There are, 
however, no reports of m arked clinical im provem ents of Alzheim er's disease patients 
adm inistered with cholinergic agents. Additionally, cholinergic agents can inflict severe
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side effects (Adem, 1992).
The drug  trials reported to date have failed to demonstrate major relief of the cognitive and 
non-cognitive symptoms associated with Alzheimer's disease. Perhaps new strategies are 
required given that aspects of signal transduction are also altered in the disease and that (1A4 
deposition is now thought to be a central, possibly instigative event in the neurodegenerative 
process. Indeed, a recent report has suggested that anti-inflammatory compounds can slow the 
onset of Alzheimer's disease (see Schnabel, 1993), although a detailed report has yet to be 
published.
2.4. Models of Alzheimer's disease.
One of the major lim itations in Alzheim er's disease research is the necessity to use 
postm ortem  tissue which, in effect, analyses the end point of the disease. W hile this 
approach  has estab lished  certain  characteristic  neurochem ical an d  patho log ical 
abnormalities, this strategy gives little indication of the sequence of events that lead to such 
changes. It is necessary, therefore, to develop suitable m odels which allow controlled 
investigation of various param eters known to be altered in the disease to identify the 
causative agents and explain the temporal progression of this condition. Additionally, such 
m odels would be extremely valuable in assessing the effects of therapeutic intervention. 
A lthough there has recently been significant progress in the developm ent of m odels 
representing the pathological changes associated with senile plaque and  neurofibrillary 
tangle formation, this research is still in its infancy. The majority of studies have therefore 
concentrated on the neurochemical anomalies associated with Alzheimer's disease.
The two cholinergic pathway, originating from the Nucleus basilis of M eynert complex 
(NBMC) and the m edial septal nucleus to innervate, prim arily , the neocortex and 
hippocam pus respectfully, have been the main focus of intervention to induce deficits
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characteristic of Alzheimer's disease (reviewed by Smith, 1988; Francis et al., 1992). In 
rodents and primates, several different lesion techniques have been employed: electrolytic 
lesioning; neurotoxic lesioning; and surgical transsection of neuronal circuits. Although these 
techniques are not entirely selective for cholinergic neurons, there have been significant 
improvements in the selectivity and reproducibility of lesions induced by neurotoxins. The 
m ost comm only employed agents are the excitotoxins: N-m ethyl-D aspartate (NMDA), 
kainate, ibotenate quisqualate and quinolinic acid; ethylcholine m ustard  azirid in ium  
(AF64A), a toxic analogue of choline which d isrupts the high affinity choline uptake 
m echanism  (Tamer et a lv 1992); and colchicine, which disrupts cytoskeletal elements has 
been shown to induce cholinergic denervation (Ginn & Peterson, 1992). Excitotoxins produce 
relatively selective lesions that destroy neuronal dendrites and cell bodies but spare axons 
(reviewed by M eldrum & Garthwaite, 1991). The magnitude of the lesion induced cholinergic 
deficit, as assessed by changes in choline acetyltransferase (ChAT) and acetylcholineesterase 
(AChE) activity and loss of immunopositive neurons, can vary. Factors which influence the 
degree of cholinergic denervation include the choice of neurotoxin and concentration employed 
(Rugg et al., 1992; Beal et al., 1991), the post-treatment survival period (Tamer et al., 1992), 
and lesion placem ent (Wenk et al., 1984) Similarly, m arkedly different degrees of 
cholinergic denervation are achieved by partial compared to full transsection of the fimbria- 
fomix connections (Lapchak et al., 1991b).
Investigations, conducted on animals with cholinergic brain lesions have produced evidence to 
support a disruption in the abilities of animals to learn and recall certain tasks (Gray et al., 
1990). Common techniques include the radial arm  maze, and hole boards as well as place 
navigation in the w ater m aze where rats learn the location of subm erged platform s. 
Although similar im pairm ent of cognitive function following excitotoxic lesioning of the 
medial septal area and the NBMC are reported (Arendt et al., 1989), different responses to 
the two lesion models have also been observed (Gray et al., 1990).
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Although similar impairm ent of cognitive function following excitotoxic lesioning of the 
medial septal area and the NBMC are reported (Arendt et al., 1989), different responses to 
the two lesion models have also been observed (Gray et al., 1990).
Behavioural and  neurochem ical investigations of anim als w ith induced cholinergic 
deficiency, has proved to be a useful system for exam ining the capacity of neuronal 
populations to compensate for selective denervation, and to examine the effects of various 
treatm ents on the recovery process. Lapchak et al, (1991b) dem onstrated, for example, a 
compensatory increase in hippocampal acetylcholine synthesis 3 weeks after partial fimbrial 
transsection; and Tamer et al, (1992) also conclude that the cholinergic d isruption of the 
hippocampus by AF64A is reversible.
Investigations of the integrity of receptor coupling to signal transduction systems, have been 
conducted, albeit to a limited extent. Two studies have shown that in rats lesioned at the 
NBMC, the stimulation of of phosphoinositol degredation by carbachol is comparable with 
control anim als (Scarth e t al., 1989; Raulli et al., 1989). Scarth e t al, (1989) a ls o  
dem onstrated that neurotoxic lesion of the cortex caused a m arked reduction on carbachol 
induced inositol-1-phosphate accumulation. Decreased Ga o mRNA in NBMC lesioned 
animals has been reported: the reduction was observed at 3 days post-lesion and returned to 
norm al a t 28 days (Wood & de Belleroche, 1990). Enhanced carbachol stim ulation, of 
phosphoinositide hydrolysis following electrolytic lesion of the septum  has been described 
(Connor & Harrell, 1989). A similar finding was reported following fimbrial transection 
(Smith et al., 1989), although this enhancem ent response was less m arked in aged rats 
compared to young adult rats (Court et al., 1990).
Lesions of the entorhinal cortex, which destroys the glutam atergic projection to the 
hippocam pus, (Geddes et al., 1992), have also been employed as paradigm s for Alzheimer's 
disease. Geddes and colleagues (1985) have shown that lesion of this pathw ay results in cell
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loss and a complex reorganisation of neuronal circuits. In Alzheimer's diseased brains the 
entorhinal cortex exhibits severe pathology (Hyman et al., 1987) which is likely to damage
i
the connection between the entorhinal cortex and the dentate gyrus (Geddes) et al., 1986). 
Lesions of the entrohinal cortex has also been shown to potentiate the increase in inositol 
phospholipid hydrolysis by excitatory amino acids (Nicoletti et al., 1987). Recently, Geddes 
et al. (1992) has shown that following partial lesion of the fimbria-fornix pathw ay in the 
rat, there is complex changes in the intrinsic circuitry and glutamate binding in selected areas. 
The relationship between these alterations and the changes observed in Alzheim er's disease 
is yet to be established, but future work should generate exciting information on the plastic 
response of the hippocampus to denervation.
D espite the fact that denervation m odels have provided  valuable insigh t into the 
neurochemical and behavioral changes, the failure of such models to induce the pathological 
characteristics of (3-amyloid deposition severely weakens the confidence w ith which these 
findings can be considered to reflect the Alzheimer's disease condition. Nonetheless, models 
of the pathological features are beginning to emerge. For example, transgenic mice have been 
developed which express APP protein fragments and neuropathological features associated 
w ith Alzheimer's disease (Kammesheidt et al., 1992). It has also been reported  that the 
injection of abnormally phosphorylated tau into rat brain induces filam ent form ation and 
am yloid deposition (Shin et al., 1993). Refinements of these m odels, to achieve the 
expression of selected APP fragm ents in specific brain areas, w ill g rea tly  facilitate 
Alzheimer's disease research.
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2.5 Aims of this thesis
At the onset of this study it was apparent that transmem brane signalling activities of the 
CNS, in most cases, involves G-proteins which are the first components in the intracellular 
signalling mechanism. It was also clear that a characteristic of Alzheimer's disease is the 
degeneration of certain neuronal populations, especially the cholinergic system. Thus, this 
investigation sought to establish whether the receptors are functionally coupled to G- 
proteins, and whether alterations in signal transduction dow n stream  of the receptor had 
occurred as a consequence of the disease process. It is imperative that the status of this aspect 
of cellular signalling is determ ined if, in Alzheim er's disease, effective therapeutic  




The m ajority of reagents used were of the highest grade comm ercially available and 
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Sigma Chemical Company Ltd. Poole. Dorset. UK:
Tris, ethylenedianinetetraacetate (EDTA), sodium  deoxy cholate, trichloroecetic acid, 
glycerol, am m onium  persulphate, N ^N V N '-teram ethylene-ethylenediam ine (TEMED), 
tw een-2 0 , ortho-dianosidine, diam inobenzam idine, neutral chrom atographic alum ina, 
imadazole, sodium  salt of cyclic 3'-5' adenosine m onophosphphate (cAMP), sodium  salt of 
adenosine triphosphate (ATP) sodium  salt of guanosine triphosphate  (GTP), creatine 
phosphate, creatine phospho kinase, aluminium chloride, sodium  fluoride, acetyl coenzyme 
A, acetonitrile, kalignost (sodium  tetra phenyl boron), bovine serum  album in, diethyl 
pyrocarbonate, 2-m ercaptoethanol, charbacol, baclofen, com m asie b rillian t b lue  R, 
thim erosal, ouabain, brom ophenol blue, trypsin, d ith io threito l, charcoal, folic acid, 
perchloric acid.
BDH Ltd.. Glasgow. UK :
Sodium chloride, magnesium chloride, potassium cloride, triton X-100, hydrogen peroxide, 
folic acid, coppersulphate, sodium patassium tartrate.
Fisons Ltd.. Loughborough. Leicester. UK:
Acrylamide, bisacrylamide, sodium hydroxide, sodium carbonate,
Genetic Research InstrumentationLtd.. Dumow. Essex. UK:
Fugi RX X-ray film and Saran wrap.
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Amersham International PLC. Buckinghamshire. UK:
12^1 labelled anti rabbit IgG from donkey (5-20|iCi/|a.g protein), 8 -^H cAMP (ammonium salt 
1;1 in ethanol; 30Ci/mmol), 14C-acetyl coenzyme A (60Ci/mmol), y-32p ATP (ammonium salt 
in 5mM 2-m ercaptoethanol; 3,000 C i/m m ol), y - ^ p  GTP (am m onium  salt in 5mM 2- 
mercaptoethanol; 3,000C/mmol).
Biorad Laboratories Ltd.. Hemel Hempstead. Hertfordshire, U.K:
Dowex resin (AG50W-X4 200-400 mesh), mixed bed resin (AG501-X8 20-50 mesh) and polyprep 
columns.
BRL Ltd.. Uxbridge. Middlesex. U.K:
Pre-stained molecular weight markers for Immunoblotting.
May and BakerLtd.. Dagenham. Essex. U.K:
Ethanol, methanol, acetic acid, hydrochloric acid and isopropanol.
Anderman and Co. Ltd.. Dumow. Essex.. UK:
Nitrocellulose (Schleicher and Schuel, 0.2pM)
Packard Bell. Reading. Berkshire. UK:
Ecoscint (a toluene based scintillation fluid).
Scottish Antibody Production Unit. Carluke. Lanarkshire. UK:
Norm al rabbit serum, normal sheep serum, anti-rabbit peroxidase linked sheep antisera, 
anti-mouse peroxidase linked rabbit antisera. Supplied free of charge.
3.2 Clinical details of subjects.
H um an brains used in this study were obtained postmortem w ith ethical perm ission from 
Gartnavel Royal and the Southern General Hospitals, Glasgow. The control subjects had no 
know n history of neuropathological or psychiatric illness. Alzheim er’s diseased patients 
had a clinical diagnosis of dementia that was subsequently confirmed by histopathological 
quantification of senile plaques. The autopsy criteria for diagnosis was as described by 
K hachaturian, (1985): a minimal of three areas of the neocortex was examined; w ithin a 
microscopic field of 1 mm square, patients between the age of 50-65 years m ust have a 
m inim um  of 8  senile plaques; in patients between 66-75 years, the num ber of plaques m ust 
exceed 10; any patient greater than 75 years, the senile plaques m ust exceed 15 per field. All 
samples were assayed for the activity of choline acetyltransferase (ChAT) since deficits in
i
this enzym e is a basic hallm ark of Alzheim er's disease (Perry; r 1986). Patient 
information which is of relevance to this biochemical investigation are shown on Tables la  
and lb .
3.3 Dissection of hum an brains.
At autopsy, brains were removed and transported to the Wellcome neuroscience category 2  
containment laboratory. The brain dissections were performed inside a flowhood after which 
all utensils and work surfaces were washed with chloros.
The brainstem  was removed and remaining brain tissue sliced into 1cm thick coronal sections 
from the frontal to the occipital poles. Discrete anatomical brain regions were carefully 
dissected from the left and right hemispheres of alternate brain slices. The frontal cortex 
(Brodmann area) and hippocampus (dissected out at the level of the lateral geniculate body) 
used in this thesis werer from the left hemisphere. The tissue blocks were quickly frozen by 
immersion into isopentane at -40°C then placed into sealable plastic bags and covered with
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dry ice. Tissue blocks were stored at -80 0  C until required. The remaining brain material was 
fixed in formaldehyde and used for histopathological analysis. Blocks were marked on one 
side w ith indian ink to indicate the anterior face in relation to histological sections. Blood 
samples were routinely taken and screened for hepatitis and Creutzfeldt-Jakob syndrome. 
The stored brain m aterial was only used when clearance of potential pathogens was 
confirmed.
3.4 Plaque quantification.
All histological analysis was carried out in the N europathalogical un it at the Southern 
General Hospital by Professor Graham. Tissue blocks, adjacent to the regions used for 
biochem ical analysis were fixed in 1 0 % form aline and  used  for histopathological 
examination. 28|iM thick sections were stained by Kings amyloid silver stain to identify 
neuronal plaques (Chalmers et al., 1990). Plaque numbers were counted in superficial and deep 
cortical layers and in the subiculum of the hippocampus using the Quantim et 520 analyser. 
Plaque densities were expressed as number per mm (Tables 9 and 10).
3.5 Dissection of grey and sub-cortical white matter from hum an brain tissue.
It w as in tended that the brain m aterial should be used to investigate a variety  of 
biochemical processes, but the stability of many had not been confirmed in postmortem tissue. 
Thus, every precaution was taken to minimise possible harmful physical m anipulation of the 
tissue and it was decided not to routinely dissect grey from sub-cortical white m atter since this 
w ould require thawing the material and also greatly reduce the am ount of tissue available 
for analysis. However, one control cortex sample was dissected to give some indication of the 
contribution of grey and white matter to transduction events.
A tissue block from C23 temporal cortex was placed on a petri dish on a tray of ice and allowed
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to thaw. The grey and subcortical white matter were carefully separated using a scalpel. The 
rem aining tissue was considered to be a m ixture of grey and white m atter. The grey, 
subcortical white and grey/w hite mixture were powdered on liquid nitrogen and processed for 
membrane preparation as described in the section 3..
3.6 Assay of choline acetyltransferase activity.
Analysis of choline acetyl transferase activity was based on the m ethod developed by 
Fonnum (1977). Tissue homogenates (5% weight per volume) were prepared in lOmM Tris HC1, 
pH  7.4, and ImM  EDTA as described in section 1.3. The homogenates were activated by the 
addition of an equal volume of 1% triton X-100 in 20mM EDTA and 10pl of activated 
homogenate was added to 25|il of substrate solution. The final concentration of the incubation 
mixture was; 0.2mM [14 C] acetyl CoA (approximately 125.000 dpm ), 300mM NaCl, 50mM 
sodium  phosphate buffer pH  7.4, 8mM choline bromide, 20mM EDTA (pH 7.4) and O.lmM 
physostigmine. The reaction was initiated by the addition of activated tissue homogenate. 
The tubes were incubated at 37°C. for 15 minutes, then placed on ice for 5 minutes. The reaction 
tubes were then carefully cut in half, placed in a scintillation vial and the contents washed 
out w ith 40mM chilled sodium  phosphate buffer, pH 7.4. 2 mis of acetonitrile containing 
lOmgs of kalignost and lOmls of toluene scintillation mixture were added to the vial which 




The dpm  values used in this calculation
control cortex sample tissue homogenate.
dpm  values minus assay blank (890 dpm) 
Total [*4  C] acetyl choline per tube 
Sam ple
Amount of acetyl choline per tube 
Specific activity of I4 4  C] acetyl choline 
Since lpCi=2 .22  x 10^ dpm, 
then 22,7500 dpm/2.22 x 106  
Thus, 0.102 pCi 
Cold acetyl choline
Therefore, a total of 7.2 nmoles of acetyl cl
Incubation time 
Enzyme activity
the mean of assay triplicates measured in a
22,7500 dpm  
2255 dpm
=50pCi/pmole
=0 .102  pCi of [14 C] acetyl choline 
=2.04 nmole [*4  C] acetyl choline per tube 
=0.2mM=5 nmoles per tube 
is added to each reaction tube.
=15 minutes and 45mg of protein assayed 
=2255/227500 x 7.2
=0.071nmoles/15minutes/45mg of protein 
=633 nm oles/hour/m g of protein.
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Table2(a). Information available on the control subjects.
Patien t Age PMD Storage time Sex 
(Years) (Hours) (Months)
Cause of death Drug treatmenl
C8 80 23 37 F Bronchopneumonia Thyroxine
C14 88 11 37 F Bronchopneumonia Thyroxine
Cl 5 87 12 37 F Pulmonary thromboembolism 
Renal failure/Cervical pelvic 
abscess
Diam orphine





C18 86 19 35 F Sigmoid carcinoma Diam orphine
C19A 84 7 33 F Myocardial infarction Diam orphine
C20 78 14 34 F Myocardial infarction None
C21 90 11 29 F Carcinoma of the colon None
C22 72 8 17 F NK NK
C23 74 4 19 M Peritonitus None
C24 96 3 16 F NK NK
C25 67 12 16 M Myocardial infarction None
C28 55 12 13 M NK NK
C33 92 2 10 F Bronchopneumonia Thioridazine
C34 83 6 9 F NK NK
C35 66 7 9 M Myocardoal infarction Diam orphine
C37 86 6 8 M Bronchopneumonia NK
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Table2(b). Information available on the Alzheimer's disease subjects.
P atien t Age PMD Storage time Sex Cause of death Drug treatment
(Years) (Hours) (Months)




A18 85 3 39 F Bronchopneumonia M orphine
A21 80 6 36 F Conjestive cardiac failure N K





A23 92 15 34 F Bronchopneumonia Bendrofluazide
A26 76 2 33 F Pulmonary' oedema/ 
Cardiac failure
None
A 29 97 4 31 F NK N K
A30 85 4 30 F NK N K
A33 71 8 28 F Bronchopneumonia None
A35 NK 3 28 F Bronchopneumonia T hioridazine/
O rphrenadine/
D iam orphine.





A54 84 6 13 F Respiratory failure 
Pneumonia
M orphine
A55 91 19 13 F NK N K
A56 88 16 13 F NK N K
A63 93 9 8 F Bronchopneumonia T hioridazine
Tem azapam
M orphine
A65 76 11 6 F Bronchopneumonia Diam orphine
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3.7 Human and rat brain tissue preparations.
All hum an tissue dissection and homogenate preparations were carried out in a category 2 
containment facility. The entire blocks of frozen hum an tissue were powdered in a pre-chilled 
mortar in liquid nitrogen. Alternate control and Alzheimer's disease samples were powdered, 
transferred  to a universal container and returned  to liquid  nitrogen. A liquots of 
approximately 0.5g of powdered tissue were removed for processing and the remaining tissue 
stored at -80°C. This provided a reservoir of homogeneous tissue powder thereby allowing 
repeat analysis if required. Tissue aliquots were homogenised by Polytron Homogeniser in 5 
volumes of ice chilled buffer composed of lOmM Tris/H Cl ImM  EDTA pH  7.4. lOOjil of 
homogenate solution was removed and stored at -20°C for subsequent analysis for choline 
acetyltransferase activity.
From the rem aining tissue homogenate, crude m embrane fractions were prepared by a
modification of the method described by Milligan, (1993b). Small sample preparations, that
i
required  sam ple volum es less than 2 mis, were perform ed in  a Beckman benchtop 
ultracentifuge. Homogenates were centrifuged at l ,000g Kav for 15 minutes a t 4°C to remove a 
nuclear, mitochondrial and cytoskeletal fraction. The supernatant was carefully removed and 
centrifuged at 4°C for 20  minutes at 37,000g Kay  The crude membrane pellet was washed by 
resuspension in a chilled solution of lOmM Tris/HCl and ImM  EDTA pH  7.5 followed by 
recentrifugation at 37,000g for 20 minutes. The final pellet was resuspended in chilled lOmM 
Tris/H C l pH  7.4. The membrane preparations were aliquoted and stored in 1.5ml eppendorf 
tubes at -20°C until required for biochemical analysis.
Eight control and eight Alzheimer's disease samples were prepared for the frontal cortex and 
hippocam pus studies (see table 1 for a list of the samples designated to each region). The 
control and Alzheimer's disease samples were homogenised alternately and stored on ice until 
all samples were obtained. Similarly, individual centrifugation steps such as removal of the
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supernatant, were carried out by alternating between control and Alzheim er's disease 
samples. Sample centrifugations were performed in a Bechman J21 rotor which has the 
capacity for eighteen tubes which allowed all samples to be processed at the same time thus 
eliminating batch variations.
3.8 Protein quantification.
Protein levels were assayed in duplicate by the m ethod of Lowry et al. (1951) employing 
bovine serum albumin as a standard. Protein samples were diluted to 25pl w ith distilled H2 O 
with a minimal dilution of 1 /4  required for accurate protein determination. At this dilution 
there was no interference of the sample buffer on the optical density value. 1ml of a fresh 
so lu tion  com posed of 0 .0 2 % (w eigh t/vo lum e) sodium  po tassium  ta rtra te , 0 .0 2 % 
(weight/volum e) copper sulphate and 2 % (weight/volum e) sodium carbonate, was added to 
the diluted sample and the tubes vortexed. lOOpl of Folins reagent (Sigma Ltd) diluted 1:1 
was added to each tube, the tubes revortexed and left at room tem perature for 2 0  minutes. 
Optical density values were then measured at 680nm.
3.9 Polyacrylamide gel electrophoresis.
3.9.1 Protein denaturation and alkylation.
For routine denaturation of samples, lOOpg of membrane proteins were extracted in a solution 
of 0 .1 % (weight/Volume) sodium deoxy cholate in a total volume of 1ml and precipitated on 
ice w ith  the addition of trichloroacetic acid to 5% (w eight/volum e). Sam ples were 
centrifuged briefly at lOOOg av- The pellets were neutralised by the addition of a small 
volume of 1M Tris base pH  10.8 (a 20|ll1 volume of Tris base was found to be sufficient to 
neutralise 100|ig of membrane preparation). Denaturation was achieved by adding an equal 
volume of buffer composed of bromophenol blue indicator, 5M urea, 5% dithiothreitol (DTT),
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5% sodium dodecyl sulphate (SDS) and 0.1M Tris HCI pH 8.0.
W here required, protein alkylation was carried out in a 1.5 ml microfuge tube in a total 
volume of 50pl containing 100|ig of protein in lOmM Tris, ImM EDTA, pH  7.4, buffer containing 
lOmM DTT and 5% weight/volum e SDS. Tubes were incubated at 90°C for 15 minutes then 
placed on ice for 5 minutes. 10(0.1 of lOOmM N-ethyl malanide (NEM) was added and the tubes 
incubated at room temperature for 15 minutes followed by the addition of 20p.l denaturing 
buffer. Such samples were ready for electrophoresis.
3.9.2 Denatured gel electrophoresis.
The discontinuous slab gel system ofj Laemmli(1970) was used. Resolving gels were composed 
of 12.5% acrylamide, 0.062% bisacrylamide, 0.38M Tris/H C l, pH  8.4, 0.1M SDS and 4.2% 
glycerol. Stacking gels contained 3% acrylamide, 0.08% bisacrylamide, 0.38M T ris/H C l, pH 
6 .8 , and 0.1% SDS. In both the human and rat medial septal immunoblot studies (sections 4.4 
and 4.6 respectively), control and diseased/lesioned samples were loaded onto alternate lanes 
of the gels. In addition, rat brain control preparations and prestained molecular weight 
m arkers were run  with each immunoblot. For a single gel, the protein samples were run 
through the stacker at 20mA and through the resolver overnight a t 8mA in a w ater chilled 
LKB electrophoresis apparatus.
In order to obtain reproducible resolution of the G ail and Gai2 subtypes, which are detected 
w ith the same antibody, the dye-front was ran off the gel and electrophoresis continued until 
the 18 KDal pre-stained m arker protein approached the end of the gel. Analysis of fresh 
sam ples and samples left at room tem perature confirmed that im m unopositive, small 
molecular weight proteins did not migrate off the gel as a result of this modification.
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3.9.3 Protein detection by immunoblotting (Western blotting).
Details of the primary antibodies and the dilutions employed for each are listed in Table 3. 
Proteins were transfered to nitrocellulose m em brane by a m odification of the m ethod 
described by Towbin et al. (1979). After electrophoresis, the 3% acrylam ide stacker was 
removed and the resolving gel incubated for 2 0  minutes in a chilled transfer buffer composed of 
190mM glycine, 25mM Tris and 20% methanol. The gel was then placed on top of three sheets 
of W hatman number 1 filter paper which had been pre-soaked in transfer buffer. A sheet of 
the nitrocellulose paper was soaked in transfer buffer and placed on top of the resolving gel. 
A ir bubb les w ere carefu lly  rem oved by ro llin g  a g lass p ip e tte  ov er the  
nitrocellulose/resolving gel stack. Three sheets of wet W hatman num ber 1 filter paper was 
placed on top of the stack, enclosed in a plastic holder and placed in a LKB transfer tank. 
Proteins were transferred at 75V for 3 hours in transfer buffer which was chilled by a water 
cooling system.
After transfer the nitrocellulose films were carefully removed and the non-specific binding 
sites were blocked by incubating the nitrocellulose film with T ris/salt (0.5M NaCl and 20mM 
Tris/H C l pH  7.5) containing 3% dried milk for 3 hours at room tem perature. Nitrocellulose 
sheets were then washed briefly in distilled/deionised H 2O, and incubated overnight at room 
tem perature with a primary antibody prepared in a solution of T ris/salt containing 1 % dried 
milk. Nitrocellulose sheets were then rinsed twice in T ris/salt containing 0.05% Tween 20 
each for 10  minutes.
For the detection of G « 0 / G a il  and Ga i2, and glial fibrillary acid p ro te in  (GFAP), 
nitrocellulose sheets were incubated with peroxidase linked secondary antibody (supplied by 
the Scottish Antibody Production Unit) at a 1/200 dilution in 1% dried milk in T ris/salt a t 
37°C for 3 hours at room temperature. Immunoreactive bands were visualised by the formation 
of a colour complex using 0.02% (w eight/volum e) ortho-dianosidine substrate in lOmM
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Tris/H Cl, pH  7.4, and the reaction catalysed by adding hydrogen peroxide (10ml of 30% per 
50mls of substrate solution). Analysis of G as and Gp proteins required a m ore sensitive 
technique and [125 l]-anti-rabbit Ig G (Amersham International) was used as a secondary 
antibody. Immunoreative complexes were visualised by autoradiography on FUJI RX X-ray 
film. Initial experiments were performed using normal rabbit serum as a prim ary antibody to 
confirm that the secondary antibodies did not crossreact with the proteins of interest. Some 
batches of secondary cross reacted with proteins of molecular weights approxim ately 60KDal.
Thimerosal was routinely added to antibody solutions to prevent bacterial contamination. 
The prim ary antibody solutions, and the peroxidase labelled secondary antibody solutions 
could be used for three separate immunoblot experiments without any significant effect on the 
specificity or the intensity of the immunocomplex. Fresh solutions were however employed in 
the hum an and rat semiquantitative studies.
3.9.4 Coomassie blue staining of acrylamide gels.
Gels w ere routinely stained, post transfer, by im m ersing the gels overn igh t a t room 
tem perature  in a solution of 40% (volume /volum e) m ethanol, 10% glacial acetic acid 
containing 0.1% (weight/volum e) coomassie brilliant blue (R). The gels were destained by 
several washes in 40% methanol and 10% glacial acetic acid until protein bands were visible. 
A lthough m ost of the original protein loaded on to the gel had  been transferred  to 
nitrocellulose, there remained a sufficient quantity of the high m olecular w eight stained 
proteins to permit visual comparison of the amount of protein loaded for each sample.
3.10 Densitometric analysis of immunoblots.
Densitometric analysis of both stained blots and autoradiography were perform ed using a 
Q uantim et 970 (Cambridge Instruments, Cambridge UK) computer assisted image analysis.
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Images on the blots or autoradiography were illuminated in computer controlled intensity by 
light emitted from four 24 W lamps. The images were focused by a micro zoom lens connected 
to a video camera. Immunoreactive bands were analysed by spot densitom etry and values 
expressed as optical density readings. To ensure reproducible readings, the image analyser 
was routinely calibrated using Kodak neutral density filter (O.D =0 1). Optical density values 
are the mean of two readings.
Densitometric analysis of glial fibrillary acid protein (GFAP) imm unoblots were perform ed 
on a Joyce-Loebl Chromoscan 3 system. This system generated a scanning profile w ith six 
discernible peaks. The GFAP data reported in this thesis corresponds to the peak high values 
obtained by scanning densitometry. A comparison of both densitometric m ethods concluded 
that the data generated by spot densitometric analysis of G-proteins was comparable to the 
peak height measurements by scanning densitometery.
3.11 Antisera production.
All G-protein antisera were supplied by Dr G Milligan of the Departm ent of Biochemistry, 
Glasgow University. The a  and P subunits antibodies (CS1, SG2, OC1 and BN1) were raised in 
New Zealand white rabbits against the synthetic peptides (Table 3) coupled to keyhole- 
lim pet haemocyanin by gluteraldehyde. The synthetic peptides corresponded to the various 
protein sequences: CS1 corresponded to the C-terminal decapeptide of Gas; SG2 corresponded 
to the C-terminal of transducin, which crossreacts w ith G a il/G a i2  and Gai3 (Milligan & 
Unson, 1989); OC1 corresponded to the C-terminal of Gao (Mullaney et al.j 1988) and BN1 was 
raised against the sequence corresponding to amino acid 1-10 of p i subunit (Carr et al., 1990). 
Anti GFAP antibody was purchased from DAKO limited and raised in rabbit against GFAP 
purified from bovine brain.
75
Table 3. Generation and characterisation of the antisera employed for the immunoblot 
analysis of G-protein subunits and for glial fibrillary acidic protein (GFAP).




CS1 RMHLRQYELL Gash, GcxsL 44,42 1 /2 0 0
SG2 KENLKDCGLF G ail/ G ai2 40,41 1 /2 0 0
OC1 ANNLRGCGLY Gao 39 1 / 10,000
BN1 MSELDQLRQE Gp 36 1 /2 0 0
Anti-GFAP purified bovine brain GFAP approx 55-30 1 / 2 ,000
3.12 Liquid scintillation analysis.
All isotopes were measured on a Packard 1900 CA TRI-CARB Liquid Scintillation Analyser. 
Quantification of [3 ^p] was calculated from the cpm values since the operational efficiency 
was greater than 90%. [14C] choline and [3H] cAMP cpm values were converted to dpm  using 
appropriate quench curves. For quantitation of GTPase activity (section 3.13.), 500|il of 
radioactive supernatant was mixed with 8 mls of ecosinct and counted for 4 m inutes. 
Quantification of the adenylate cyclase assay (section 3.14)required 4mls of column eluate to 
be m ixed w ith 16mls of ecoscint and counted for 4 minutes. For quantitation of [4 4 C] 
acetylcholine (section 3.5) the contents of the reaction tube was w ashed ou t w ith 5mls of 
50mM sodium phosphate buffer, then extracted from the aqueous phase by adding 2mls of 
acetonitrile containing lOmg of Kalignost followed by lOmls of toluene. The vials are left 
overnight then counted for 4 minutes.
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3.13 Assay of GTPase activity.
The analysis of GTPase activity was based on the method developed by Cassel & Selinger, 
(1976) but incorporated modifications described by others (Hilf & Jakobs, 1989; Hoss et al., 
1988). The GTPase assay was conducted in an ATP-regenerating system that inhibits both GTP 
hydrolysis by nonspecific nucleosidase and the transfer of phosphate from GTP to ATP.
All samples were assayed in triplicate and each assay included a ra t brain  m em brane 
preparation as control. The assay m edium  contained final concentrations of, 5-10pg of 
membrane protein, ImM ATP, O.lmM 5'-adenyl-imidodiphosphate (AppNHp), ImM  oubain, 
15mM creatine phosphate, 60U /m l creatine phosphokinase, 2mM dith iothreito l, 5mM 
M g C ^  lOOmM NaCl^ O.lmM EDTA, 20mM Tris HC1 (pH 7.4) and GTP a t either 0.2mM or 
O.lmM concentrations and [y 32P] GTP (60,000-80,000 cpm).
For a final assay volume of lOOpl, 20|il of membrane suspensions in a buffer of lOmM Tris/HCl 
(pH 7.4), 0.5mM EDTA were pipetted into 1.5ml microcentrifuge tubes. Each tube contained 
the following solutions prechilled on ice; 50jxl of reaction mixture, 10(4.1 of deionised distilled 
H 2 O or where applicable, 1 0 (4.1 of lOmM receptor agonist (carbachol or baclofen), and 10(4.1 
Im M  GTP. 20ml of sample buffer replaced membrane sample to determine endogenous free y  
3^P [Pi] (assay blank) and the total radioactivity per tube of each assay.
The reaction was initiated by the addition of membrane suspension, incubation was for 15 
m inutes at 25°C and was term inated by the adding 900|il of chilled 5% (w eight/volum e) 
charcoal in 20mM phosphoric acid (pH 2.5). A fresh charcoal solution was prepared each 
day. lOg of charcoal was mixed in 200mls of 20mM phosphoric acid, allowed to sediment, 
then lOOmls of 20mM phosphoric acid was removed and replaced with a fresh solution. The 
total am ount of radioactivity per tube for each assay, was determ ined by adding 900ml of 
20mM phosphoric acid (minus charcoal). Samples were kept on ice for 10 m inutes then
77
centrifuged at lOOOg av f°r 10 minutes in a Beckmans E microcentrifuge. A 500ml aliquot of the 
supernatant was removed for liquid scintillation analysis. For practical purposes, each assay 
was restricted to a maximum of 60 tubes. This assay size allowed 3 individual samples and a 
rat control to be assayed for non-specific, basal and stim ulation of basal GTPase by two 
agonists. For the hum an (section 4.4) and the medial septal lesion study (section 4.6), samples 
were assayed over three days.
Appropriate modifications were employed in preliminary experiments to characterise the 
assay of fresh rat brain preparations. To assess the contribution of the nonspecific, low 
affinity GTPase to the effect of the agonists, a final concentration of ImM  agonist was added 
to reaction tubes containing lOOmM GTP. No significant differences were observed with either 
carbachol or baclofen compared to non-stimulated samples. To exlude the possibility that 
significant hydrolysis of GTP occured on ice, the basal, stimulated and nonspecific activity 
was determined after a 15 minute incubation on ice. No significant activity was observed.
As described by Cassel & Selinger (1976), the high affinity GTPase activity can be calculated 
by subtracting the cpm values m easured with 100pM GTP (low affinity GTPase) from that 
observed with 0 .2 |iM GTP. The complete data obtained from the postm ortem  (section 4.3.3) 
hum an (sections 4.4.3 and 4.4.6.) and medial septal lesion (section 4.6.3) GTPase analyses, are 
illustrated as the total, high affinity (basal) and low affinity (nonspecific) values.
SAMPLE CALCULATION
The cpm values used in this calculation are the mean of assay triplicates m easured in 500ml 
aliquots of supernatant from a representative rat brain sample. 5pg of membrane protein was 
incubated for 15minutes.
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cpm values minus blank (105 cpm)
Total 36,530
Nonspecific 299
Basal (high affinity) 2208
Carbachol 3139
Baclofen 3029
AMOUNT OF HOT GTP PER TUBE
Hot GTP per tube 2 x 36530 cpm = 73,060 cpm
Since lpC i of [32P] GTP~2.22xl06  cpm, then 73,060/2.22xl06 = 0.032pCi
lpCi of hot GTP=0.1nmole GTP, then 0.032 |iCi=3.2pmole GTP is added.
AMOUNT OF COLD GTP PER TUBE
High affinity measurements 20 pmoles per tube
Low affinity 
Basal activity
10 nmoles per tube 
=[(2208-299)/36530] x(20+3.2)
=1.212 pmoles per 15 minutes per 5|ig of protein 
=16.16 pmoles per minute per mg of protein
Carbachol stim ulated [(3039-299) /36,530] x 23.2=1.74
=23.2 pmoles per minute per mg of protein
=23.2/16.1
=144% of basal GTPase activity
Nonspecific activity [299/36,530] x lOnmoles GTP 
=0.0818nmoles per 15minutes per 5pg 
=1.09nmoles per minute per mg of protein
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3.14 Assay of adenylate cyclase activity.
3.14.1 Adenylate cyclase catalysed production of cAMP.
A denylate cyclase activity was assayed by a m odification of the m ethod described by 
Salomon et al. (1974). The final reaction mixture was composed of 20pg of m em brane 
preparations, lOOmM Tris/H C l pH  7.5, 50mM NaCl, 5mM MgCl, ImM cAMP, 200|iM ATP 
containing lpC i of a-[3 2 P] ATP, 20mM creatine phosphate and lOOU/ml of phosphocreatine 
kinase. W here receptor-independent stimulation of adenylate cyclase was investigated, the 
reaction mixture included 10pM aluminium chloride and 5mM sodium fluoride. The reaction 
was initiated by the addition of 20pl of membrane preparation in lOmM Tris/H C l buffer and 
the tubes were incubated at 30°C for 15 minutes. In assay blanks, 20pl of lOmM Tris/H C l 
replaced the m em brane preparation. Termination of the reaction was achieved by adding 
150|il of a solution containing 2% (weight/volume) SDS, 40mM ATP, 1.3mM cold cAMP and 
[3 H] labelled cAMP (approximately 30,000 cpm) which serves as an internal standard used to 
calculate the column recovery. Assay tubes were transferred to ice for 10 m inutes then placed 
in boiling w ater bath for 10 minutes. At this stage the samples can be stored overnight at - 
20°C.
3.14.2 Separation of cAMP from ATP.
The [32P] cAMP formed was isolated on Dowex and aluminia columns. Dowex columns were 
preactivated w ith 1M HC1 then rinsed with distilled H2 O. The alum inia colum ns were 
equilibrated with 0.1M imidazole pH  7.5. 600pl of distilled H20  was added to reaction tubes 
and the total contents then loaded onto the dowex column which was w ashed with 2mls of 
distilled H20  and the eluate discarded. A further 4mls of distilled H 20  was added and the 
eluate was allowed to run into the aluminia column. Aluminia columns were washed with 1ml 
of 0.1M imidazole and initial eluate discarded. The bound fraction was eluted with 4mls of
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0.1M imidazole into vials containing 16mls of ecoscint and the radioactivity quantified by 
liquid scintillation.
SAMPLE CALCULATION








Actual sample counts 
Column recovery 













1240/2,000,000 X 20,000pmols =12.4pmoles per tube 
(12.5/15) X (1000/20)=41.66.
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3.15 Induction of postmortem interval in rat (the interval between death and freezing of 
brain tissue).
Male Sprague-Dawley rats weighing between 250-300g were used in this study. Rats were 
sacrificed by cervical dislocation and after the designated postm ortem  tim e period (zero 
hours for control animals) the anim als were decapitated and the brains were rapidly  
removed, dissected and stored at 4°C. A period of 15 minutes, between the physical cervical 
dislocation and brain removal was typical for the control ( zero hour) samples. The rats that 
were subjected to postmortem delay were therefore left a t room tem perature for 15 m inutes 
after sacrifice, then stored at 4°C for periods of 6,12,24 and 48 hours.
The brains were removed and processed as follows; the cranium  was exposed by elongated 
laceration from the back of the head to the snout, muscle and skin tissue was removed and the 
cranium carefully opened, the dura was carefully cut and the brain eased out of the skull and 
placed onto a petri dish kept on ice. Superflous blood was washed away with saline and the 
cortex, cerebellum, hippocampus and subcortical regions dissected out. Specific brain regions 
were placed into universal containers (prechilled in liquid nitrogen) and dropped into liquid 
nitrogen. Samples were stored at -80°C until required. One control brain was severely 
damaged during removal and not included in the study. In total, five animals were prepared 
for controls and all other time points consisted of three animals.
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3.16 Medial septal lesion of the rat.
Experiments were performed on male Sprague-Dawley rats (250-300g). Rats were housed in an 
environm ent of natural day /n igh t cycles and kept at 21°C. for a minimal period of 7 days 
prior to surgical intervention. Post surgery, animals were weighed and their food and water 
intake closely monitored. Any animals exhibiting signs of distress were examined by a 
veterinary surgeon and when necessary sacrificed. In this study a total of 24 animals 
underw ent surgical intervention of which three animals required to be sacrificed because of 
animal w elfare/ legislation requirements.
3.16.1 Stereotactic lesioning of rat medial septal nucleus.
Rats were placed in a perspex box into which anaethsetic gas was flowing composed of 70% 
nitro oxide, 30% oxygen and 2% halothane. Anaesthesia was m aintained during surgical 
procedure by injection i.p. of chloral hydrate (400mg/Kg) and diazepam  (2mg/Kg). The rats 
were placed in a stereotaxic frame and restrained using ear bars and an incisor bar. The scalp 
was incised, the underlying tissue retracted from the skull, and a burrhole was made anterior 
to the bregma. Buffered ibotenate or saline was injected into the medial septum  in a total 
volume of 0.6ml at the rate of O.lml/minute. The stereotoxic co-ordinates used to determine 
the injection site were 0.8mm inferior to bregma at the midline, and lowered 5.8mm below the 
surface of the dura, Horsburgh et al. (1993).
At 21 days survival rats were sacrificed by decapitation, and the brains were rapidly 
removed as described in section 4.13. The brains were placed on to a petri dish, on ice and 
sliced transversely behind the injection site. The anterior portion of the brain was fixed in 
1 0 % form aldehyde and used for subsequent histological analysis to examine the medial 
septum . Subcortical tissue was carefully removed and the hippocam pus was carefully 
dissected free from the cortical tissue, placed in a 1.5ml microfuge tube, rapidily frozen in
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isopetone -40 °C. and stored at -80 °C.
3.16.2 Histological examination of medial septum post surgery.
For haemotoxylin and eosin and cresyl violet staining, brain tissue was fixed in formal saline 
then paraffin embedded. 10pm  sections were dehydrated by incubating with xylene and 
rehydrated through a series of decreasing alcohol solutions. Formaldehyde fixed tissue was 
paraffin em bedded, and 1 0pm  microtome cut sections processed for cresyl violet and 
haemotoylin and eosin staining by the standard methods.
3.17 Immunocytochemistry of brain tissue.
The objective of this investigation was to examine by means of histological distribution to 
determine whether discrete alterations in the laminar pattern of G-protein localisation occurs 
as a consequence of neurodegeneration. Thus, the antibodies used in this study (Table 3) were 
em ployed in the immunocytochemical analysis of brain tissue. In addition, anti-GFAP 
antibody was employed since successful immunocytochemical analysis of this protein has been 
dem onstrated with postm ortem  tissue and therefore served as a antibody control. The 
following is an outline of the techniques and modification employed in this study.
Microscope slides were coated with either gelatine or 1% w eight/volum e poly lysine solution. 
10pm  thick sections were frozen on dry ice then fixed in formal saline for 30 minutes. In some 
experim ents a variety of fixation solutions (e.g.acetone, gluteraldehyde) were employed. 
Sections were dehydrated by immersion in a series of 70,90 and 100% alcohol solutions. 
Endogenous peroxidase activity of the sections was blocked by incubating in m ethanol 
containing 0.3% volum e/volum e hydrogen peroxide. Sections were then dissected ready for 
immunocytochemistry. They were washed twice for ten minutes in a solution of Tris buffered 
saline containing 0.01% volum e/volum e Triton-X 100 (TTBS). Nonspecific binding sites were
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blocked by incubating w ith normal goat serum  at a 1 / 1 0  d ilution for 1 hour a t room  
temperature. The blocking antisera was poured off and the sections incubated overnight with 
anti-GFAP prim ary antisera diluted 1/400 with 1/10 dilution of normal goat serum. Sections 
were then incubated at 4 0  C overnight. After this incubation, the sections were again washed 
twice with TTBS, then incubated for 1 hour at room temperature with horse radish peroxidase 
linked secondary antibody diluted 1/50 in Tris buffered saline before again being washed in 
TTBS for 2xl0minutes. To enhance tire immunocomplex, the sections were incubated for 1 hour 
at room  tem perature with peroxidase linked antiperoxidase antibody diluted 1/50 with Tris 
buffered saline. Immunopositive cells were visualised by incubating the sections w ith 0.5% 
diaminobenzamidine containing 0.01% hydrogen peroxide prepared in 50mM Tris/H C l, pH 
7.4, and examined microscopically to ensure that the cells were sufficiently stained. The 
sections were counterstained by immersion in haemotoxylin solution for 5 minutes and placed 
in Scotts tap water until the nucleus was stained blue. The sections were then dehydrated, 
cleared in Histoclear solution and mounted.
While GFAP staining was successful in both human and rat tissue, no convincing staining was 
obtained with any of the G-protein antibodies. Since these antibodies were raised against 
specific peptide sequences, it was likely that the epitopes were inaccessible in fixed sections. 
To try and overcome this a variety of pretreatments were tried including incubation of sections 
w ith  trypsin  (1 %), folic acid (10% volum e/volum e to neat solution) and SDS (0.1% 
w eight/volum e to 1%) and a range of fixation methods. However non of these m ethods were 
successful. Perhaps polyclonal antibodies raised against purified G-proteins are required 
since such a population of antibodies would react with various epitopes some of which may be 
exposed in tissue sections.
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3.18 Statistical analysis of data.
Statistical analysis was performed using Macintosh Statswork software programme. Sample 
groups were compared by unpaired Student's t-test where sample distribution was normal. 
Groups were considered to by significantly different a t significance levels of 5% and 1%. 
Correlation analysis was conducted by simple linear regression and significant correlations 
designated at 5% and 1% confidence level. Data generated in sections 4.3 and 4.5 were 
analysed by one way analysis of varience (ANOVA). Post hoc calculations of the statistical 
power of particular experimental designs were assessed from the following equation:
n = ~ 2  f e i - c o + e p ] 2
A
where n= number of observations in the group 
o= standard deviation 
A= difference between control and experimental group 
with the values of £ ( i  -a ) + £ p  obtained from tables of the 
inverse normal function (with typically a=5% and (3=80%)
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RESULTS
4.1 Standardisation of the immunoblot technique.
4.1.1 A ntisera characterisation.
Preliminary experiments were conducted to assess the specificity of the various antisera 
employed in this study, and to confirm the ability of these antisera to cross-react with both 
rat and hum an brain preparations. Since the pertusis toxin sensitive G-proteins G a il/ Ga i2 
and Goto have similar molecular weights of 41, 40 and 39Kd respectfully (Birnbaumer et al., 
1990), it was necessary to obtain electrophoretic separation of these proteins so that the 
specificity of the anti-Gao and  anti-Ga i antisera could be determ ined. The resolution of 
these proteins was enhanced by employing low amounts of bisacrylamide in the resolving gel 
and covalently m odifying the proteins by alkylation. F igure 1(A) dem onstrates the 
immunoblot profile of rat brain preparations analysed under these conditions. Antisera SG2 
(Table 3) reacts with two polypeptides in the expected position of the two G ai species G ail 
and Gai2. Similarly, the antisera OC1 detects one polypeptide species in the expected 
position of Gao- A solution containing both SG2 and OCl antisera at the appropriate dilution 
(1 /2 0 0  and 1 / 10 ,000  respectively) detects three immunoreactive bands corresponding to Ga il/ 
G a i2 and G ao- The SG2 and OCl antisera therefore cross-react w ith polypeptides as 
described by M illigan and Unson, (1987) and M ullaney et al. (1988) This experim ent 
dem onstrated the selectivity of the antisera and that Gao/ G a il/ and G ai2  could be detected 
w ithin the same immunoblot. Nevertheless, it was decided to analyse the G ao and G ai 
subtypes on separate immunoblots because it was probable that analysis of the hum an samples 
w ould produce variation in the relative intensities of the different proteins which could 
potentially restrict the resolution of the three protein bands.
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Normal rabbit serum failed to detect any protein bands with these preparations. However, 
antisera occasionally cross-reacted with a faint protein band at approximately 60 KDal. The 
identity of this protein remained unknown but since it had a migration distance distinct from 
the G a subunits, its presence was not considered to have any practical significance.
The anti G-protein antisera O C l, SG2, CS1 and BN1 cross-react w ith proteins of near 
identical molecular weight from membranes prepared from rat and hum an brains (Figure 
1(B)). This suggests that these antisera can detect the appropriate G-protein subunits in both 
species. However, the anti Gas antisera CS1 detects two species in hum an, Ga s L (large) and 
GotsS (small), whereas in rat, the G ash  predom inates w ith GqcsS barely visible. Thus, the 
relative am ounts of the G as subtypes varies between species. Antisera BN1, in addition to 
detecting G0, also reacts with an unknown protein at approxim ately 60 KDal which was 
detected in both hum an and rat. Subsequent analysis of grey and sub-cortical white matter 
demonstrated this protein predominates in white matter (see section 4.5.1)
W ith fresh rat brain preparations, anti glial fibrillary acidic protein (GFAP) antibody cross­
reacted with a predom inant polypeptide of approximately 55 KDal and w ith less abundant 
lower molecular weight protein bands which were just visible. W ith postm ortem  hum an 
brains however, the same antibody cross-reacted with multiple polypeptides ranging in size 
from approximately 35-55 KDal as illustrated in Figure 1(C). Densitometric analysis of the 
hum an samples using the Joyce Loebl Chromoscan 3 system  (section 3.10) detected six 
discernable peaks. Thus, the GFAP data reported in sections 4.4 and 4.5 are expressed as peak 
heights which corresponds to the polypeptides designated bands 1 to 6 .
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FIGURE 1. The immunoblot profile and selectivity of the anti G-protein antisera and anti 
glial fibrillary acidic protein (GFAP) antibody in hum an and rat membrane protein extracts.
(A) 100jig of alkylated rat membrane extract incubated with SG2 at 1/200 dilution detects 
both G ail and Gai2; 50|ig of membrane incubated with OCl at 1/10,000 dilution detects Gao- 
A m ixture of both SG2  (1/200) and OCl (1/10,000) detects G ail/ Ga i2 and Gao- (®) Both 
hum an and rat brain tissue react w ith anti-G-protein antisera; OCl (1/10,000) reacts w ith  
Gao/ SG2  (1/200 dilution) reacts with G a il and Gai2, CS1 (1/200) reacts with GasL and GasS 
and BN1 (1/200) reacts Gp subunits. In rat GasL is the major G as subtype with GasS just 
visible. Antisera BN1 in addition to detecting Gp proteins also crossreacts w ith a protein 
approxim ately 60 KDal referred to as BN1-A (artifact). (C) Immunoblots with anti GFAP 
antibody displays a multiple band appearance in humans that is distinct from protein pattern 
of rat brain. Where densitometric analysis was performed on GFAP immunoblots, the values 
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4.1.2 Linearity of the immunoblot technique.
The intensity of immunoreactive complexes detected with anti Ga o and anti Ga i sera over a 
range of protein concentrations are illustrated in Figure 2 . Densitometric measurements of the 
immunoblots are shown in Figure 3. The results demonstrate that while each antisera (OCl 
and SG2), yields a linear relationship between the protein content and optical density value, 
the relationship is however saturable. Therefore, by loading the appropriate am ount of 
m em brane protein  and routinely  em ploying rat b rain  controls the in tensity  of the 
immunocomplex generated from the membranes being investigated invariably fell w ithin the 
linear range of the technique. A similar experiment was conducted in this laboratory to 
establish the optimal amount of protein required for the detection of G as (Ross, 1992).
Antibody BN1 became available only in the latter stages of the study and the relationship 
between the intensity of the immunocomplex was not performed over the range of protein 
loaded onto the gel. However, 75pg of hum an and rat membrane protein gave 50% of the 
signal generated for 150pg of protein which would suggest that this am ount of protein 
satisfies the sensitivity requirements of the immunoblot conditions for Gp analysis.
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FIGURE 2. Im m unoblot profile of Ga  subtypes, Gao, G a il and Gai2 obtained from 
polyacrylam ide gels loaded with a range of rat brain extract (pg) and deftected with the 
indicated antisera. (A) OCl diluted 1/10,000, (B) SG2 diluted 1/200.
FIGURE 3. Densitometric analysis of immunoblots of the Goo, G ail and Gafi2 subtypes over 
a range of rat brain protein (pg) loaded onto polyacrylamide gels. (A) O C l at 1/10,000 
dilution gave a linear signal to protein relationship for Gtto UP to approximately lOOpg. (B) 
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4.2 Characterisation of the GTPase assay.
4.2.1 Linearity of the GTPase assay.
Preliminary experiments were carried out to examine the relationship between the rate of 
GTP hydrolysis, the amount of membrane protein (pg) and the assay incubation period. Figure 
4 (A) dem onstrates that with 5pg of rat brain tissue, the rate of both high and low affinity 
GTPase is linear for up  to 20 m inutes incubation period. Figure 4 (B) shows the effect of 
increasing the protein concentration on the linearity of the reaction and illustrates that the 
high and low affinity GTPase reactions are linear up to 20pg of brain extract. Therefore, with 
5-10pg of membrane protein extract the substrate concentration and the creatine phosphate 
ATP regenerating components are not limiting over 15 minutes.
4.2.2 Kinetic analysis of GTPase activity.
The kinetics of GTPase hydrolysis was analysed in whole rat brain and hum an membrane 
preparations from the frontal cortex of Alzheimer's disease sample 30 and control sample 35. 
Figure 5 illustrates the effect of GTP concentration on percent hydrolysis of [y^P ] GTP. There 
is a sharp fall in the hydrolysis of the total [y^P] GTP up to approximately 5pM GTP. Above 
this concentration the rate of hydrolysis is more gradual. This observation is consistent with 
the GTP hydrolysis profile described by Cassel and Selinger, (1976), and indicates the 
presence of two enzyme species, the high and low affinity (non-specific) GTPase, operating 
w ith differing enzyme kinetics.
By extrapolating Lineweaver Burk plot of the data as shown in Figure 5, the Vmax and Km 
values for each species (the high affinity and low affinity GTPase respectfully), can be 
estim ated (Figure 6). It should be noted however, that there are only three points of GTP 
concentrations used to estimate the low affinity activity in the hum an samples, and in any
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case the calculations are with impure enzymes. Thus, the values generated are only 
approximates. The calculated values are listed in Table 4. These values suggest that the 
kinetics for high and low affinity GTPase are comparable for rat, hum an control and 
Alzheimer's disease brain tissue. Although the Km values for the low affinity GTPase of the 
control and Alzheimer diseased samples are similar, the Vmax value obtained would appear 
to be higher for the Alzheimer's disease sample when compared with the hum an control 
sample. Similar observations were made in the hum an frontal cortex and hippocam pus 
studies (sections 4.4.3 and 4.4.6).
Table 4. Km and Vmax values of high and low affinity GTPase in membranes from rat 
brain and from the frontal cortex of Alzheimer's disease and age-matched 
control subjects.
LOW AFFINITY HIGH AFFINITY
Km(mM) Vmax Km(mM) Vmax
(pmol/min/mg) (pmol/m in/m g)
RAT 48.4 1092 0.467 39.1
Alzheimer 30 66.7 910 0.783 52.8
Control 35 52.9 789 0.756 46.3
93
FIGURE 4. The effect of assay incubation period and the amount of membrane protein 
extract from  w hole ra t brain  on the hydrolysis of GTP. (A) High and low affinity 
(nonspecific) GTPase activity measured in assays incubated for up to 60 minutes at 25° C. (B) 
High and low affinity (nonspecific) GTPase measured within a range of l-20pg of protein.
FIGURE 5. Analysis of GTP hydrolysis at concentration of 0 .02-100 |iM GTP expressed as the 
percent hydrolysis of the total [y^P ] GTP. (A) lOpg of membrane prepared the frontal cortex 
of sample C35; (B) lOpg of m embrane prepared the frontal cortex Alzheimer's disease (AD) 
sample 30; (C) 5p,g of whole rat brain sample.
FIGURE 6. Lineweaver-Burk plots of the high affinity GTPase activity (A), and low 
affinity GTPase activity (B), in  hum an control (C35), Alzheimer's diseased (AD 30) and rat 
brain preparations. Data from these experiments quantifies the magnitude of GTP hydrolysis 
at a series of GTP concentrations from 0.02 to 1.02pM GTP (A), and 5 to lOOpM GTP (B). Within 
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4.2.3 Agonist stimulation of GTPase.
The dose response stimulation of the basal high affinity GTPase activity with the muscarinic 
agonist carbachol, and the GABAb agonist baclofen was assayed in rat and hum an brain 
sam ples (Figure 7). The rat brain preparation gave stim ulation of 130-150% of the basal 
activity which was achieved routinely. The hum an samples, on the other hand, failed to 
dem onstrate the same m agnitude of stim ulation w ith  either carbachol or baclofen. 
Alzheimer's diseased sample 30 demonstrated an increase of only approxim ately 125% of 
basal while a negligible degree of stimulation was observed for the control sample 35.
Given that a requirement of GTPase activity is the presence of low concentrations of Mg^+ 
(Gilman, 1987) and that nucleotides (present at high concentrations in the assay medium) 
have a chelating capacity (Bartfai, 1979), the possibility existed that the hum an samples 
required  a specific d ivalent ion concentration for m axim um  stim ulation. This was 
investigated by conducting the GTPase assay over several concentrations of the divalent 
chelator EDTA (Figure 8 ). Maximum stimulation with carbachol and baclofen was achieved 
for the rat and Alzheimer sample 30 at O.lmM EDTA, whereas both agonists failed to 
stim ulate the control hum an sample. While it remained possible that specific perm utations 
of the selective ion concentration of the assay cocktail are required for stim ulating hum an 
GTPase activity, this experiment gave no indication that the ionic environm ent of the assay 
was the source of the poor stimulation. Subsequent analysis suggested that the interval 
between the removal and freezing of brain had a significant influence on the activity (section 
4.3.3).
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FIGURE 7. Effect of the muscarinic agonist carbachol and the GABAb agonist baclofen on 
rat and hum an brain high affinity GTPase activity. Human frontal cortex membranes (lOjug) 
from control 35 (A), Alzheimer's disease (AD) sample 30 (B), and whole rat brain membrane 
(5pg) (C) were assayed in the presence of the agonists at the concentration indicated. The 
basal GTPase activities were assayed with lOmM Tris/HCl, pH7.4, replacing the agonists in 
the assay m edium . The degree of stim ulation is expressed as the percent of basal high 
affinity GTPase activity.
FIGURE 8. The effect of EDTA concentration on the activity of high and low affinity 
(nonspecific) GTPase measured in rat brain and human control and Alzheimer's disease frontal 
cortex preparations. The high affinity GTPase was assayed in the presence and absence of 
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4.3 The influence of the interval between death and brain freezing on G-proteins.
This experiment examined the influence of the interval between death and freezing of brain 
on the stability of G-protein subunits and their high affinity GTPase activity. Rats were 
sacrificed and stored at 4°C for different time periods. The brains were then dissected and 
frozen until required (section 3.5).
4.3.1 Immunoblot analysis of the G-protein subunits Gao/ G ail, Gai2, G(3.
The effect of the interval from death to the freezing of the brains (postm ortem  interval) on 
the stability of the proteins Gao/ G ail/ Ga i2, and Gp was m easured by the formation of an 
immunocomplex. Figure 9 illustrates the immunoblot pattern obtained for (A) Ga o; CB) Ga il 
and Ga i2; (C) G p. None of the G-protein subunits analysed showed any visible sign of protein 
degradation which would have been suggested by either a decrease in the signal intensity of 
the specific protein(s), or by the appearance of low molecular w eight im m unopositive 
degradation products containing the epitope fragment. Densitom etric analysis of the 
imm unoblots are shown in Figure 10. As previously stated (section 4.1.1), the G p  antisera 
(BN1) became available at the latter stages of the project. By this time, the postm ortem  
interval samples had been stored for a prolonged period. This is likely to have contributed to 
the large variation in signal intensity for each time period when compared to the G ao and 
G a i data. However, at 48 hours the G p  proteins were still visible. Analysis of the data by 
one-way analysis of variance (ANOVA) found that for each protein m easured, there was no 
difference between the postmortem delay values when compared to the zero hour controls. 
The stability of G as over prolonged postmortem interval was confirmed in an earlier study in 
this laboratory (Ross, 1992).
This experiment demonstrated that G-proteins are not subjected to gross degradation during 
the postmortem intervals that are encountered with hum an brain material. Indeed, there was
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no significant correlation between the postmortem interval and the intensity of G-protein 
levels observed in the study of Alzheimer's disease (section 4.4.8)
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FIGURE 9. The effect of the interval between the death and brain freezing on the rat cortex 
immunoblot profile of G-proteins subunits G tt0/ Goal, Ga i2, Gp. (A) Gao of rat cortex (50|ig) 
samples stored at 4°C for 0, 6 ,12, 24, and 48 hours detected with OC1 at 1/10,000 dilution; (B) 
G ail and Ga i2 (lOOpg) detected with SG2 (1/200); (C) Gp (50pg) incubated with BN1 (1/200).
FIGURE 10. Densitometric analysis of the G-protein immunoblots of rat cortex postmortem 
interval samples (Figure 9). (A) Gtto level presented as the mean±SEM where n=5 at zero 
hour and n=3 at all other points; (B) G a il and Ga i2 level; (C) Gp. Statistical analysis by 
ANOVA failed to dem onstrate a significant difference (P>0.05) betw een the zero hour 
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4.3.2 Analysis of choline acetyltransferase activity (ChAT).
The activity choline acetyltransferase was assayed in aliquots of the homogenate fraction of 
the rat cortex postm ortem  interval samples. Figure 11 illustrates the stability choline 
acetyltransferase activity with increasing postmortem delay to brain freezing. There was a 
14% reduction in choline acetyltransferase activity at 6  hours postm ortem  com pared to the 
activity m easured in the fresh, zero hour control samples. Statistical analysis by ANOVA 
dem onstrated that the overall reduction observed did not achieve statistical significance. 
Thus, the activity of choline acetyltransferase was m inim ally affected by postm ortem  
in terval.
4.3.3 Analysis of basal and agonist stim ulation of the high affinity GTPase activity.
This experim ent dem onstrated that the period between the removal and storage of brain 
tissue had a significant effect on the activity of the high affinity basal GTPase and on the 
stimulatory capacity of carbachol and baclofen on the high affinity GTPase (Figure 1 2 ). The 
low affinity (nonspecific GTPase) activity however, was stable over the range of postmortem 
intervals investigated and this is in agreement with the findings of Nicol et al. (1981). When 
com pared to the fresh zero hour samples, the basal high affinity activity were reduced by 
50% and 56% for the postmortem interval periods of 24 and 48 hours respectively. Statistical 
analysis by ANOVA dem onstrated that these reductions were statistically significant 
(P<0.05).
This study also demonstrated that the stimulatory capacity of carbachol and baclofen of the 
high affinity GTPase activity was compromised in brains which had been left for prolonged 
periods before freezing. Carbachol stimulation was reduced from 147% of basal GTPase 
activity in fresh samples, to 124%, 116%, 112% and 108% at 6 ,1 2 , and 24 hours postm ortem  
interval respectively. Analysis by ANOVA dem onstrated that com pared to the fresh
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samples, these reductions achieved statistical significance at the 24 hour and the 48 hour 
time intervals (P<0.05). Baclofen stimulation was also reduced from 134% of basal GTPase 
activity in fresh samples to 128%, 125%, 113% and 102% at 6 , 12, and 24 hours postmortem 
intervals. Analysis by ANOVA dem onstrated that com pared to the fresh samples, the 
reduction observed for the 48 hour time point achieved statistical significant (P<0.05). Thus, 
the integrity of the G-protein coupling to muscarinic and GABAb receptors were influenced by 
prolonged delays between death and freezing of brain tissue.
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FIGURE 11. The effect of the period between death and brain freezing (postmortem 
interval) on the activity of choline acetyl transferase (ChAT) of rat cortex. Rats were 
sacrificed and the brains rapidly removed and frozen (zero hours) or stored at 4°C for 6  to 48 
hours. The activity was m easured in aliquots of the tissue homogenates from cortex dissected 
from the rat brains. The values shown are mean±SEM where n=5 for zero hour controls and n=3 
for all other postm ortem  time points. At 6  hours postmortem interval, the activity was 
decreased by 14 percent compared to the zero hour sample. This reduction failed to reach 
statistical significance (P>0.05) when the data was analysed by ANOVA.
FIGURE 12. The effect of the period between death and freezing (postmortem interval) of 
rat brain on the activities of the high and low affinity GTPase and the agonist stimulation of 
high affinity GTPase of rat cortex. Rats were sacrificed and the brains rapidly removed and 
frozen (zero hours) or removed after the rats were stored at 4°C for 6-48 hours. (A) GTPase 
activity was assayed w ith 5pg of membrane preparation and the total (high and low 
affinity), basal (high affinity) and nonspecific (low affinity) GTP hydrolysis are shown as 
mean±SEM. At zero hours n=5 and n=3 at all other postm ortem  interval time points. 
Statistical analysis by ANOVA demonstrated a significant reduction in the total and basal 
GTPase levels at 24 and 48 hours compared to the zero hour samples (where * denotes p<0.05). 
(B) The high affinity GTPase assayed in the presence and absence of carbachol(lmM) and the 
presence and absence of baclofen (ImM). The effect of the agonists is expressed as tire percent 
stim ulation of basal high affinity activity. Comparison of the zero hour values to that 
obtained for the postmortem samples by ANOVA demonstrated a significant reduction in the 
m agnitude of stim ulation by carbachol at 24 hour and 48 hour time intervals; and in the 
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4.4 G-proteins and related mechanisms in Alzheimer's disease.
In order to gain the maximum information on the effect of Alzheimer's disease on G-protein 
m ediated transduction event, crude membranes were prepared in sufficient quantities from 
each sample to perm it the analysis of a variety of G-proteins and related activities. This 
study was performed on the frontal cortex and hippocampus regions since these regions have 
been shown to be severely effected by the disease at both the neurochemical and pathological 
level. In each region studied, a group size of eight controls and eight Alzheimer's disease 
samples were chosen since this was the maximum num ber of samples that can be analysed 
within the same immunoblot. Choline acetyltransferase (ChAT) activity was also m easured 
in the same homogenate fraction from which the membranes were prepared. Therefore, the 
various measurements within each region can be compared directly.
4.4.1 Analysis of choline acetyltransferase activity in  the frontal cortex and hippocam pus.
Figure 13 illustrates the scatter distribution of ChAT activity measured in tissue homogenates 
prepared from the frontal cortex (A), and the hippocam pus (B) of eight control and eight 
Alzheimer's disease samples. In both brain regions there is a significant reduction in the 
activity m easured in the Alzheimer's disease group when compared to the control level. The 
frontal cortex activity was reduced by 47% and the hippocampus activity was reduced by 65% 
w hich is in agreem ent w ith the cholinergic deficit alm ost universally  observed in 
Alzheim er's disease.
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FIGURE 13. Choline acetyltransferase activity (ChAT) of eight Alzheimer's disease (AD) 
subjects and eight age matched control subjects measured in frontal cortex (A) and hippocampus 
(B) tissue homogenates. The activity measured in the frontal cortex was reduced by 47% in the 
Alzheimer's disease group compared to the control group sample mean. The hippocam pus 
Alzheimer's disease values was reduced by 65% compared to the mean value of the control 
group. Statistical analysis by Students t-test demonstrated that the reductions observed in 
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4.4.2 Immunoblot analysis of G-proteins in the frontal cortex.
The immunoblot profile of the Got subunits Gao/ G ail, Gai2, Ga sL, GasS and the Gp subunits, 
of eight control and eight Alzheimer's disease samples are shown in Figure 14 and the results 
of the densitometric analysis of the immunoblots is shown as scatter plots in Figure 15. Since 
antisera SG2 is raised against an epitope which is identical for both Ga il  and Ga i2 (section
3.9) then direct comparisons can be made between the level of each G ai subtype. Similarly 
both GasS and GasL are detected with the same antisera (CS1) and these subtypes can be 
compared. Figure 16. illustrates the ratio of G ail to Ga i2 and also GttsS to Ga sL.
Each G protein subunit(s) measured typically gave a coefficient of variance of between 25 to 40 
percent. This variability is similar to that encountered in m ost studies of A lzheim er's 
disease. Statistical analysis by Student's t-test failed to dem onstrate a significant difference 
in the levels of Gao/ G ail/ Ga i2, GasL and GasS m easured in Alzheimer's disease samples 
w hen compared to control samples. Similarly, the ratio of G ail to Ga i2 was not significantly 
different between the two control and Alzheimer's disease groups. The difference between the 
ratio of GasL to Ga sS observed in the Alzheimer’s samples compared to the control samples 
was found to be statistically significant when analysed by Student's t test (P<0.05).
The m ean Gp subunit level was reduced by 57 percent in the Alzheim er's samples when 
compare to the mean control values. This reduction achieved statistical significance when 
analysed by Student's t-test (P<0.05). Two factors should be considered which are relevant to 
the Gp data; first, the analysis of the GP subunit was conducted on membrane samples which 
had been stored for 10 months (section 4.1.1); second, the Gp immunoblot, Figure 14 (A), also 
detected a major band at approximately 100 KDal which w as not observed w ith  fresh 
preparations. Taken together, these factors could indicate that the frontal cortex samples 
had been subjected to proteolysis during storage. Nonetheless, the sharp intense signal of the 
BN1-A and the GP proteins suggests that these proteins have remained undegraded.
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FIGURE 14. Immunoblot analysis of G-protein subunits Goo, G ail, Gai2, GasL, Ga sS and Gp 
detected w ith  eight A lzheim er's disease and eight control frointal cortex m em brane 
preparations. (A) Gp (50pg) detected with BN1 at 1/200 dilution; (IB) G tto (50pg) detected 
w ith OC1 at 1/10,000 dilution; (C) G a il and Gai2 (lOOpg) detecfted with SG2 at 1/200 
dilution; (D) GasL and GasS (50|ig) detected with CS1 at 1/200 dilution.
FIGURE 15. Scatter distribution presentation of the densitometric analysis of the G-protein 
subunit immunoblots (Figure 14) with the mean values indicated by the  plain line (—). (A) Gp 
values. (B) Gtto values. (C) G a il and Gai2 are shown on the samte graph since both G ai 
subtypes are detected  w ith  the antisera SG2 and the values ifor each are therefore 
comparable. (D) GasL and GasS also shown on the same graph siince both detected with 
antisera CS1 . Statistical analysis by Student's t-test dem onstrated  that the reduction 
observed for the level of Gp in the Alzheimer's disease samples com pared to control levels 
achieved statistical significant (where * denotes P<0.05).
FIGURE 16. Com parison of the ratio of Ga i l /G a i2 and G a sL /G a sS  detected w ith the 
frontal cortex of eight A lzheim er's disease and eight control frontal cortex m em brane 
preparations. Both G a il and Ga i2 are detected within the same im m unoblot by antisera 
(SG2 ), similarly GasL and GasS are both detected with antisera CS1. Therefore, the level of 
each subtype can be expressed as a ratio. Statistical analysis by Student's t-test demonstrated 
a significant difference betw een the ratio of G a $L/GasS m easured in Alzheimer's disease 
samples com pared to controls (where* denotes P<0.05). The difference between the ratio of 
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4.4.3. Immunoblot analysis of glial fibrillary acidic protein in the the frontal cortex.
Glial fibrillary acidic protein (GFAP) was examined to access the contribution of both sub- 
cortical white matter and cortical astrocytes to the membrane preparations which were used 
for the investigation of signal transduction activities. The antibody used for this analysis 
detected m ultiple protein bands of between 55 and 30 KDal (section 4.1.1). Analysis by 
scanning densitometry routinely detected six peaks which are referred to as bands 1 to band 6 . 
The immunoblot obtained with this antibody is shown in Figure 17 (A) and the mean peak 
hight values (±SEM) of the six protein bands plus the sum of the six bands are presented in 
Figure 17 (B). While the mean values for each protein band and the sum of the peak heights 
were elevated in the Alzheimer’s disease samples, the differences between the control and 
Alzheimer samples failed to reach statistical significance P>0.05 (Student's t-test).
107
FIGURE 17. Immunoblot analysis of glial fibrillary acidic protein (GFAP) of eight control 
and eight Alzheimer's frontal cortex membrane preparations. (A) The im m unoblot detects 
multiple polypeptides of between 55 and 30 KDal. Scanning densitometry produced a profile 
where six peaks were clearly detected. These peaks were annotated bands 1 to band 6 . (B) 
Histogram  presentation of the mean peak heights ±SEM and of the sum  of the six bands 
referred to as the total GFAP. The differences between the measurements for the control and 
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FIGURE 17.
4.4.4. Analysis of GTPase activity in the frontal cortex.
The GTPase assay was employed to analyse the basal intrinsic GTPase activity associated 
w ith G-proteins and to assess the integrity of G protein-receptor coupling. The basal high 
affinity GTPase, low affinity (nonspecific) GTPase and total (high and low affinity) GTPase 
activities were m easured in m embrane preparations from the frontal cortex of eight control 
and eight Alzheimer's disease samples (Figure 19). Statistical analysis by Student's t-test 
dem onstrated the specific basal GTPase activity was significantly decreased (by 25 percent) 
in the Alzheimer's disease group w hen compared to the activity m easured in the control 
samples (P<0.05). In contrast, the nonspecific, low affinity GTPase activity was significantly 
increased by 34% when compared to control values (P<0.05).
The effect of the muscarinic agonist carbachol, and the GABAg agonist baclofen on the high 
affinity GTPase activity was examined. Figure 2 0  illustrated the degree of stim ulation 
achieved with each agonist with the control and Alzheimer's disease samples. The data are 
expressed as a percent of basal GTPase activity. Analysis by Student's t-test found that there 
was no significant difference between the m agnitude of stimulation (achieved by baclofen or 
carbachol) observed with the Alzheimer’s disease samples when com pared to the control 
samples. In the majority of the hum an samples, the magnitude of stimulation achieved with 
carbachol and w ith baclofen failed to reach the level of stimulation routinely achieved with 
fresh ra t brain (130 to 150 percent of the basal activity). As reported in section 4.3.3, the 
length of the interval between death and the removal and freezing of the tissue may influence 
the responsiveness of G-proteins to the agonists carbachol and baclofen. However, there was 
no correlation between the postmortem interval and the degree of agonist stim ulation of the 
basal GTPase activity (section 4.4.10).
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FIGURE 18. Scatter distribution of GTPase activity measured in membranes prepared from 
the frontal cortex of eight Alzheimer's disease and eight control samples. (A) illustrates the 
total rate of GTP hydrolysis assayed in the presence of 0.2jiM cold GTP and the specific high 
affinity basal GTPase; (B) shows the low affinity (nonspecific) GTPase activity assayed in 
the presence of IOOjiM cold GTP. The specific high affinity activity shown in (A) is  
calculated from the difference between the total and nonspecific cpm values. The basal high 
affinity GTPase activity of the Alzheimer's disease group was significantly reduced when 
compared to the control sample values by Student's t-test (where * denotes P<0.05).
FIGURE 19. Agonist stimulation of high affinity GTPase activity of membranes prepared 
from the frontal cortex of eight Alzheimer's disease (AD) and eight age matched control 
samples. The activity of the high affinity GTPase was assayed in the presence and absence 
(basal) of carbachol (ImM) and in the presence and absence of baclofen (ImM) at 0.2pM cold 
GTP. The values are expressed as the percent of basal values indicated by the dashed line (—
-). Com parison of the mean values (---- ) by Student's t  test dem onstrated that for both
carbachol and baclofen stimulation, there was no significant difference (P>0.05) between the 
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FIGURE 19.
4.4.5 Analysis of adenylate cyclase activity in the frontal cortex.
The adenylate cyclase activity of eight control and eight Alzheimer's disease frontal cortex 
m em brane preparations m easured in the presence (stim ulated) and absence (basal) of 
fluoroalum inate is show n in F igure 20. The basal adenylate cyclase activity  was 
significantly reduced in the Alzheimer's disease group by 44% (p<0.01 Student's t-test) with 
a sim ilar reduction observed for the absolute activity assayed in the presence of 
fluoroaluminate. There was no significant difference in the m agnitude of stimulation above 
the basal values by fluoroaluminate observed for Alzheimer's disease and control samples. 
Thus, the basal adenylate cyclase activity is reduced in Alzheimer's disease compared to age 
m atched control levels, yet both groups have the same capacity for receptor independent 
stimulation as assessed by fluoroaluminate.
I l l
FIGURE 20. Adenylate cyclase activity of membranes prepared from the frontal cortex of 
eight A lzheim er’s disease (AD) and eight age matched control samples. (A) Scatter 
distribution of the am ount of cAMP formed in the presence (stimulated) and absence (basal) of 
fluoroaluminate (5mM sodium fluoride and 10|iM aluminium chloride); (B) Stimulation above 
basal values of the samples expressed as percent of the basal adenylate cyclase activity. 
Statistical analysis by Student's t-test demonstrated a significant reduction in the basal 
values (where ** denotes P<0.01) of the Alzheimer's disease samples compared to activity 
in the control samples. There was no significant difference between the receptor independent 
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4.4.6 Immunoblot analysis of G-proteins in the hippocampus.
The immunoblot profile of the G a subunits Ga o/ G ail/ Ga i2, G asU  Ga sS and the Gp subunits, 
of eight control and eight Alzheimer’s disease samples are shown in Figure 21 and the results 
of the densitometric analysis of the immunoblots is shown as scatter plots in Figure 2 2 . Since 
antisera SG2 is raised against an epitope which is identical for both Ga il  and Ga i2 (section
3.9) then direct comparisons can be made between the level of each G ai subtype. Similarly 
both GasS and GasL are detected with the same antisera (CS1) and these subtypes can be 
compared. Figure 23 illustrates the ratio of Ga il to Ga i2 and also GttsS to GttsL- Statistical 
analysis by Student's t-test failed to demonstrate a significant difference in the levels of Gao/ 
G a il, Gai2, G asU  GasS and Gp measured in Alzheimer's disease samples when compared to 
control samples. Similarly, the ratio of Ga il to Ga i2 and GttsL to GttsS were not significantly 
different between the two control and Alzheimer’s disease group (P>0.05).
4.4.7 Im m unoblot analysis of glial fibrillary acidic protein in  the hippocam pus.
Glial fibrillary acidic protein (GFAP) was examined to access the contribution of both sub- 
cortical white m atter and cortical astrocytes to the hippocam pus m em brane preparations 
which were used for the investigation of signal transduction activities. Figure 24 shows the 
GFAP immunoblot (A), and a histogram presentation of the mean peak height values±SEM of 
the individual protein bands 1 to 6  (section 5.1.1, Figure 1) and the sum of protein bands 1 to 6  
(total) m easured in Alzheimer's disease and control samples. Statistical comparisons of the 
levels in Alzheimer’s disease and control samples found no significant difference (P>0.05) in 
the intensity of either the individual polypeptides bands or the sum  of the anti-GFAP 
immunoreactive polypeptides.
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FIGURE 21. Immunoblot snslysis of G-protein subunits Gqjq/ Godl, Gq}2/ Gq^L, G^gS 3nd GP 
detected w ith eight Alzheimer's disease (AD) and eight control hippocam pus m em brane 
preparations. (A) Gp (50jng) detected with BN1 at 1/200 dilution; (B) Gtto (50pg) detected 
w ith OC1 a t 1/10,000 dilution; (C) Ga il  and Ga i2  (lOOpg) detected w ith SG2  a t 1/200 
dilution; (D) G asU  GasS (50|ig) detected with CS1 at 1/200 dilution.
FIGURE 22. Scatter distribution plots of the densitometric analysis of the G-protein subunit 
immunoblots shown in Figure 21 with the mean values (—). (A) Gp values; (B), Gao/ (C) G a il, 
Ga i2 are plotted on the same graph since both Gai subtypes are detected with the antisera 
SG2 and the values for each are therefore comparable; (D) GttsL and GasS also plotted on the 
same graph since both detected with antisera CS1 . Statistical analysis by Student’s t test 
found no significant difference (P>0.05) between the levels or ratio of any of the G-protein 
subunits detected in Alzheimer's disease and control hippocampus samples.
FIGURE 23. Comparison of the ratio of G a il /G a i2  and Ga sL /G a sS detected with eight 
Alzheimer's disease and eight control hippocampus membrane preparations. Both G ail and 
Ga i2 are detected within the same immunoblot by antisera (SG2), similarly GasL and GasS 
are both detected w ith antisera CS1, therefore the level of each subtype can be expressed as a 
ratio. Statistical comparison of the Alzheimer's disease and control values by Student's t test 
found no significant difference (P>0.05) in the ratio of Ga sL/GosS or G a il/G a i2.
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FIGURE 24. Imm unoblot analysis of glial fibrillary acidic protein (GFAP) of eight control 
and eight Alzheimer's disease hippocam pus membrane preparations. (A) The immunoblot 
detects m ultiple polypeptides of between 55 arud 30 KDal. Scanning densitometry produced a 
profile where six clear peaks could be observed. These peaks were annotated bands 1 to band 
6 . (B) H istogram  plot of the m ean peak heights ±SEM and of the sum of the six bands, 
referred to as the total GFAP. Statistical comparison by Student's t-test of the GFAP 
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4.4.8 Analysis of GTPase activity in the hippocampus.
The basal high affinity GTPase, the low affinity GTPase (nonspecific) and total (high and 
low affinity) GTPase activity m easured in the hippocampal m em brane preparations from 
eight control and  eight Alzheim er's disease samples (Figure 25). Statistical analysis by 
Student’s t-test found no significant difference (P>0.05) between the total and specific basal 
GTPase activity measured with Alzheimer’s disease samples when compared to the activity 
of the control samples. However, the mean specific basal activity of the Alzheimer's disease 
sam ples were reduced by 26 percent compared to the controls which failed to achieve 
statistical significance (P=0.51).
The m ean nonspecific, low affinity GTPase values of the Alzheimer's disease group were 
increased by 55 percent from the control values. The variation about the mean of each group 
were comparable (38 and 37 percent coefficient of variance for Alzheimer's disease and control 
groups respectively) and Student’s t test demonstrated a highly significant change (p<0.01). 
A similar increase in the Alzheimer's disease nonspecific GTPase was observed in the frontal 
cortex study, however the m agnitude of the change (34 percent) was not as m arked as that 
observed for the hippocampus study.
The effect of the muscarinic agonist carbachol, and the GABAg agonist baclofen on the high 
affinity GTPase activity w as examined. Figure 26 illustrated the degree of stim ulation 
achieved with each agonist with the control and Alzheimer's disease samples. The data are 
expressed as a percent of basal GTPase activity. Analysis by Student’s t test found that there 
was no significant difference (P>0.05) between the m agnitude of stim ulation (achieved by 
baclofen or carbachol) observed with the Alzheimer's disease samples w hen com pared to the 
control samples.
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FIGURE 25 Scatter distribution of GTPase activity measured in membranes prepared from 
the hippocam pus of eight control and eight Alzheimer's disease samples. (A) illustrates the 
total rate of GTP hydrolysis assayed in the presence of 0.2fiM cold GTP and the specific high 
affinity basal GTPase; (B) shows the low affinity (nonspecific ) GTPase activity assayed in 
the presence of lOOpM cold GTP. The specific high affinity activity shown in (A) is 
calculated from the difference between the total and nonspecific cpm values. Comparisons of 
the control and Alzheimer’s disease values by Student's t-test found no significant change 
between the two groups. However, the basal specific activity was reduced by 27 percent 
which bordered of statistcal significance (where +  denotes P=0.51). The nonspecific activity 
was significantly elevated in the Alzheimer's disease group (55 percent) when compared to 
the control group (where ** denotes PcO.Ol).
FIGURE 26. Agonist stimulation of high affinity GTPase activity of membranes prepared 
from the hippocam pus of eight Alzheimer's disease (AD) and eight age m atched control 
samples. The activity of the high affinity GTPase was assayed in the presence and absence 
(basal) of carbachol (ImM) and in the presence and absence of baclofen (ImM) at 0.2|iM cold 
GTP. The values are expressed as the percent of basal values indicated by the dashed line (—
-). Com parison of the mean values (---- ) by Student's t-test dem onstrated that for both
carbachol and baclofen stimulation, there was no significant difference (P>0.05) between the 
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4.4.9 Analysis of adenylate cyclase activity in the hippocampus.
The adenylate cyclase activity of eight control and eight Alzheimer's disease frontal cortex 
m em brane preparations m easured in the presence (stim ulated) and absence (basal) of 
fluoroalum inate are shown in Figure 27. Statistical analysis by Student's t test found no 
significant difference (P>0.05) between the basal and stim ulated activity of the Alzheimer's 
disease group w hen compared to the control group. Similarly, there w as no significant 
difference (P>0.05) in the m agnitude of stimulation achieved by fluoroalum inate w hen the 
data was expressed as a percent of the basal values.
4.4.10 Linear regression analysis of hum an data.
It has been established that specific components of signal transduction mechanisms have a 
biological relationship. For example, the activation of Goes proteins leads to the stimulation 
of adenylate cyclase activity (Gilman, 1987). In this thesis, the individual param eters were 
all m easured within the same membrane samples prepared from Alzheim er’s disease and 
control tissue block. The data generated for the different parameters were analysed by linear 
regression. Additionally, factors such as the interval between death and brain freezing, age 
and period of freezer of the brains were examined. Several significant correlations were 
identified and are listed in Table 5 as a hierarchy from most significant to least significant. 
It is acknowledged that by examining the different param eters w ithin the same sample 
preparation the measurements are no longer statistically independent which weakens the 
statistical power of this analysis. Thus, although the significant correlations listed in Table 
5 are suggestive of biological relationships, the are not conclusive. Figure 28 shows examples 
of significant correlations identified in the frontal cortex and hippocampus control samples.
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FIGURE 27. Adenylate cyclase activity of membranes prepared from the hippocam pus of 
eight A lzheim er's disease (AD) and eight age m atched control samples. (A) Scatter 
distribution of the am ount of cAMP formed in the presence (stimulated) and absence (basal) of 
fluoroaluminate (5mM sodium fluoride and IOjoM aluminium chloride) with mean values; (B) 
Stimulation above basal values of the samples expressed as percent of the basal adenylate 
cyclase activity. M ean values are illustrated by a plain line (— ). Statistical analysis by 
Student's t-test found no significant difference between Alzheimer's disease and control groups 
in  e ither the basal or stim ulated adenylate cyclase activity, or in the m agnitude of 
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TABLE 5. Linear regression analysis of parameters measured in the frontal cortex (A) and 
hippocam pus of control and Alzheimer's disease samples. Significant correlations are shown 
as Pearson's correlation (r). Abbreviations: Control samples (C); Alzheimer's disease samples 
(AD); adenylate cyclase (AC); fluoroaluminate stimulate AC expressed an percent of basal 
activ ity  (percent); total adeny late  cyclase activity  assayed in the p resence of 
fluoroaluminate (absolute).
Parameter versus r P
FRONTAL CORTEX
(C) Storage (months) (C)GP 0.928 <0.002
(C) Gai2 (C) stimulated AC 0.883 <0.01
(C) Goto (O  G«i2 0.835 <0.01
(C) Gotil (C) basal GTPase 0.826 <0.02
(C) Ga i l (C) stimulated AC 0.809 <0.02
(C) Gai2 (C) basal GTP 0.792 <0.01
(C )G ao (C) basal GTPase 0.790 <0.01
(C) G«i2 (C) baclofen stimulated GTPase 0.781 <0.05
(O  Gao (C) basal AC 0.753 <0.05
(C )G ao (C) Ga i l 0.751 <0.05
(C) Gai2 (C) basal AC 0.739 <0.05
(AD) Gao (AC) GP 0.856 <0.01
(AD) Ga i2 (AC) stimulated AC (percent) 0.793 <0.02
(AD) ChAT (AC) basal AC 0.775 <0.05
(AD) Gao (AC) stimulated AC (percent) 0.765 <0.05
(AD) GTPase (AC) stimulated AC (absolute) 0.749 <0.05
(AD) Gao (AC) stimulated AC (absolute) 0.739 <0.05
HIPPOCAMPUS
(C) Gao (C) carbachol stimulated GTPase 0.939 <0.002
(C )G ao (C) baclofen stimulated GTPase 0.873 <0.01
(O  G ail (C) basal GTPase 0.853 <0.01
(C) basal GTPase (C) basal AC 0.846 <0.01
(C)Gp (C) carbachol stimulated GTPase 0.839 <0.01
(C) Gp (C) G«i2 0.795 <0.01
(C) Gtti2 (C) basal GTPase 0.758 <0.05
(C) Gao (C)GP 0.744 <0.05
(C) basal GTPase (C) stimulated AC (absolute) 0.734 <0.05
(AD) GP (AD) GTPase 0.900 <0.01
(AD) Gao (AD) GP 0.842 <0.01
(AD) Gao (AD) G«i2 0.794 <0.02
(AD) Gai2 (C) basal GTPase 0.731 <0.05
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FIGURE 28. Examples of significant correlations determined by linear regression analysis 
between various parameters measured in frontal cortex and hippocam pus preparations from 
control samples. The Pearson's correlation coefficients (r) are shown and the confidence 
intervals for P are denoted *<0.05, **<0.02, ***<0.01, ****<0.002. (A), (B), and (C) 
illustrate the correlations between GTPase and G ail, GTPase and G a il, and GTPase and Gai2 
m easured in the frontal cortex of control subjects. The correlsponding m easurem ents in 
Alzheimer's disease samples failed to achiecve statistical significance. (D), (E), and (F) 
illustrate the correlations between basal GTPase and G ail, basal GTPase and G ai2 , and basal 
GTPase and basal adenylate cyclase activity measured in the hippocam pus of control subjects. 
The corresponding measurements recorded in Alzheimer's disease samples failed to achiecve 
statistical significance except for the relationship between basal GTPase and G a il (r=0.731; 
P<0.05).
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FIGURE 28.
4.5 The distribution of G-proteins and adenylate cyclase activity in human brain
4.5.1 G-protein distribution in  cortical grey and sub-cortical white matter.
The relative amounts of the G proteins subunits Gao/ G a il, Gai2, Ga sU Ga sS Gp and glial 
fibrillary acidic protein (GFAP) in cortical grey, sub-cortical white and a mixture of grey and 
white m atter were analysed by immunoblotting. The crude membranes were prepared from 
cortical grey, sub-cortical white and a mixture of grey and white m atter dissected from a 
control hum an temporal cortex, sample number C23 (section 3.5). The immunoblot profile of 
the G-proteins and GFAP are shown in Figure 29 with the corresponding densitometric values 
shown in Figure 30.
In grey matter, the level of Gao/ G ail/ Gai2 , GasL and Gp were higher than that measured in 
sub cortical white matter. In white m atter the level of G asS and the level of the BN1-A 
artifact protein (see section 4.1.1) are more abundant compared to the levels observed in grey 
matter. In grey matter GasL is the more abundant G as subtype while in white m atter GasS is 
more abundant than GasL- A similar reversal in the predominance of the two G ai subtypes 
was observed although the altered ratio in grey and white m atter was not as marked as that 
observed for the G as  proteins. Similarly, the intensity of the six polypeptide proteins 
detected with anti-GFAP antibody in grey matter gave an inverted profile compared to that 
observed with the sub-cortical white matter sample.
4.5.2 Enzymatic activity of grey and sub cortical white matter of hum an brain.
The following enzym es were assayed in  cortical grey and  sub-cortical w hite m atter 
preparations: GTPase m easured in the presence and absence of carbachol and baclofen; 
adenylate cyclase assayed in the presence and absence of fluoroalum inate and choline 
acetyltransferase. The results are shown as histogram plots in Figure 31. The basal GTPase,
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basal adenylate cyclase, and choline acetyltransferase was m arkedly lower in sub-cortical 
white compared to grey matter. The nonspecific GTPase activity, and the percent stimulation 
of basal adenylate cyclase activity by fluoroaluminate were similar in grey and sub-cortical 
white m atter. Both agonists carbachol and baclofen failed to stim ulate the basal high 
affinity GTPase in any preparation.
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FIGURE 29. Immunoblot profile of the distribution of G-protein subunits and glial fibrillary 
acid protein (GFAP) between sub-cortical white m atter (W), a mixture of grey and  w hite 
matter (M) and grey m atter (G) membrane preparations from the temporal cortex of subject 
C23. (A) GP and BN1-A (artifact) (50|i.g) detected with antisera BN1 at 1/200 dilution; (B) 
G ao (50pg) detected with OC1 at 1/10,000 dilution; (C) G ail and Gai2 (lOOfxg) detected with 
antisera SG2 at 1/200 dilution; (D) GttsL and Ga sS (50|ig) detected with antisera SG2 at 1/200 
dilution; (E) GFAP detected with 25pg protein at 1 /2,000 dilution.
FIGURE 30. Semi-quantitation by densitometric analysis of the G-protein subunit and 
GFAP polypeptides detected by immunoblot shown in Figure 29. (A) Gp subunit; (B) Gao/ (C) 
G ail and Ga i2; (D) GasL and GasS; (E) GFAP bands 1 to 6  (section 4.1.1).
FIGURE 31. Distribution of enzymatic activity measured in sub-cortical white matter(W), 
a mixture of grey and white m atter (M) and grey matter (G) membrane preparations from the 
tem poral cortex of subject C23. (A) choline acetyltransferase activity; (B) low affinity 
(nonspecific) GTPase and high affinity basal GTPase assayed in the presence of carbachol and 
baclofen; (C) adenylate cyclase activity m easured in the presence and absence of 
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4.5.3 Regional distribution of G-protein subunits and related enzymatic activity in  hum an 
brain.
In this study, membranes prepared from five brain regions, the frontal cortex, hippocampus, 
striatum, cerebellum and pons of three control brains (C14, C19A and C34) were analysed by 
im m unoblotting and assayed adenylate cyclase activity. Due to freezer failure, aliquots 
which were reserved for GFAP and GTPase activity were considered to be no longer suitable 
for accurate and reliable biochemical analysis. The immunoblot profile of the G a subunits are ‘ 
shown in Figure 32. The Ga s  immunoblot also identified a third band in the striatum  samples 
w ith a molecular weight between that for GasL and Ga s S. This autoradiogram  was over­
exposed so that this polypeptide could be illustrated photographically (Figure 32 B). The 
data generated from densitometric analysis of the immunoblot is presented as mean±SEM in 
Figure 33. G ail and Gai2 are plotted on the same graph since both G ai subtypes are detected 
with the antisera (SG2) and the values for each are therefore comparable. Similarly, GttsL 
and GasS are also plotted on the same graph since both are detected with antisera CS1. The 
adenylate cyclase activity measured in each brain region is illustrated in Figure 34.
Statistical analysis by ANOVA dem onstrated that the level of each G -proteins were 
heterogeneously distributed between the brain regions examined. There was no significant 
difference (P>0.05) between different brain regions in the basal adenylate cyclase activity, or 
the absolute stim ulated activity (assayed in the presence of fluoroaluminate). The percent 
stim ulation of adenylate cyclase was significantly different in selected brain region (for 
example cerebellum compared to hippocampus P<0.025). The rank order of abundance of the 
various G-proteins and adenylate cyclase activity m easured in different brain regions are 
shown in Table 6 .
The different param eters were examined for biological relationships by conducting linear 
regression analysis. Significant correlations are shown in Table 7.
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FIGURE 32.. Immunoblot profile of membrane fractions prepared from the frontal cortex (F), 
hippocampus (H), striatum  (ST), cerebellum (C) and pons (P) of the three control subjects C14, 
C19A and C34. (A) Ga s L and Ga sS (50pg) detected with antisera CS1 at 1 /200 dilution; (B) 
the Goes immunoblot was exposed for three times longer than the film shown in (A). Note that 
in the striatum samples a third band is visible between G ash and GasS*; (C) G a il and Gai2 
(lOOjig) detected w ith SG2 at 1/200 dilution; (D) Gao detected with antisera OCl at 1/10,000 
dilution.
FIGURE 33. Densitometric analysis of the immunoblots shown in Figure 32. The values are 
presented as the mean±SEM of three control samples C14, C l9A and C34. Statistical analysis 
by ANOVA dem onstrated that each G-protein subunit was heterogeneously d istributed 
between the different brain regions. The abbreviations for the different regions are: frontal 
cortex (FCX); hippocam pus (HIP); striatum (ST); cerebellum (CBL); pons (PONS).
FIGURE 34. Regional distribution of basal and stimulated adenylate cyclase activity. (A) 
adenylate cyclase activity m easured in the presence and absence of 5mM sodiumfluoride and 
IOj iM  alum inium  chloride; (B) Fluoroaluminate stimulation expressed as percent of the basal 
activity. The abbreviations for the different regions are: frontal cortex (FCX); hippocampus 
(HIP); striatum  (ST); cerebellum (CBL); pons (PONS). Statistical analysis by ANOVA found 
no significant difference (P>0.05) between regions in activity m easure in the presence or 
absence of fluoroalum inate. There was however significant differences (P<0.05) between 
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TABLE 6 . The relative order of abundance of G-proteins and adenylate cyclase measured in 
five brain regions of three control human samples. The adenylate cyclase activity 
was expressed as basal (no fluoraluminate) absolute activity m easure in the 
presence of fluoroalum inate (absolute), and the m agnitude of stim ulation by 
fluoroaluminate as a percent of the basal activity (percent)
Param eter Relative order of abundance in different brain regions
G(xsL cerebellum > frontal cortex > hippocampus > striatum > pons
G(xSS cerebellum > pons > neostriatum > frontal cortex > hippocampus
G ail frontal cortex > hippocampus > striatum > cerebellum > pons
Ga i2 frontal cortex > hippocampus > striatum > cerebellum > pons
Gao frontal cortex > hippocampus > striatum > cerebellum > pons
Basal AC frontal cortex > hippocampus > striatum > cerebellum > pons
Stimulated AC
(absolute) frontal cortex > hippocampus> pons >cerebellum > striatum
Stimulated AC
(% of basal) pons > cerebellum > striatum > hippocampus > frontal cortex
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TABLE 7. Linear regression analysis of the relative amounts of G-proteins and adenylate 
cyclase measured in various hum an brain regions. The relationship between G-protein levels 
and adenylate cyclase activity was performed using linear regression analysis and shown as 
Pearsons correlation (r). Abbreviations: Total Gas refers to the sum of the optical density 
values obtained for Ga sL and GasS; Total God refers to the sum of the optical density values 
obtained for G ail and Gai2; Total PTX refers to the sum of the optical density values obtained 
for the pertussis toxin sensitive G-proteins Ga il, Ga i2 and Gtto- Basal adenylate cyclase 
refers to the activity recorded in the absence of fluoroalum inate; stim ulated adenylate 
cyclase refers to the % of basal activity achieved by fluoroaluminate.
Param eter versus r P
Gao Total Gai 0.849 <0.002
Gao Gail 0.846 <0.002
Gao Gai2 0.784 <0.002
Gao GsL/GsS 0.673 <0.01
Basal adenylate cyclase Gai2 0.791 <0.002
Basal adenylate cyclase Gail 0.765 <0.002
Basal adenylate cyclase GasL/GasS 0.696 <0.01
Basal adenylate cyclase Gao 0.599 <0.02
Basal adenylate cyclase GasL 0.517 <0.02
Stimulated adenylate cyclase Total G as/Total PTX 0.881 <0.002
Stimulated adenylate cyclase Total PTX -0.861 <0.002
Stimulated adenylate cyclase Gao -0.845 <0.002
Stimulated adenylate cyclase Total Gai -0.835 <0.002
Stimulated adenylate cyclase Gai2 -0.786 <0.002
Stimulated adenylate cyclase G aP -0.745 <0.002
Stimulated adenylate cyclase GaiS 0.535 <0.05
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4.6 The effect of medial septum lesion on signal transduction activities.
The hippocam pus receives a major cholinergic and y-aminobutyric acid (GABAergic) input 
from the the medial septal and diagonal band. Several studies have dem onstrated in rat 
that following denervation of the septal/hippocam pus pathway there is a complex neuronal 
structural and neurochemical reorganisation within the hippocampus. One of the hallmarks 
of Alzheim er's disease is a hippocampal deficit in the cholinergic marker enzyme choline 
acetyl transferase. Thus, animal models lesioned at the medial septum  can provide valuable 
inform ation on the plasticity of the hippocam pus similar to that described in Alzheimer's 
disease. In this study, the effect of denervation of the cholinergic m edial septum - 
hippocam pus pathw ay in the rat was examined by lesioning the medial septum  with the 
neurotoxin ibotenate. The group size composed of twelve lesioned and twelve sham lesioned 
(injected w ith saline) animals that served as controls. From these animals eight were chosen 
at random  for biochemical analysis since this is the maximum number (total of 16) that can be 
examined within the same immunoblot.
4.6.1 Histological and neurochemical assessment of medial septum  lesion.
The location and size of the lesion was examined by microscopic analysis of cresyl-violet 
stained sections of the medial septum. Figure 35 (A) shows a representative example of the 
histology of a control (A) and lesioned (B) animal. The lesion was localised to the medial 
septal in all animals with minimal damage to the lateral septum  and vertical diagonal band. 
In control animals (injected at the medial septum with phosphate buffered saline) there was 
minimal evidence of neuronal damage.
The activ ity  of choline acetyltransferase (ChAT) w as m easured  in h ippocam pal 
homogenates prepared from control and lesioned animals and is presented in Figure 35 (c). The 
ChAT activity was significantly reduced by 24% (P<0.01) in the lesioned animals compared
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to the control group (Student’s t-test). Sample (L3) the recorded the lowest ChAT activity, 
and in this animal the lesion area appeared larger that the other samples of the lesion group. 
Thus, the m agnitude of cholinergic deficite appears to correlate with the degree of neuronal 
damage in the medial septum.
FIGURE 35. Histological evaluation of ibotenate lesion in the medial septum. Coronal 
sections through the medial septum  were stained by with cresyl violet. (A) Control animal 
(C5): cell bodies are visible ( arrow) with minimal density of glial cells (arrow heads). (B) 
Lesioned animal (L6 ): neuronal cell bodies are absent and glial cells are present at a high 
density. Magnification = xl30. (C) Choline acetyl transferase recorded with hippocam pal 
preperations from control and lesioned animals (±SEM). The activity was significantly 
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4.6.2 Im m unoblot analysis of G-proteins in  the hippocam pus of rats lesioned at the m edial 
septum.
The immunoblot profile of the Got subunits Gao/ G ail/ Gai2, GasL and the Gp subunits of eight 
control (sham lesion) and eight lesioned animals are shown in Figure 36 . The results of the 
densitometric analysis of the immunoblots are shown as scatter plots in Figure 37. Although 
the G asS signal could not be accurately analysed densitometrically, there was no obvious 
difference between the GasS levels of the control and lesioned groups. In this study there is 
clearly no significant difference in the level of any of the subunits m easured in each group, 
which was confirmed by Student's t-test (P>0.05).
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FIGURE 36. Immunoblot analysis of G-protein subunits Goo/ Ga il, Goi2, Gosh, (Ga sS was 
ju st visible) and GP detected w ith  eight lesioned and eight control (sham  lesioned) 
hippocam pus membrane preparations. (A) Gp (50pg) detected with BN1 at 1/200 dilution; (B) 
G a o (50pg) detected with OCl at 1/10,000 dilution; (C) Ga s L, (50pg) detected w ith CS1 at 
1/200 dilution; (D) G ail and Gai2 (lOOpg) detected with SG2 at 1/200 dilution.
FIGURE 37. Scatter distribution of the values obtained by densitometric analysis of the 
immunoblots shown in Figure 36 with the mean values indicated by the plain line (—). (A) Gp 
values; (B), G ao/ (C) G a il/ Gai2 are plotted on the same graph since both G ai subtypes are 
detected w ith the antisera SG2 and the values for each are therefore comparable; (D) GttsL. 
Statistical analysis by Student's t test found no significant difference (P>0.05) between the 
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4.6.3 Analysis of GTPase activity in  the hippocampus of rats lesioned at the m edial septum.
The analysis GTPase activity was conducted in the same preparations used for the 
im m unoblot analysis. Data for the total, basal and stim ulated high affinity and the 
nonspecific GTPase was conducted in the same preparations used for the immunoblot analysis 
(Figure 38). The mean basal high affinity GTPase activity was increase by 20% in the 
lesioned group com pared to controls. The difference however failed to reach statistical 
significance with Student's t-test (P<0.05). The low affinity GTPase was also increased but 
again failed to reach statistical significance. There was no significant difference between the 
degree of stim ulation achieved with both carbachol and baclofen, although the mean 
stimulation was higher with both agonists in the lesioned group.
4.6.4 Analysis of adenylate cyclase activity in the hippocam pus of rats lesioned at the 
m edial septum.
The adenylate cyclase activity of the hippocam pus m em brane preparations from  eight 
control (sham lesion) and eight lesioned were m easured in the presence (stimulated) and 
absence (basal) of fluoroaluminate are shown in Figure 37. One sample shown on the scatter 
distribution illustration was found to exhibit abnormally low basal activity and was omitted 
from the statistical analysis. This sample was re-assayed and gave similar values. This 
sam ple showed no other abnorm ality and the cause of the low activity is unknow n. 
Statistical analysis by Student’s t test found no significant difference (P>0.05) between the 
basal and stimulated activity of the Alzheimer's disease group when compared to the control 
group. Similarly, there was no significant difference (P>0.05) in the m agnitude of stimulation 
achieved by fluoroaluminate when the data was expressed as a percent of the basal values.
This study found that following lesioning of the medial septum, there is no gross alteration in 
the level or activity of G-proteins and related activity in the hippocampus.
134
FIGURE 38. Scatter distribution of the GTPase activity measured in membranes prepared 
from the hippocam pus of eight lesioned and eight control (sham lesioned) samples. (A) 
illustrates the total rate of GTP hydrolysis assayed in the presence of 0.2pM cold GTP and the 
specific high affinity basal GTPase; (B) shows the nonspecific (low affinity) GTPase activity 
assayed in the presence of lOOpM cold GTP. The specific high affinity activity shown in (A) 
is calculated from the difference between the total and nonspecific cpm values. Comparisons 
between the activities of the control and lesioned groups by Student's t test found no significant 
difference (P>0.05) The activity of the high affinity GTPase was assayed in the presence and 
absence (basal) of carbachol (ImM) and in the presence and absence of baclofen (ImM ) at 
0.2pM cold GTP (C). The values are expressed as the percent of basal values. Comparison of 
the lesion and control values by Student's t test demonstrated that for both carbachol and 
baclofen stim ulation, there was no significant difference (P>0.05) in the m agnitude of 
stimulation.
FIGURE 39. Adenylate cyclase activity of membranes prepared from the hippocam pus of 
eight lesioned and eight control (sham lesioned animals). (A) Scatter distribution of the 
am ount of cAMP formed in the presence (stimulated) and absence (basal) of fluoroaluminate 
(5mM sodium  fluoride and lOpM alum inium  chloride) with mean values indicated by the 
plain line (—); (B) Stimulation above basal values of the samples expressed as percent of the 
basal adenylate  cyclase activity. M ean values are illustrated by a p lain  line (— ). 
Statistical analysis by Student's t test found no significant difference between the basal or 
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4.7 Summaiy of results.
The findings of this thesis are summerised in the follwing tables. Table 8  lists the results 
reported in section 4.3 which examined the effect of the interval betw een death and the 
freezing of brain tissue (postmortem interval) on G-protein levels and related activities. 
Values are expressed as mean±standard deviation (SD). Statistical analysis was conducted 
using one way analysis of varience (ANOVA) where * denotes P<0.05 and ** denotes ** 
P<0.01.
Tables 9 and 10 summerise the findings reported in section 4.4 which examined the effect of 
Alzheimer's disease on G-protein controlled signal transduction in the frontal cortex (Table 9) 
and hippocampus (Table 10). Values are expressed as the mean±SD. Statistical comparisons 
between control and Alzheimer's disease groups were conducted using Student's t-test where 
** denotes P<0.01 and * denotes P<0.05.
Table 10. summerises the findings of section 4.6. which examined the effect of medial septal 
lesion of the rat on G-protein controlled signal transduction in the hippocampus. Values are 
expressed as the mean±SD. Statistical comparisons between control (sham  lesion) and 
lesioned animals were conducted using Student's t-test where ** denotes P<0.01 and * denotes 
P<0.05.
Table 8. The effect of the interval between death and freezing of brain tissue
(postmortem interval=T) on G-protein levels and GTPase activity. Values
are mean±SD wher n=5 at T=0, and n=3 at all other time points.
Param eter T=0 hours T=6  hours T=12 hours T=24 hours T=48 hours
ChAT (nm ole/m g/hr) 
P value >0.05 >0.05 >0.05 >0.05 >0.05
jao
P value
57±11 54±7 55±3 48±10 54±5
>0.05 >0.05 >0.05 >0.05 >0.05
G ail
P value
72±6 83±5 75±3 72±4 58±15
>0.05 >0.05 >0.05 >0.05 >0.05
Gai2
P value
60±3 71±6 70±7 67±4 50±13
>0.05 >0.05 >0.05 >0.05 >0.05
Gp
P value
24±11 13±4 26±22 9±7 12±2
>0.05 >0.05 >0.05 >0.05 >0.05
Total GTPase 
P value
15.4±2.3 15.1±2 13.1±2.5 10+1.6















Low affinity GTPase 
P value
19.2+4 20.6+1.5 17.6+6 15.515 19.212.1
>0.05 >0.05 >0.05 >0.05 >0.05
Carbachol stimulated 
(% of basal GTPase)
P value
147+14 124+7 116+10 112116 108+13
>0.05 >0.05 >0.05 <0.05* <0.05*
Baclofen stimulated 
(% of basal GTPase) 
P value
134+9 128+16 125+15 113+14 10218
>0.05 >0.05 >0.05 >0.05 <0.05*
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Table 9. Summary of the results from the investigation of the effect of Alzheimer's 
disease on G-proteins in the frontal cortex. Values are mean ±SD where 
n=8 control and n =8 Alzheimer's disease samples. Statistical analysis by 
Student's t-test.
Param eter Control Alzheimers P value
Age (Years) 79±9 85±7 0.15
Postmortem delay (Hours) 10±3 11±6 0.98
Tissue storage (Months) 27±11 19±10 0.17
Plaque density/mm2 0 .1±0.1 45.7±5.5 0.0013
ChAT (nmole/m g/hour) 3.62±0.84 1.92±0.79 0 .0013
Gao 148+38 134±55 0.186
Gail 75±20 58+14 0.064
Gai2 94±16 90±18 0.578
G ail/G ai2 0.788±0.11 0.656±0.13 0.656
Gash 170±42 154±37 0.442
GasS 82±26 101±24 0.132
GasL/GasS 2.19+0.49 1.58±0.48 0.0253
GP 34±18 15±8 0.0143
GFAP band 1 30.1±14.8 71.8±88.5 0.209
GFAP band 2 18.2±9.9 54.2±75.7 0.204
GFAP band 3 32.1±28.8 97.8±85.9 0.059
GFAP band 4 55.6±43.5 124.6±87.0 0.065
GFAP band 5 64.1±71.1 132.0±72.3 0.077
GFAP band 6 79.5±66.7 133.7±87.1 0.184
GFAP total 279±193 615±453 0.075
Total GTPase 6.38±1.22 5.00±1.52 0.067
Basal GTPase 5.82±1.13 4.54±1.11 0.037:
Low affinity GTPase 
Carbachol stimulation
0.477±0.12 0.64±0.17 0.046
(% of basal GTPase) 
Baclofen stimulation
108±7 104±5 0.164
(% of basal GTPase) 114±11 105±6 0.058
Basal adenylate cyclase 
Fluoroaluminate stimulated
50.1±19.6 28.1±6.5 0.009
(% basal activity) 
Fluoroaluminate stimulated
259±31.2 246±45.8 0.510
(absolute activity) 132±53 70±20 0.009
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Table 10 . Summary of the results from the investigation of the effect of Alzheimer's 
disease on G-proteins in the hippocampus. Values are mean ±SD where 
n =8 control and n=8 Alzheimer’s disease samples. Statistical analysis by 
Student's t-test.
Param eter Control Alzheimers P value
Age (Years) 81±5 8317 0.59
Postmortem delay (Hours) 11±7 614 0.11
Tissue storage (Months) 22±13 28110 0.39
ChAT (nmole/m g/hour) 2.9±1.1 1.010.6 0 .00 1**
Plaque density/m m 2 0.2±0.5 7.917 0 .00 1**
G ao 146±20 133134 0.168
G a il 49±18 43118 0.472
G a i2 38±12 37110 0.848
G a il/G a i2 1.33±0.52 1.1810.53 0.58
G asL 133±32 154147 0.305
GasS 86±22 113139 0.225
G asL/G asS 1.05±0.45 1.4110.28 0.080
c p 25±10.1 2117.2 0.358
GFAP band 1 144±49 131134 0.536
GFAP band 2 84±30 68136 0.357
GFAP band 3 139±13 116139 0.138
GFAP band 4 141±13 131134 0.468
GFAP band 5 79±54 113147 0.202
GFAP band 6 76±62 120149 0.142
GFAP total 667±123 6811194 0.848
Total GTPase 11.9±1.7 12.014.1 0.957
Basal GTPase 10.0±1.56 7.413.2 0.051
Low affinity GTPase 
Carbachol stimulated
0.7710.29 1.9210.72 0 .0 0 1**
(% of basal) 
Baclofen stimulated
110111.2 106113.0 0.449
(% of basal) 124113.8 118117.7 0.501
Basal adenylate cyclase 51.7110.3 53.7114.4 0.755
Flouroaluminate % basal 320134 322125.6 0.936
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Table 11. Summary of the results from the investigation of the effect of partial 
denervation of the septal/hippocam pal pathway on the level and related 
activities of G-proteins in rat hippocampus.
Param eter Control Lesion P vali
ChAT (nmole/mg/hour) 22.9±1.9 17.7±2.7 0.001
G ao 42.6±2.4 40.7±4.5 0.315
G ail 66.8±9.5 68.3±9.4 0.776
G a i2 66.3±10.7 68.1±10.0 0.742
GasL 42.2±12.1 45.1±12.3 0.646
Gp 26.7±7.9 26.8±10.1 0.991
Total GTPase 14.0±3.0 16.5±2.6 0.069
Basal GTPase 9.77±2.42 11.86±2.12 0.089






(% of basal) 124±14 131±18 0.420






(% basal) 319±37 328±17 0.438
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DISCUSSION
The intensity w ith which the scientific community has pursued the aetiology of Alzheimer's 
disease has been driven by the devastating nature of this condition on the sufferer and their 
family. Furthermore, it has been estimated that in Europe as m uch as 10% of the aged 
population of 80-89 years may develop Alzheimer's disease (Rocca et al., 1991) which will 
impose a severe social and economical strain on the community. The research aims are to 
identify the significant event(s) particular to this disease so that appropriate therapeutic 
strategies can be adopted in the hope of either preventing the onset of Alzheimer's disease, or 
at least alleviate the im pairm ent of cognitive processes. By achieving these aim s the 
dependence of patients on nursing and community care should be reduced. However, effective 
therapeutic treatm ent of Alzheimer's disease cannot be realised if transduction mechanisms 
of cellular signalling are compromised. The present study was conducted to examine the 
integrity of the biochemical transmembrane signalling processes in Alzheim er's disease. 
Specifically, the in tegrity  of guanine nucleotide b ind ing  p ro teins (G-proteins) w as 
investigated. These proteins are a central control elem ent of transm em brane signalling 
systems which operate via num erous receptors to m odulate a m ultiple array of diverse 
cellular processes (for reviews see Gilman, 1987; Bimbaumer et al., 1990; Simon et al., 1991)
This thesis reports the findings of an investigation of G-protein controlled signal transduction 
activities in neurodegenerative conditions. The G-proteins were examined at various levels:
1) The coupling of G-proteins to selective receptors, specifically muscarinic and y-am ino- 
butyric acid B-type (GABAg) receptors, were assessed by analysing the response of the basal 
high affin ity  GTPase w hen challenged w ith the agonists carbachol and  baclofen. 
Additionally, the measurement of the basal GTPase in membranes assessed the collective 
activity of the various G-proteins associated with membranes in the resting, unstim ulated 
state. 2) The relative abundance of five G-proteins a  subunits G ail/ Ga i2 , Ga o/ Ga sS, G otl­
and Gp subunit were compared by the semiquantatative immunoblot technique. 3) Effector
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molecule activaty was assessed by analysing the basal and receptor independent stimulation 
of adenylate cyclase.
These analyses were performed on the frontal cortex and hippocampus of Alzheimer's disease 
and age matched control, samples. These are two regions which are associated with learning 
and memory and exhibit severe pathology in Alzheimer's disease as dem onstrated by a high 
density of plaques and tangles and by deficits in choline acetyltransferase (ChAT) (for review 
see Rossor and  Iverson, 1986; Pearson and Powell, 1989; H enderson & Finch, 1989). 
Additionally, the param eters reported in this thesis were m easured (where appropriate) 
w ithin the same m embrane preparations to eliminate possible variations which m ay be 
encountered between different batch preparations. This approach allows comparisons to be 
m ade between different param eters to establish the existence of a biological relationship. 
However, the statistical power of such comparisons is comprom ised since the different 
measurem ents are no longer considered independent. Nonetheless, the advantages of this 
strategy were considered to outweigh the statistical limitations encountered by conducting 
m ultiple analyses within the same tissue preparations.
5.1 Effect of postmortem interval on G-protein mediated signal transduction.
Each of the G-proteins and their related activities were examined for the effect of the 
interval from death to freezing of the brain to tem peratures where biological processes of 
interest are arrested (postmortem interval). This experiment dem onstrated that the subunits 
G ail/ Gai2, G ao and Gp were not subjected to gross proteolysis during prolonged postmortem 
intervals. A separate study in the same laboratory also confirmed that both species of G as 
(GasS and GosU were undegraded during prolonged postmortem intervals (Ross, 1992). Thus, 
the relative levels of G-protein subunits could be reliably analysed in hum an postm ortem  
material which is frequently subjected to extended intervals between death and the freezing 
of brain  material. The stability of the G-proteins was further supported  by the lack of
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correlation between the G-protein level and postm ortem  interval in the hum an studies 
(section 4.4.10). These findings are in agreement with Young et al. (1991) who also concluded 
that postmortem interval did not affect the immunoreactivity of G-protein subunits. In this 
laboratory, Ross (1992) also concluded that adenylate cyclase is stable over prolonged 
postmortem intervals which is in agreement with a study conducted by Nicol et al. (1981).
Although G-protein subunits and adenylate cyclase activity were stable during  prolonged 
postm ortem  intervals, the basal high affinity GTPase activity and the degree of agonist 
stim ulation of the GTPase were compromised with extended postm ortem  intervals (section 
5.3.3). The basal GTPase activity was significantly reduced a t an interval of 24 hours 
com pared to the activity of fresh material (P<0.05). The degree of stim ulation achieved 
with carbachol was significantly decreased after a postmortem interval of 24 hours (P<0.05), 
while baclofen stimulation was significantly reduced after a postmortem interval of 48 hours 
(P<0.05). To my knowledge, there have been no investigations on the effect of postm ortem  
interval on the high affinity GTPase. However, there is some evidence, albeit indirect, that 
G -protein/receptor coupling is affected by the interval between death and the storage of brain 
material. Smith et al. (1987) observed that the ability of Mg2+ (which is a requirem ent for 
G -protein/receptor interaction) to enhance carbachol binding was attenuated a t 24 hours 
postmortem interval compared to fresh preparations. Reductions in the num ber of muscarinic 
receptor binding sites with extended postmortem have also been reported (W hitehouse et al., 
1984; Syapin et al.,1987). W hitehouse et al. (1984) also observed that after a 48 hours 
postm ortem  interval, scatchard analysis ofp-aminoclonidine binding to a 2  adrenoceptors 
revealed two binding sites while only a single binding site was evident in fresh tissue. This 
could result from an alteration in the proportion in the high and low affinity state of the a 2 
adrenoceptor which is consistent with an alteration in GTPase activity.
The exact mechanism responsible for the reduced GTPase activity reported in this thesis is 
unclear. However, changes in membrane lipid composition (Farooqui & Horrocks, 1991) and
143
protein phosphorylation (Florez et al.,1991; Girault et al., 1989) during prolonged postmortem 
intervals has been shown to influence GTPase activity (Ben-Arie et al., 1988; Sauvage et al., 
1991; Bushfield et al., 1990a). Although the GTPase appears to be com prom ised w ith 
increasing postmortem interval, its analysis was considered worthwhile since the control and 
the Alzheimer’s disease samples were closely matched for postmortem delay and this enzyme 
gives an excellent insight into a central activity associated w ith G-protein function.
5.2. The partitioning of G-proteins and related activities betw een hum an grey and sub- 
cortical w hite m atter
One of the major methodological considerations of this project w as w hether the tissue 
preparations should be made from grey matter dissected free of sub-cortical white m atter or 
alternatively from the entire tissue block. For most analyses, the preparation of the entire 
tissue block was chosen since this allowed preparation of adequate m aterial for m ultiple 
analyses. This approach also eliminated the introduction of a prolonged thaw ing of the 
tissue which would then have to be re-frozen in liquid nitrogen for subsequent preparation. 
A lthough the analysis of pure grey m atter w ould reduce the variation associated with 
unequal contamination of sub-cortical white matter, it did not merit compromising the tissue 
yield or the introduction of a unnecessary, potentially d isruptive, thaw /freeze  cycle. 
Nevertheless, a pilot study was conducted to assess the partitioning between grey and sub- 
cortical white m atter of the G-proteins subunits, GTPase and adenylate cyclase activity, and 
glial fibrillary acidic protein (GFAP). Since hum an brain tissue from selected regions (frontal 
cortex and hippocampus) were limited, the measurements were conducted in  a temporal cortex 
of a control sample with minimal postmortem delay.
Of the G-protein subunits measured, Gao/ G ail, Gai2, and Gp levels were more abundant in 
grey matter than white matter, a finding which is in agreement w ith a quantitative study of 
prim ary cultures of astrocyte and neuronal cells (Brabet et al., 1988). Asano et al. (1987 &
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1990) also described a high concentration of Gao *n grey matter while minimal amounts of Gao 
was observed in white. The distribution of these proteins is consistent w ith their role in 
synaptic transmission.
The present study also showed that in sub-cortical white m atter the ratio of G asL /G a sS was 
inverted compared to grey matter. Although Jones et al. (1990) reported that both Gtts species 
exhibited similar biochemical properties, others have suggested that the two G as species 
have different efficacy for adenylate cyclase in selected cell cultures (Walseth et al., 1989). 
A similar reversal in the ratio of the Ga i species was evident (Ga i2 more abundant in grey 
and G a il predom inating in white matter) although not as m arked as that observed for the 
G as subtypes. The inverted G-proteins ratio in grey compared to sub-cortical white m atter 
could reflect the different signal transduction requirements of neurons and glia cells. Indeed 
differential coupling of muscarinic and adrenergic receptors to the phosphoinositol and 
adenylate cyclase pathw ays have been described for neurons com pared to glia cultures 
(Wilson et al., 1990; Atkinson & Minneman, 1991).
H igher activities of the enzymes choline acetyltransferase (ChAT), GTPase and adenylate 
cyclase in  grey m atter again reflects their role in neurotransm ission. The high affinity 
GTPase activity would be expected to parallel the G-protein distribution, particularly G ao 
since this is the most abundant protein in the CNS (Brabet et al., 1988; Asano et al., 1990). 
The low affinity nonspecific GTPase activity was m arginally increased in  w hite m atter 
compared to grey. This may reflect axonal or astrocytic activity associated with cytoskeletal 
proteins polymerisationj (Carlier and Pataloni, 1981; Shpetner and  Vallee, 1992). As 
discussed previously (section 5.1), the lack of stimulation of the basal GTPase by carbachol 
and baclofen may be due to a contribution of the effects of the postm ortem  interval, aging 
(Villalobos-Molina et al., 1992; Yamagami 1992) and alterations in the lipid bilayer (Ben- 
Aire et al., 1988). The higher activity of adenylate cyclase in grey m atter compared to sub- 
cortical white is in agreement with Ebersolt et al. (1981) and with the forskolin binding (as a
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m easure of activatable adenylate cyclase) study of Poat et al. (1988). The m agnitude of 
stimulation by the receptor independent activator, fluoroaluminate, was comparable for grey 
and sub-cortical white matter (260% of basal activity). Thus, the difference in Ga sL /G a s S 
ratio does not alter the maximal stimulatory capacity of these proteins for adenylate cyclase. 
In fact the sum of the densitometric values for GasL and GasS in grey and in w hite matter 
were approximately equal. This suggests that fluoroaluminate action on Ga s L and Ga sS is 
addative.
The GFAP immunoblot detected multiple protein bands in grey and sub-cortical white matter. 
The presence of multiple GFAP bands has been described in rat brain and suggested to be the 
result of calcium dependent proteolysis (De Armond et al., 1983). A similar m ultiprotein 
pattern (which was proposed as a proteolytic event) has been described in rats that were 
protected from N-methyl-D-aspartate (NMDA) induced neurodegeneration by the antagonist 
MK801 (Haglid et al., 1991). In this thesis there was also a striking reversal in the GFAP 
protein pattern observed in grey compared to sub-cortical white matter. The lower molecular 
weight species being more abundant in the white matter fraction which also has higher total 
content of GFAP positive proteins (Figure 29). The different GFAP patterns m ay reflect 
different dynamics of microtubule assembly and GFAP turnover in the astrocyes present in grey 
compared to sub-cortical white matter.
The studies in this thesis demonstrated a higher density of G-proteins and their related 
enzymatic activity in grey matter compared to sub-cortical white m atter. This is consistent 
with these proteins having a central role in neurotransmission and therefore localised within 
synaptic-rich grey matter. The presence of these components at a low er density  in white 
m atter is probably associated with glia cell activity although contribution of axonal content 
should not be overlooked.
5.3. Regional distribution of G-proteins and adenylate cyclase in the human brain.
Several studies of rat brain have been described which examined the relative distribution of 
various G-proteins such as Gao (Worley et al., 1986a), Gai (Asano et al., 1990) G as (Largent et 
al., 1988) and of adenylate cyclase (Poat et al., 1988; Gehlert, 1986; Xia et al., 1991). 
However similar studies, conducted on hum an brains, have been limited (Bergstrom et al., 
1991; Mengod et al., 1988; De Keyser et al., 1988). Furthermore, there has been no systematic 
study which has examined G-proteins and adenylate cyclase activity in tandem. The study in 
this thesis was conducted to examine the relative abundance of five G-proteins (Ga il, Ga i2 , 
G a o  GasS and GttsL) and adenylate cyclase activity in discrete brain regions of control 
hum an brains. Additionally, since these param eters w ere analysed w ith in  the same 
m em brane preparations, the protein levels and enzymatic activity could be com pared to 
determine whether any putative relationships were evident.
The rank order for the abundance for G ao *n different regions of hum an brain (Table 6 ) 
paralleled that for G ail and Gai2. The order of abundance of Gao/ G a il and Gai2 is similar 
to that described for rat brain (Asano et al., 1990). However, Asano et al. (1990) concluded 
that in all regions examined, Ga i2 was m arkedly more concentrated than  Gail* The 
discrepancy between the findings of the study in this thesis compared to that of Asano et al. 
(1990) may be due to species differences. Indeed, the ratio of the G as species is dissimilar in 
rat brain when compared to hum an brain (Granneman & Bannon, 1991). Alternatively, the 
discrepancy between the G ai ratio described in this thesis compared to the findings of Asano 
et al. (1990) m ay be due to different methodology. Asano et al. (1990) used seperate antisera 
for each G ai analysed whereas this study employed an  antisera (SG2) which w ould 
theoretically be equally reactive for the two Gai species since it had been generated against a 
common epitope (Milligan & Unson, 1989).
The rank order for G ao and both Ga i subtypes parallels the basal GTPase activity m easured
147
in rat (Ghodsi-Hovsepian et al., 1990) and hum an brain (Franklin & Hoss, 1984). Given that 
Goto and Gai are thought to be the most abundant species of G-proteins in brain (Brabet et al., 
1988; Asano et al., 1990), these proteins (particularly Gtto) may be the major contributor to the 
basal activity of GTPase. Worley et al. (1986b) has dem onstrated a similar distribution for 
protein kinase C (PKC) which may involve G ao and G ai/ although Gq has recently been 
implied as the prim e controller of this effector via phospholipase C (Camps et al., 1992). 
Indeed, the regional distribution of Gq is similar to that reported for PKC (Worley et al., 
1986; Milligan, 1993).
The two Gas/ gave a rank order of abundance in different brain regions which was distinct 
from that observed for G ao and G ai proteins w ith the highest levels recorded in the 
cerebellum (Figure 33). In addition, there was a reversal in the ratio of Ga sL /G asS  in the 
striatum, cerebellum and pons when compared to the frontal cortex and hippocampus. Unlike 
Gao and Gai/ the distribution of Gas protein in brain has been poorly documented. Analysis of 
the mRNA by in situ hybridisation for Gtts has been described by Largent et al. (1988) who 
found significant staining in the rat cortex, hippocampus and cerebellum whereas the striatum 
exhibited low levels. Mengod et al. (1988) reported the highest G as mRNA levels to be in the 
hum an cerebellar granular layers. Additionally, high Gtts mRNA levels were found in the 
hippocampus and cortex with lower levels in the brainstem. Although the G as mRNA levels
i
does not necessarily parallel the protein levels (Walseth et al., 1989; Granneman et al.,| 1990), 
these studies would agree with the protein distribution pattern described here. Granneman 
and Bannon (1991), employed the polymerase chain reaction (PCR) to examine G as mRNA as 
a proportion of total G as mRNA in hum an brain and found that in the striatum GasS mRNA 
was ~35% of total Gtts mRNA whereas the cortex and hippocam pus expressed only ~20% of 
G asS mRNA compared to total G as mRNA. However, one of the lim itations of the PCR 
technique is that it is not quantitative since there m ay be different efficiencies of 
amplification for separate substrates. Cooper et al. (1990) has shown that G as m rat striatum 
is predominantly GasS whereas GttsL is the major species present in the rat cerebellum. Since
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the protein levels reported in this thesis do not parallel the relative proportion of GqcsL to 
GasS observed by Cooper et al. (1990), this would support the suggestion made by Granneman 
et al. (1990) and Copper et al. (1990) that these proteins maybe differentially transcribed and 
perhaps have distinct turnover rates.
An interesting observation of this present study was that the immunoblot of the Ga s  subtypes 
with antisera CS1, (see Table 3), revealed a third protein band with a molecular weight that 
was intermediate to those for Ga sL and Ga sS (Figure 32). This protein was detected in the 
three striatum  samples but not in any other samples. It could be speculated that the third 
protein band represents an additional G<xS protein subtype. Indeed, a third Ga s  isolated 
originally from olfactory tissue (Jones & Reed, 1989) and referred to as G aolf has a similar 
molecular weight to the protein detected with CS1. The Ga o if protein has a high degree of 
sequence homology with the other G aS subtypes (Jones et al., 1990) and can be detected with 
the CS1 antibody (Milligan unpublished observation). The mRNA encoding G aolf protein 
has been identified in the striatum and reported to be ten times the level of Gtts mRNA 
(Drinnan et al . , 1 1991). A recent report has confirmed that striatum  and substantia nigra 
contain significant levels of G aolf protein (Herve et al., 1993). Taken together, these 
observations would suggest that the immunoreactive protein band detected in the striatum  
region with CS1 antibody is the Gaolf protein. Also, a novel adenylate cyclase mRNA has 
been identified in the rat striatum and termed A C st (Glatt & Snyder, 1993). W hile the 
mRNA for A C st is concentrated in the striatum, type I, II, and III adenylate cyclase mRNA 
were not detected (Glatt & Snyder, 1993). Additionally, the sensitivity of adenylate cyclase 
to stim ulation by forskolin and inhibition by acetylcholine is different in ra t cortex when 
com pared to rat striatum  (Dokas & Ting, 1993). Taken together, these findings could be 
interpreted to suggest that within the striatum  G aolf and the putative adenylate cyclase 
A C st rnay interact in a specific manner to meet the cAMP requirements of the neurons of the 
striatal areas. This may be reflected by atypical dopamine binding and G-protein coupling 
characteristics which has been reported to occur within this tissue (De Kyser 1989b, Sidhu et
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al., 1991).
The regional distribution of adenylate cyclase was heterogeneous and exhibited a rank order 
which paralleled the Gao and Gai distribution; the highest activity was found in the frontal 
cortex followed by the hippocampus, striatum, cerebellum and then the pons (Figure 34). This 
pattern agrees, in general, with that described in rat brain for type 1 (Calmodulin sensitive) 
adenylate cyclase (Xia et al., 1991), although the highest staining was noted to occur in the 
cerebellum. A distribution pattern for hum an brain adenylate cyclase, comparable to the data 
described in this present study was reported by Bergstrom et al. (1991). However, Bergstrom 
et al. (1991) found the highest adenylate cyclase activity to be in the cerebellum. Bergstrom 
et al. (1991) adopted conditions which were optimal for examining receptor m odulation by 
including lOpM GTP in their reaction solution. Thus, the difference in cerebellum activity, 
compared to the results reported in the present study, may be due to different methodological 
conditions.
The basal adenylate cyclase activity is thought to be controlled by the balance between the 
G as and  G as activities (Katada et al, 1984a & 1984b; Gilman, 1987). In the present study 
however the basal activity of adenylate cyclase paralleled the regional d istribution of Ga i 
proteins but not the G as proteins (Figure 32). This suggests that under resting unstim ulated 
conditions, G ai has a more potent effect on adenylate cyclase than the G as proteins. This was 
supported by linear regression analysis which revealed a strong correlation w ith the G ai 
proteins measured in all samples versus the adenylate cyclase activity in the samples (Table 
6 ). W hile the individual G as proteins failed to correlate w ith basal activity, a significant 
correlation with the ratio of G as^ /G asS  with basal adenylate cyclase was observed. This 
suggests that in the resting state, the relative proportion of GttsL to GasS, rather than the 
level of the individual proteins, exert the stim ulatory inpu t on basal adenylate cyclase 
activity. A similar proposal was suggested by Granneman et al. (1990). Alternatively, the 
optimal G asL/G asS ratio requirement of different regions may be governed by the proportion
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of the calmodulin sensitive to calmodulin insensitive forms of adenylate cyclase (Cooper et 
al., 1990).
The receptor independent stimulation of adenylate cyclase by fluoroalum inate gave an 
inverted rank order compared to the basal activity of the enzyme. Gelhert (1986) observed a 
similar regional pattern of adenylate cyclase levels in rat when fluoroaluminate was used to 
enhance forskolin binding (as a marker for of activatable adenylate cyclase). It has been 
dem onstrated that fluoroaluminate treatment is capable of activating God (Inoue et al., 1990), 
Gq (Fisher et al., 1993) as well as Ga s . Thus, the inverse relationship betw een the basal 
adenylate cyclase and the magnitude of stimulation of adenylate cyclase by fluoroaluminate 
may be due to activation of the G ai proteins which dom inate the activity of Gas* This 
proposal is supported by the strong negative correlation between Ga i protein levels and the 
m agnitude of stimulation of adenylate cyclase by G ai subtypes (section 4.5.3, Table 7). This 
may be achieved by direct inhibition of the enzyme by G ai or indirectly by contributing free 
pY complexes (Tang & Gilman, 1991; Taussig et al., 1993).
Linder et al.! (1990) hypothesised that the supply of free Py complexes can inhibit adenylate 
cyclase activity by binding to and inactivating the free Gtts proteins. If this was the case, the 
G ao protein, which is the most abundant G-protein in brain, would be able to influence the 
activity of adenylate cyclase by modulating the levels of free Py dimers. Indeed, there was a 
strong correlation between Gtto anc* the m agnitude of stimulation of adenylate cyclase by 
fluoroaluminate (r=0.841; P<0.002).
In conclusion, this study has demonstrated a heterogeneous distribution of five G-proteins 
G ao/ Gai^/ Gai2, GasS and G ash and adenylate cyclase in the the hum an brain. In general, 
the highest levels of these parameters were observed in cortex and hippocam pus. This is in 
general agreement with the distribution of adrenergic (Joyce et a ljl9 9 1 ;; De Vos et al., 1992)
151
and muscarinic receptors (Levey et al., 1991) and is consistent with their role in learning and 
memory (Xia et al., 1991). This study also suggests that adenylate cyclase regulation in  the 
striatum  is distinct from other brain regions. Furthermore, these results suggest that the basal 
and stim ulatory adenylate cyclase response is controlled by the balance betw een the 
stim ulatory and inhibitory G-proteins although G ao is also implicated. Finally, these 
results may be suggestive of the cross-talk which exists between the different G-proteins and 
different signalling pathways.
5.4 Analysis of G-protein mediated signal transduction activities in Alzheimer's disease.
5.4.1 Analysis of G-protein levels
In an original study of a small sample size (n=6 ) the levels of Got subunits were found to be 
robust in Alzheimer's disease brain regions compared to controls (McLaughlin et al., 1991). 
Considering the heterogeneous nature of Alzheim er's disease and  the variability  of 
biochemical measurements, increasing the sample size may help to detect subtle changes in 
the measurments in Alzheimer's disease compared to controls. Therefore, in the present study, 
the group size consisted of eight samples. Although, in this followup study Got subum it levels 
rem ained unchanged, a significant difference was observed in the frontal cortex between the 
ratio of the Gots subtypes GotsS/Ga s L in Alzheimer's disease com pared to controls. The 
samples used in present study, were assayed for sodium /potassium  dependent ATPase, which 
is a m arker for plasma membrane (Begin-heick, 1990) and were similar for Alzheim er's 
disease and control samples (Ross, 1992). Thus, the membrane preparations of Alzheimer's 
disease and contol samples were of a similar purity. Additionaly, the GFAP immunoreactive 
proteins levels were analysed which served as a marker for astrocytes. A lthough the levels 
of the individual GFAP bands were elevated in the frontal cortex Alzheim er's disease 
samples, the difference between Alzheimer's disease and control measurements did not reach 
statistical significance. Thus, while the increased levels of GFAP protein bands m ay reflect 
the process of reactive gliosis which occurs in Alzheimer's disease (Duffy et al., 1980; Beach 
et al., 1989), the dilutional effect on the m embrane preperations by astrocytes was not 
significant.
The investigation of this thesis strongly suggests that alteration in the Got subunit level is not 
a central feature of A lzheim er's disease. Nonetheless, it is conceivable tha t subtle 
alteration, beyond the sensitivity of the immunological detection approach employed here, 
would have significant functional consequences. Indeed modest reductions of 10-15% in the
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pertussis toxin (PTX) sensitive G-proteins (Gao  and Ga i) have been shown to induce m arked 
changes in membrane ion channel activity (Innes et al., 1991). However, PTX catalysed ADP- 
ribosylation of G-proteins is believed to prefer the heterotrimeric confirmation of G-proteins 
and m ay therefore reflect the proportion of the inactive G-protein complex (Katada et al., 
1986) rather than the absolute amount of the G a subunit. Indeed, following an ischaemic 
insult in rat brain there was a reduction in the level of the PTX labelled G-proteins, while 
immunoblot analysis found the level of Gai and Gao were preserved (Takenaka et al., 1991). 
These authors proposed that this disparity was due to a reduction in the free GDP bound G a 
PTX sensitive proteins since addition of free Py complexes failed to restore the ADP 
ribosylation level to that achieved in the non-ischaemic animal.
H arrison et al. (1991) dem onstrated, by in situ hybridisation, that Ga s  mRNA in the 
hippocam pus and temporal cortex were significantly increased in Alzheimer's disease. This 
suggests that an increased rate of transcription of the G as Is required to m aintain the G as 
protein levels. Alterations in G as mRNA levels to preserve to protein corresponding protein 
levels have been observed in the adipocytes of rats which were exposed to cold tem peratures 
(Granneman et al., 1990). In another study, Ross et al. (1992) found no significant alteration in 
mRNA for Gtts *n the frontal cortex of Alzheimer’s brains while a low signal intensity for Gtts 
in the hippocam pus prevented accurate densitometric analysis. However, Ross et al. (1992) 
observed a large variability in the integrity of the mRNA material isolated from different 
hum an brain samples. Ross et al. (1992) concluded that the small sample size employed in his 
study  and large variability in the intensity of the G as mRNA which he encountered 
prevented a definitive conclusion being draw  regarding the effect of Alzheimer's disease on 
the level G as mRNA.
Although the present study found no significant alteration in the level of Ga  subunits in 
Alzheimer’s disease, there was a significant reduction in the GP (35/36 KDal) subunit(s) 
m easured in the frontal cortex of Alzheimer's disease compared to control samples. This
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analysis was performed on membrane samples that were stored for 10 m onths at -80°C and 
had been through 3 freeze/thaw  cycles (section 4.4.2). The Gp im m unoblot of the frontal 
cortex samples also identified a prominant high molecular weight protein (Figure 16). It was 
also found that within the frontal cortex control group, there was a strong correlation between 
the level of GP and freezer storage time (r=0.928, p<0.001). These observations may indicate 
that the samples have been subjected to a proteolytic process during the prolonged storage.
Thus, the Gp analysis was conducted on samples that did not meet the stringent criteria for 
sample handling, storage and preparation which was adopted throughout this project to 
ensure a high standard of biochemical analyses. However, the GP proteins (Figure 16) were 
detected as sharp and clearly visible bands which would indicate that the Gp proteins were 
minimally affected by the prolonged storage.
There is now convincing evidence that the Gp subunit m ay play an active role in the 
m odulation of effector systems rather than serve a relatively passive role involving the 
aggregation and  dissociation of the heterotrim er on receptor activation. It has been 
dem onstrated that the Gp, or more specifically the GPy complex, can directly activate the 
calcium /calm odulin insensitive adenylate cyclase activity (Federman e t al., 1992; Tang &
j
Gilman, 1991; Taussig et al., 1993); inhibit calcium sensitive adenylate cyclase activity (Tangjetal., 
1990; bu t see Mangels et al., 1992); directly activate phospholipase C (Camps et al., 1992) and 
m odulate muscarinic receptors activity (Haga & Haga, 1992). The reductions in Gp observed 
in this thesis could lead to a significant m odulation in the activity of adenylate cyclase 
activity, a finding that is indeed observed in this study. It is also possible that the putative 
alteration in the Py levels could affect the inositol phosphate  signalling  pathw ays. 
Alterations in the protein kinase C (PKC) translocation in Alzheimer's disease (Cole et al.,
1988; Masliah et al., 1990c; Shimohama et al., 1990; but see H orsburgh et al., 1991) strongly 
indicates an alteration in the inositol signalling system. However, a recent report has shown 
that phospholipase C, which is m odulated by Gp (Camps et al., 1992) is not altered in 
Alzheimer's disease (Shimohama et al., 1992; but see Shimohama et al., 1991).
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Alterations in G-protein levels have been described for psychiatric conditions and in 
neurodegenerative disorders other than Alzheimers disease. Young et al. (1992) reported a 
significant increase of both GasL and Ga sS in the prefrontal cortex (22%) and occipital cortex 
(80%) in patients with bipolar affective disorders. Since Young and co-workers, (1991) found 
increased Ga s  in patients that had received lithium and those that had not, it is unlikely 
that lithium  had induced these changes. A recent investigation of olivopontocerebellar 
atrophy disease reported increased levels of G as and reduced Gai proteins in cerebellar cortex 
(Kish et al., 1993). A lthough the significance of these alterations, regarding neuronal 
function and the neurodegenerative process, are unclear, they demonstrate that alterations in 
G -protein levels can occur within selected brain regions in specific neurodegenerative 
disorders.
5.4.2. Analysis of GTPase activity
The high affinity GTPase activity was found to be significantly reduced (by 25%) in the 
frontal cortex of Alzheimer's disease .when compared to control samples. A reduction in high 
affinity GTPase was also observed in the hippocampus of Alzheimer's disease samples (27%) 
which failed to reach statistical significance (reduced by 27% P=0.051). Post hoc power 
analysis w ould suggest that for the level of variability encountered for the basal GTPase 
activity, a group size of 18 samples would be required to to give a significant difference at the 
5% level with 80% statistical power using a two-tailed Student's t-test.
These findings present evidence for a functional alteration in G-protein m ediated signal 
transduction process in Alzheimer's disease. There are several reasons to explain the 
reduction in GTPase activity in Alzheimer’s disease. First, there is evidence that G ai can be 
phosphorylated (Bushfield et al., 1991) which has been shown to lower the intrinsic GTPase 
activity of hum an brain extracts (Sauvage et al., 1991). Recently, it was reported  that
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several G-proteins (Ga s S, Ga s L, Ga il, Ga i2 , Ga i3, Ga o  and purified transducin) are 
phosphorylated at tyrosine residues by the product of the potential oncogene pp60c' src 
(Hausdorff et al., 1992). Functional analysis of GttsS revealed that phosphorylation was 
inhibited by Py subunits in a dose dependent m anner and that basal and agonist stim ulated 
GTP7S binding was enhanced by phosphorylation (Hausdorff et al., 1992). Taken together, 
these observation suggest that the GTPase activity associated w ith G -proteins can be 
m odulated by phosphorylation of the Got subunits and this mechanism of controlling G- 
protein activity is sensitive to the level of free Py dimers. In Alzheimer's disease, aberrant 
protein phosphorylation of for example tau and neurofilaments ( Grundke-Iqbal et al., 1986; 
Bancher et al., 1991; Zhang et al.,1989), and synapsin I (Parks et al., 1991) is well documented. 
This has been partly attributed to alterations in the action of various kinases such as protein 
kinase C (Cole et al., 1988; Masliah et al., 1990c; Shimohama et al., 1990; bu t see Horsburgh 
et al., 1991), casein kinase II (Iimoto et al., 1989), tyrosine kinase (Shapiro et al., 1991), and 
recently, m itogen activated protein (MAP) kinase (Drewes et al., 1992). These findings 
support the contention that abnormal phosphorylation activities in Alzheimer's disease may 
be involved in the modification of GTPase activity.
Second, the activity of GTPase has been shown to be influenced by the lipid content of the 
m em brane (Ben-Arie et al., 1988). In Alzheimer's disease changes in m em brane lipid 
composition has been reported (Soderberg et al.,1992; Sofic et al., 1991) and m ay therefore 
result in altered GTPase activity. Finally, alterations in GTPase activity has been shown to 
occur as a result of specific point mutations of G as and G ai proteins isolated from endocrine 
tum ours (Landis et al., 1989; Wong et al., 1991) and with remonbinant Gq (Conklin et al., 1992). 
Detailed analysis of the amino acid composition of G-proteins isolated from Alzheim er’s 
disease brain is required to determine if point mutations are the cause of the reduced GTPase 
activity observed in the present study.
The nonspecific, low affinity GTPase activity was significantly increased in both the frontal
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cortex and hippocam pus in Alzheimer's disease. The GTPase assay was conducted under 
conditions that selectively enhanced the high affinity activity over the low affinity 
activity. This was achieved by including an ATP regenerating system and subtracting the 
hydrolysis of [y-^P] GTP measured in the presence of excess cold GTP. The inclusion of lOOfiM 
cold GTP was used to minimise the low affinity activity, and under these conditions the assay 
rem ains sensitive for the low affinity GTPase as dem onstrated by the linear rate of 
hydrolysis against time and protein level (Figure 4). The source of the low affinity GTPase 
associated w ith crude membrane preparations is unclear. The presence of GFAP in these 
samples confirm that cytoskeletal proteins are co-sedimented by this method. It is tem pting 
to speculate that the activity reflects the GTP hydrolysis associated w ith cytoskeleton since 
tubulin (Carlier & Pantaloni, 1981) and dynamin (Shpetner &Vallee, 1992) have higher GTP 
hydrolysis rates than G-proteins (Kcat 2-4 minutes). Indeed, Hoss et al., (1988) reported that 
purification of synaptic membranes gave an enhanced signal to noise ratio of the high to low 
affinity GTPase when compared to washed membranes. The increased low affinity GTPase 
activity in Alzheimer's disease may thus be due to an enhanced cytoskeletal associated 
GTPase action. This suggestion is supported by the recent dem onstration that tau isolated 
from Alzheimer's disease brain is less effective in enhancing tubulin polymerisation than tau 
isolated from non-demented brain (Lu & Wood, 1993).
The GTPase activity measured in membranes reflects the cycling between the inactive and the 
active configurations of G-proteins and this cycle is dependent on the presence of receptors (see 
section 1 .2 ). Although the basal activity gives some insight into the integrity of G-protein 
coupling to receptors this method is unable to distinguish between the individual receptors 
and their G-proteins. This can be partly overcome by m easuring the GTPase activity in 
response to selected agonists. Various studies have indicated that the coupling of specific 
receptors to G-proteins is altered in Alzheimer's disease. These receptors include the M l 
muscarinic receptor (Smith et al., 1987; Flynn et al., 1991) and nicotinic receptors (Nordberg et 
al., 1992) although Pearce & Potter (1991) reported that the high affinity M l receptor site
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was preserved in Alzheimer's disease. Other receptors that have been reported as having an 
altered coupling with G-proteins in Alzheimer's disease are the dopam ine D 1 receptor (De 
Keyser et al., 1990) and the a2-adrenoceptor (Pascual et al., 1992). O'Neill et al. (1991a & 
1991b) reported that the coupling of G-proteins to the ot2 and 5HT receptors were unaltered in 
Alzheimer's disease.
In the present study, receptor/G-protein coupling was examined by monitoring the m agnitude 
of agonist stimulation of basal GTPase activity. Carbamylcholine (carbachol) was used as it 
can in teract w ith  the M l and M3 subclasses of m uscarinic receptors to stim ulate 
phospholipase C activity via a  pertussis toxin insensitive G-protein (probably the Gq). 
Carbachol can also interact with M2 and M4 receptors to inhibit adenylate cyclase via G ai 
proteins (Peralta et al., 1988; Fukamauchi et al., 1991). Baclofen, (a selective GABAg 
agonist) was also examined. GABAg receptors are thought to inhibit voltage dependent 
calcium channels via pertussis sensitive G-proteins possibly G«o (Holz et al., 1989). Within 
the frontal cortex there was a tendency for the magnitude of stimulation by both agonists to be 
lower in the Alzheimer’s disease group compared to the controls. The reductions in the 
m agnitude of stimulation by both agonists however, failed to achieve statistical significance. 
It is also apparent from the present study that some of the hippocam pus and frontal cortex 
preparations from both Alzheimer’s disease and control samples gave a poor response to 
agonist stimulation. One the other hand, some patients gave stimulation in both the frontal 
cortex and the hippocam pus (e.g. patient C19A). It is unlikely that the poor stim ulation 
observed for some samples is due to methodolgical lim itations since both  the tissue 
preparation and GTPase analysis of the frontal cortex and hippocam pus regions were 
conducted independent of each other. There are several reasons why some of the hum an 
samples gave a poor response to agonist stimulation of GTPase. In this thesis the effect of the 
interval betw een death  and  freezer storage of rat brain (postm ortem  interval) was 
dem onstrated to reduce both the basal GTPase activity and the response of this enzyme to 
carbachol and baclofen (Figure 1 2 ). There was however no correlation between postmortem
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interval and the basal and stimulated GTPase activity of the hum an brain samples. The 
muscarinic receptor and al-adrenoceptors stimulation of GTPase stimulation has been shown 
to be reduced in aged compared to young rats (Villalobos-Molina et al., 1992; Yamagami et al., 
1992). Agonal status has been shown to effect a variety of neurochemical activities (Perry et 
alv 1982; Piggot et al., 1992; Barton et al., 1993) and may therefore influence the stim ulation 
of GTPase activity by receptor agonists.
Taken together, these data  suggest that GTP hydrolysis by G -proteins and by other 
unidentified protein(s) is altered in Alzheimer's disease. The reduction in the high affinity 
GTPase in Alzheimer’s disease frontal cortex and hippocampus may indicate an alteration in 
G-protein function. It was also noted that in the control samples the basal GTPase correlated 
with the levels of Ga o , Ga il  and Ga i2  measured in the frontal cortex, and w ith Ga il  and 
G ai2  in the hippocam pus (Table 5). There was no correlation betw een the level of these 
proteins and activity of GTPase that was m easured in the Alzheim er's disease samples, 
except in the hippocam pus of Alzheimer's disease where the basal GTPase correlated with 
the levels of G«i2 (r=0.73, P<0.05). This suggests that in Alzheim er's disease there is a 
disruption of G-protein function which is independent of an alteration in the levels of G- 
proteins. The enhanced low affinity activity may be a consequence of altered cytoskeletal 
dynamics. It is possible that these changes are related since it has been proposed that the 
cytoskeletal protein tubulin serves as a GTP sink (Rasenick & Wang, 1988). The exchange of 
GTP with Gai and G as has been shown to alter adenylate cyclase activity (Rasenick & Wang,
1988). Additionally, tubulin has been demonstrated to reduce muscarinic stim ulation high 
affinity GTPase in rat striatum (Ravindra & Aronstam, 1990). This action m ay be achieved 
by the interaction of tubulin with the G-protein a n d /o r  muscarinic receptor (Ravindra & 
Aronstam, 1991). The alteration in GTP hydrolysis observed in the present study may reflect 
a disruption of the equilibrium between the free GTP bound Ga  subunit and the receptor 
coupled G-protein heterotrimer. One consequence of this effect could be an alteration in the 
proportion of a given receptor which is in its high affinity state and  which has been
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described in Alzheimer's disease (Smith et al., 1988; Flynn et al., 1991; Nordberg et al., 1992; 
De Keyser et al., 1990; Pascual et al., 1992)
5.4.3. Analysis of adenylate cyclase activity in Alzheimer's disease.
In the present study, the basal activity of adenylate cyclase was significantly reduced by 44% 
in the frontal cortex of Alzheimer’s disease compared to control samples. There was no 
significant difference in the hippocampal basal adenylate cyclase activity of Alzheimer's 
disease compared to controls. In both regions the percentage stimulation above basal levels by 
the receptor independent action of fluoroaluminate was comparable between the Alzheimer's 
disease and control groups.
The investigation of adenylate cyclase activity in Alzheim er’s disease has now  been 
conducted by several laboratories (Danielsson et al., 1988; Ohm et al., 1991; Bergstrom et al., 
1991; Cowburn et al., 1992a; Cowburn et al., 1992b). The findings of these different studies 
have however been inconsistent. Danielsson et al. (1988), reported that the basal activity 
was significantly increased (46%) in the hippocampus of Alzheimer's disease brain bu t was 
similar to control samples in the parietal cortex. The degree of stim ulation by vasoactive 
intestinal polypeptide (VIP) and forskolin was unchanged by the presence of Alzheimer's 
disease. Ohm et al. (1991) found a significant reduction in basal adenylate cyclase activity in 
the  h ippocam pus although the percentage stim ulation achieved w ith  isoprenaline, 
Gpp(NH)p and forskolin were unchanged (although the absolute am ount of cAMP generated 
in their presence was reduced). Cowburn et al. (1991) reported that the basal adenylate 
cyclase activity of the tem poral cortex was preserved bu t som atostatin inhibition was 
reduced. In a subsequent study, Bergstrom et al. (1991) reported that in Alzheimer's disease 
that basal activity and somatostatin inhibition of adenylate cyclase was unchanged in the 
frontal cortex, hippocampus, caudate nucleus and cerebellum. Recently Cowburn et al. (1992a) 
reported that in five brain regions (frontal, occipital and temporal cortex; angular gyrus and
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cerebellum) the basal activity of adenylate cyclase was preserved in Alzheimer's disease, 
although a 26% reduction was observed in the frontal cortex. The percentage stim ulation 
achieved with fluoroaluminate and forskolin (1 and lOOmM) was significantly reduced in the 
neocortex (Cowburn et al. 1992a). Finally, Cowburn et al. (1992b) examined the inhibitory 
arm  of the adenylate cyclase system and under these conditions basal values were 
significantly reduced in the frontal and temporal cortex, the angular gyrus but was unchanged 
in the cerebellum. The inhibition achieved with fluoroaluminate was unchanged suggesting 
the Ga i activity is preserved. They also observed that while a biphasic response to 
Gpp(NH)p (lOnM-lmM) was evident in the control samples, the increased adenylate cyclase 
activity at high concentrations of Gpp(NH)p was lost in the Alzheimer's disease samples.
These studies, together with the findings of this thesis, indicate that the adenylate cyclase 
system is altered in Alzheimer's disease. They are however inconsistent regarding the 
regional and mode of altered adenylate cyclase activities. The differences may be attributed, 
in part, to the particular sample preparation procedure an d /o r the assay system employed by 
the investigators. For instance, Ohm et al. (1991) homogenised their sam ples at 37°C to 
remove endogenous cAMP and analysed the activity in the homogenates (resuspended pellet 
after 15,000g spin), yet Nicol et al. (1981) dem onstrated that adenylate cyclase in whole 
tissue homogenates is labile. Cowburn et al. (1992a), on the other hand, employed similar 
conditions to that used in the present study, yet although Cowburn et al. (1992a) reported that 
the basal activity was not significantly altered (decreased by 2 2 %), the degree of stimulation 
of adenylate cyclase was impaired. In the study by Cowburn et al. (1992a), the m agnitude of 
stim ulation of adenylate cyclase achieved by fluoroalum inate was m arkedly low er (29% 
stimulation above basal for control versus 9% for Alzheimer's disease) than that observed in 
the present study (260% above basal for control and Alzheimer's disease). Perhaps the 
discrepancy is due to methodological differences such as the inclusion of sodium  ions or 
calcium chelators. Finally, Cowburn et al. (1992b) included calmodulin in their assay mixture 
when examining the inhibitory arm of the pathway. Their assay conditions did not include
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7 Rexogenous calcium at stimulatory concentrations (10 However, it has been recently
dem onstrated that reagents commonly used in the adenylate cyclase assay are a potential 
source of calcium contam ination (Yovell et al., 1992). Thus, it is possible that the assay 
conditions employed by Cowburn et al. (1992) was influenced by the calcium /calm odulin 
sensitive adenylate cyclase subtypes. The assay conditions employed in the present study 
(repeated washing of membranes with buffer containing ImM  EDTA) reflects prim arily the 
activity of the calm odulin insensitive adenylate cyclase under stim ulatory  conditions. 
However, as dem onstrated by Caldwell et al. (1992), it is likely that particulate m embrane 
preparations contain calm odulin (since addition of only 5nM calm odulin can induce 
stimulation) Therefore, the basal activity of adenylate cyclase reported in this thesis, while 
preferential for the calmodulin insensitive enzyme, probably reflects a contribution of the 
calmodulin sensitive types.
There are several possible explanations for the reduction in basal adenylate cyclase activity 
in the frontal cortex of Alzheim er’s disease observed in this thesis. A reduction in the 
absolute am ount of adenylate cyclase may have occurred. However, in situations where 
reductions in basal adenylate cyclase activity has been described, this does not appear to be 
due to changes in the enzyme level. Gawler et al. (1987), found reduced basal activity in 
diabetic animals although Bushfield et al. (1990), reported that the enzyme level was in fact 
increased. Recently Hershberger et al. (1992) examined adenylate cyclase activity under a 
variety of conditions in failing and non-failing hearts. The basal adenylate cyclase activity 
was decreased in pathologic tissue when assayed in the absence of GTP (termed "G-protein 
conditions") bu t unaltered when GTP was present. The altered adenylate cyclase activity in 
failing heart w as attributed to an increase in a pertussis toxin sensitive God protein  
(Hershberger et al.,| 1991). Similarly, changes observed in basal adenylate cyclase activity in 
the diabetic anim al (Gawler et al., 1987) m ay be a result of an increased G «i3 level 
(Strassheim  et al., 1990). A lterations in the functional activity of the inhibitory  and  
stim ulatory G-proteins m ay also explain the decreased basal adenylate cyclase activity
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observed in diabetic animals (Bushfield et alv 1990). Thus, modifications in the levels of the 
adenylate cyclase molecule does not appear to be a common mechanism whereby cells regulate 
basal cAMP levels. Confirm ation of the preservation of adenylate cyclase levels in 
Alzheimer's disease may be achieved by immunoblot analysis of the enzyme (jMollner et al.,
1990).
There may be a reduced residual effect of G as on adenylate cyclase which is thought to exist 
under basal conditions (Birnbaumer et al., 1990) which may account for the reduced activity 
reported in this thesis. Indeed Dewar et al. (1991), observed a reduction in forskolin binding 
in the Alzheimer's disease frontal cortex and this ligand, under appropriate conditions, binds 
preferentially to the G as/adenylate cyclase complex. This finding m ay relate to the altered 
ratio of Ga sL /G a sS observed in the frontal cortex (Figure 16). It has been shown that during 
developm ent of mice brain there is a change in the ratio of G a s ^ /G a s S  proteins w ith a 
concomitant increase in basal adenylate cyclase Gpp(NH)p (Rius et al., 1991).
Norm al control of basal adenylate cyclase activity which is regulated by the equilibrium  of 
the stim ulatory and inhibitory inputs, may be compromised causing an enhanced tonic 
inhibition of adenylate cyclase. This has been reported to occur in the diabetic induced rat 
(Strassheim et al., 1990). Although correlation analysis has a limited value when applied to 
small sample sizes and the large number of potential analyses, it is interesting that in  the 
frontal cortex both G ai proteins have a positive association with the basal adenylate cyclase 
activity which is not evident in the Alzheimer's disease group (Figure 28). This may reflect a 
breakdow n in the norm al inhibitory action of G ai on adenylate cyclase which has been 
attributed to Ga i phosphorylation (Bushfield et al., 1992). It is also tem pting to speculate 
that if the reduced basal GTPase reported in this thesis is due to a lowering of intrinsic 
activity associated w ith G ai, then this may prolong the inhibitory action w ithout altering 
the protein level. Again, this may be inferred by the correlation of basal adenylate cyclase 
activity with basal GTPase in control frontal cortex which is not evident in the Alzheimer’s
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disease group. An increase of endogenous neurotransm itters, which inhibits adenylate 
cyclase, could also produce the reduction in the basal activity observed in the present study. 
H ershberger et al (1992) found that although basal activity was reduced in heart disease 
(assayed in the absence of GTP), the basal levels were preserved after treatm ent of 
preparations with adenosine deaminase to remove adenosine inhibition of adenylate cyclase. 
This proposal does not agree with the findings of Cowburn et al. (1992b) who reported that 
the inhibitory arm  of adenylate cyclase is preserved in Alzheimer's disease. As m entioned 
above however, the assay conditions employed by Cow burn et al (1992b) m ay reflect 
prim arily the calmodulin-sensitive forms of adenylate cyclase.
Finally, the reduced basal adenylate cyclase activity could be a consequence of the putative 
reduction in the G (3 protein reported in this thesis. This m ay result from  the loss of 
stimulatory action described for the Py complex (Tang & Gilman, 1991; Federman et al., 1992; 
Taussig et al., 1993) on type II and IV (calmodulin insensitive adenylate cyclase). However, 
the Py complex has also been described to have an inhibitory effect on type I adenylate 
cyclase (Tang & Gilman, 1991; Taussig et al., 1993). Thus, to achieve a net reduction in the 
basal activity, the loss of stimulation by py is required to be significantly greater than the 
loss of inhibitory action on calm odulin-sensitive activity. A lternatively, this putative 
reduction in the P subunit could result in a higher abundance of the free a  subunits of G- 
proteins. Since Gao anc* the Gai subtypes are thought to be more abundant in  brain than Ga s, 
(Asano et al., 1990) it is reasonable to suggest that these protein would be m ost influenced by 
the lower available P subunit level.
In conclusion, it can be hypothesised that the lower basal adenylate cyclase activity results 
from either a reduction in the enzyme level or a misbalance between the inhibitory and 
stimulatory constraints imposed on the enzyme under resting levels. It can be envisaged that 
an alteration in the normal localised concentration and metabolism of GTP, as indicated by 
the GTPase data, could influence the adenylate cyclase action. It is also em erging that
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p ro te in  k inase C (PKC) can selectively activate the type II adeny la te  cyclase 
(Ca^+ /calmodulin-insensitive) (Yoshimura & Cooper, 1993). Given that the activity of PKC 
is considered to be altered in Alzheimer's disease, this may present another mechanism to 
explain the alterations in the adenylate cyclase pathway in Alzheimer's disease.
5.4.4. Significance of G-protein mediated signal transduction in Alzheimer's disease.
The m ain findings of this investigation were as follows: the levels of G-protein a  subunits 
were preserved in Alzheimer’s disease frontal cortex and hippocampus; the basal activity of 
adenylate cyclase was reduced in the frontal cortex but not in the hippocam pus; in both 
regions, there was a decrease in the basal high affinity GTPase activity and a significant 
increase in the low affinity GTPase. In the preceding sections these observations are discussed 
in relation to the specific molecular interactions relative to signal transduction events. The 
following discussion will incorporate the significant developm ents that have been m ade 
regarding the role of the amyloid precursor protein (APP) in Alzheimer's disease. Since this 
thesis focussed on G-protein m ediated transduction events, and d id  not examine the 
amyloidogenic aspect of Alzheimer's disease, the following proposals are acknowledged as 
being highly speculative. Diagram II is a schematic representation of the possible sequence of 
events leading to the formation of senile plaques and neurodegeneration in Alzheim er's 
disease. It also includes factors which are thought to influence this amyloidogenic process 
and interact with signal transduction mechanisms.
There is convincing evidence that senile plaque formation in Alzheimer's disease results from 
abnormal processing of the transmembrane amyloid precursor protein (APP) resulting in the 
aggregation and deposition of the |3A4 protein. Several alternative proteolytic pathw ays for 
APP have been described which produce different degradation products: the normal secretory 
pathw ay involves a cleavage within the PA4 region and thus generates non-amyloidogenic 
amino and carboxy terminal products (Sisodia et al., 1990; Sisodia et al., 1990;); a secretory
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pathw ay which produces soluble PA4 fragments (Haass et al., 1992a; Seubert et al., 1993); an 
endosomal-lysosomal pathway which results in the formation of C-terminal fragments some 
of which contain the PA4 protein and are therefore amyloidogenic (Cataldo & Nixon, 1990; 
Golde et al., 1992; Haass et al.„ 1992b). It rem ains to be established w hether abnorm al 
processing of APP is instigative of neurodegeneration in Alzheimer's disease or if this is a 
secondary response to an as yet unidentified event.
Several studies have suggested that denervated brain areas of Alzheimer's disease can m ount 
an aberrant neuritic sprouting response which may indicate a defective regenerative process 
(Geddes et al., 1986; Hym an et al., 1987; Masliah et al., 1991b). Recently M asliah et al.
(1992) reported the co-localisation of GAP-43 (growth activating phosphoprotein or B50 or 
FI), which is considered to be a marker for neuritic growth (Benowitz et al., 1989), and APP in 
neurites of AD frontal cortex. This suggests that APP is involved in the putative aberrent 
sprouting response.
Several investigations have provided evidence that carboxy terminal fragm ents of APP have 
neurotoxic properties. Yankner et al. (1989) reported thatj phaeochromocytoma cells (PC12) 
transfected with APP secreted a caboxy terminal peptide (PAPP-C104) which is neurotoxic to 
cultured hippocampal neurons. This effect may be mediated by a neuronal receptor for pAPP- 
C104 (Kozlowski et al., 1992). Yankner et al. (1990) subsequently dem onstrated that NGF 
potentiated the neurotoxic effect of synthetic PA4 containing peptides. There is also evidence 
that PA4 can render neurons more susceptible to the neurotoxic action of excitatory amino acids 
(Mattson et al., 1992; Koh et al., 1990). Mattson et al. (1992) suggested pA4 acts by disrupting 
neuronal calcium homeostasis. The alteration in neuronal calcium influx has been proposed as 
an event which leads to altered phosphorylation activities and to neurofibrillary tangle 
formation (Mattson et al., 1991; Ueda et al., 1990).
There is now evidence that signal transduction mechanisms are involved in amyloidogenesis
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associated w ith Alzheimer's disease. It has been demonstrated that the activation of protein 
phosphorylation and dephosphorylation by agents which m odulate protein kinase C and 
phophatases activity can regulate the processing of APP (Buxbaum et al., 1990). This 
activity can be achieved in vitrothrough the activation of muscarinic receptors (Bauxbaumet 
al., 1992) of the M l and M3 subtypes (Nitsch et al 1992). Since the muscarinic receptors are 
coupled to G-proteins, then it likely that the stiochiometric relationship between G-protein 
subunits and receptors are altered in Alzheimer's disease.
Direct G-protein involvement in APP processing has also been demonstrated. Nishimoto et al.
(1993) report that APP is coupled to Goo through the cytoplasmic cytoplasmic domain outside 
the PA4 region . The association of Goto with APP is inhibited by GTP7S treatm ent and is 
magnesium dependent. This suggests that the interaction between Goto and APP proteins are 
similar to other G-protein receptor coupling mechanisms. Nishimoto et al. (1993) proposed 
that aberrant processing of APP may result in the over production of the G ao coupling APP 
derivative and result in constitutive activation of the protein. If this were the case, one effect 
w ould be to occupy a significant proportion of the total cellular G-protein pool thereby 
reducing the basal GTPase activity, an effect observed in this thesis. It could also be 
speculated that occupancy of the Gao by APP derivatives could induce downregulation of the 
G-protein P subunit to compensate for the shift in equilibrium between the active a  subunits 
and the heterotrimeric complex. A knock-on effect could be a release of free G a subunits such 
as G ai and Gas- Since the Gai are thought to be more abundant than G as (Asano et al., 1990), 
this could account for the reduced basal adenylate cyclase activity observed in the frontal 
cortex in the present study. However, in the present study the reduction in basal adenylate 
cyclase activity was not observed in the hippocampus. Since both regions exhibit marked 
am yloid pathology, this suggests that in Alzheimer's disease, am yloidogenesis has a 
different effect on the signalling mechanism in selected brain regions. GAP43 has also been 
shown to stim ulate the binding of GTP7S to G ao (Strittmatter et al., 1990) by a presently 
poorly defined mechanism which does not appear to require Py subunits (Strittmatter et al.,
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1991). Given that GAP 43 and APP are co-localised in Alzheim er’s disease cortex and 
hippocam pus (Masliah et al 1992), together with the ability of both proteins to interact with 
G a o , it is tem pting to speculate that APP derivatives and GAP43 have a functional 
association. GAP 43 and APP may also be intimately associated with the putative aberrant 
sprouting response.
In conclusion, the aberrant processing of APP is currently favoured as the key biochemical 
event involved in the neurodegeneration of Alzheimer's disease. Recent reports which 
examined various aspects of APP processing and neurotoxic properties support a muscarinic and 
glutamatergic involvement which may underlie an abnormal regenerative reaction. Signal 
transduction pathw ays may be effected as a consequence of changes such as alterations in 
phosphorylation and calcium regulation. Additionally, G-protein function may be directly 
altered by the action of APP and GAP43 on G ao which is the most abundant G-protein in 
brain. Further investigations of the dynamics of G-proteins action, specifically G ao, *n 
Alzheim er's disease and additional neurological disorders together w ith transfected cell 
lines may prove to be rewarding.
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Diagram  n .  The significance of G-protein in Alzheimer's disease. This schematic diagram  
illustrates the mechanisms that are thought to be involved in the developement of Alzheimer 
associated pathology. A central event in plaque and tangle formation is the missprocessing of 
APP protein. This may be due to a combination of the aging process and genetic factors. This 
process could disrupt signal transduction at various levels. Recent evidense has suggested that 
G a o is associated with APP fragments. It has also been demonstrated that PKC activity can 
influence APP processing. Thus, these components of signal transduction systems can be 
directly influenced by abberant APP processing. Signal transduction molecules may also be 
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5.5. G-protein activity in  the hippocampus of the rat following lesion of the m edial septal 
nucleus.
Animal models are frequently employed to examine various aspects of neurodegeneration as a 
consequence of the denervation of specific neuronal pathw ays. The advantage of such 
paradigm s is that factors such as diet, age, the interval between death and freezing of the 
brain, agonal state and genetics can be controlled. However, species differences impose severe 
restrictions on the confidence w ith which observations from  anim al stud ies can be 
extrapolated to the particular hum an condition of interest. Here the m edial septal- 
hippocam pal pathw ay was lesioned in the rat and the effect of hippocam pal G-protein 
m ediated transduction mechanisms examined.
The medial septum  (MS) lesion model was employed for several reasons. First, this model is 
relevant to the hypothesis that cognitive defects in Alzheimer's disease is correlated with 
the decreases in cholinergic function in the septohippocampal and basal forebrain cortical 
pathw ays (Perry et al., 1986). Second, the medial septal pathw ay has been reasonably well 
characterised: the cell bodies originating from the medial septal and diagonal band project 
th rough the fim bria fornix and term inate in a lam inar pa ttern  in  the  h ippocam pus 
innervating predom inately areas CA2-CA4 (Geddes et al., 1992; Palacios et al 1991). The 
hippocampal afferents from the medial septum /diagonal band consist of a large population of 
cholinergic and GABAergic neurons (Freund & A ntal, 1988). Third, lesions of the 
septal/hippocam pal pathway has been shown to induce impairments in the ability of rats to 
learn and recall certain maze tasks (Nagahara & McGaugh, 1992). Fourth, there is evidence 
that lesions of this pathw ay can induce alterations in the inositol phosphate signalling 
pathw ay (Smith et al., 1989, Court et al., 1990; Connor & Harell, 1989). However, there has 
been no detailed investigations of the signalling mechanisms associated with these changes. 
To date, there has been minimal investigation of the adenylate cyclase system  following 
specific neuronal lesions. Finally, the surgical expertise existed within the group to produce
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reliable septal dam age with highly reproducible reductions in choline acetyltransferase 
(ChAT) in the hippocampus (Horsburgh et al., 1993).
The present investigation established that in the although there was a significant reduction 
in the activity of choline acetyltransferase (23% P<0.01) in the hippocam pus, there was no 
alteration in the level of Ga o/ Ga il, Ga i2, Ga sL and G(L Longer exposure times of the Ga s 
autoradiogram  allowed a visual inspection of GasS which also appeared to be comparable for 
the control and the lesioned groups. While the G-protein levels were unaltered in this lesion 
model, there is clearly a loss of the presynaptic input as indicated from the reduction in ChAT 
activity and by the loss of neuronal cell bodies in the septal area (Figure 35). It could be 
postulated that the apparently maintained G-protein levels following partial cholinergic 
denervation is indicative of an upregulation of G-protein levels in the remaining cholinergic 
terminals. Compensatory alterations at postsynaptic sites are also a possibility (Joyce et al.,
1989). A lthough there is no direct G-protein evidence to suppo rt th is hypothesis, 
com pensatory changes in the hippocam pus following cholinergic denervation have been 
reported. Following partial fimbria-fornix lesion the rem aining intact cholinergic neurons 
appear to compensate for the reduced ChAT activity by upregulating their capacity to 
synthesize and store acetyl choline (Lapchak et al., 1991). This plasticity can be enhanced by 
administering nerve growth factor administration at the lesion site (Lapchak & Hefti, 1991).
The functional activity of the G-proteins as assessed by analysis of the GTPase activity was 
not significantly altered by medial septal lesion. Similarly the m agnitude of stim ulation 
achieved with both baclofen and carbachol was unaltered between the control and lesioned 
groups. Although there are no statistically significant changes in the GTPase data measured 
in either the presence and absence of agonists, the lesion group gave a slight increase in basal 
h igh affinity GTPase activity (20% above control values). The m agnitude of baclofen 
stimulation of the GTPase activity was also non-significantly increased in the lesioned group 
com pared to the controls. These observations m ay indicate a trend for an upregulatory
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response in G-protein activity following cholinergic denervation. Post hoc power analysis 
would suggest that for the level of variability encountered for the basal GTPase activity, a 
group size of 17 samples would be required to to give a significant difference at the 5% level 
with 80% statistical power using a two-tailed Student's t-test. Using this criteria, it was also 
calculated that group sizes of 19 were required to observe a statistically significant change in 
the m agnitude of agonist stimulation of GTPase by baclofen.
The adenylate cyclase activity was not significantly different in lesioned compared to control 
animals. Horsburgh et al. (1993) has used this same model to show that forskolin binding is 
increased in the polymorph layer of the dentate gyrus demonstrating a focal enhancement of 
G as coupled to adenylate cyclase. Horsburgh and her colleagues (1993) also concluded that 
phorbol ester binding to protein kinase C was unaltered in the hippocam pus proper, but 
elevated in the entorhinal cortex. Given the highly localised changes in forskolin binding, 
and that the investigation reported in this thesis was conducted on whole hippocam pal 
formations, perhaps subtle focal alterations in signal transduction mechanisms m ay occur 
beyond the spacial resolution of the approach which I employed.
The preserved levels of each G-protein related param eter m ay be interpreted to reflect a 
com pensatory response. Indeed, lesion of the fimbria-fornix is reported to induce an 
upregulation of both the M l and M2 receptors, which is partially  reversed following 
reinnervation by transplantation (Joyce et al., 1989). It has also been reported that medial 
septal lesions by AF64A increased the levels of M2 receptors but not M l receptors (Dawson & 
Wamsley, 1990). Supersensitivity responses have also been described for lesions of the nucleus 
basalis of Meynert complex (NBMC) (McKinney & Coyle, 1982). In contrast, preservation of 
receptors in the hippocampus have been reported following medial septal lesion (Overtstreet 
et al., 1980; Smith et al., 1989) and in the frontoparietal cortex following NBMC lesions 
(Raulli et al., 1989, Vige & Briley, 1989). However, Vige & Briley (1989) d id  observe an 
increase in the number of muscarinic receptors in the frontoparietal cortex following chronic
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scopolamine treatment suggesting that antagonism is capable of inducing upregulation. Smith 
et al. (1989) and Court et al. (1990) also proposed a supersensitivity response to account for the 
enhanced phosphoinositol turnover in lesioned animals w ithout a concomitant change in 
muscarinic receptor binding. A potential source of the the discrepancies regarding adaptive 
neurochemical changes may be the particular lesion system employed. Ibotenic acid lesions 
employed in this thesis produced a moderate reduction in ChAT and histological examination 
of the septal area displayed highly localised cell loss. Transsection and electrolytic lesions 
are regarded however, as being less specific both anatomically and pharmacologically.
Denervation of the septal input to the hippocampus has been shown to induce a complex 
process of sympathetic ingrowth (HSI) of noradrenergic fibres that invade the dentate gyrus 
and the CA3 region (Crutcher et al., 1981). This response may influence signal transduction 
mechanisms. Ayyagari & Harell (1992) recently showed that HSI can result in alteration in 
the affinity of phorbol ester binding to protein kinase C in the dorsal hippocam pus and 
increase in the Bmax in the ventral hippocampus. The anatomically circumscribed changes 
m ay account for an earlier observation by the group (Connor & Harell, 1989) that while 
cholinergic stimulation of phosphoinositide hydrolysis is enhanced in lesioned animals, the 
noradrenergic response is not increased. Thus, m oderate increases in GTPase activities 
reported in this thesis, could be a reflection of the HSI phenomena.
In conclusion, partial denervation of the septal hippocampal pathw ay in the rat does not 
induce gross alterations in the level or related activity of G-proteins in the hippocam pus. 
These findings are consistant w ith the results of the investigation of G -proteins in 
Alzheimer's disease hippocampus. However, while the GTPase activity was found to be 
reduced in Alzheimer's disease hippocam pus compared to control sam ples, a m oderate 
increase in basal GTPase activity was observed in lesioned animals. This m ay be interpreted 
to reflect a compensatory reaction in response to the cholinergic deficiency in animals which 
is lost in Alzheimer's disease.
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5.6. Conclusion
This thesis reports the findings of an investigation of the effect of the neurodegenerative 
disorder of Alzheimer's disease on G-protein controlled signal transduction mechanisms. The 
study has dem onstrated that while there are no gross alteration in G -protein levels, 
alterations in the GTPase and adenylate cyclase activities indicate that there is a tendency 
for the functional activities to be compromised in Alzheimer's disease. These alterations 
could be in responce to the processes involved in amyloid deposition which is characteristic of 
Alzheimer's disease. These modest changes, particularly the GTPase reductions could have a 
significant impact on the responsiveness of patients to drugs targeted at specific receptors.
This study has also shown that while the biochemical analysis of postm ortem  tissue has its 
limitations, some param eters of the transduction process can be investigated to generate 
reliable data. Investigation of transduction components in different regions has show n a 
heterogeneous pattern of distribution and suggests that common mechanisms for controlling 
adenylate cyclase activity are employed by various regions. An apparent exception however 
is the striatum and this may reflect the role of specific G-proteins expressed in this region.
Finally, although there are no animal models for Alzheimer's disease, rats lesioned at the 
m edial septal support the hypothesis that major alterations in G -protein levels are not 
employed as a compensatory mechanism to cholinergic denervation. However subtle changes 




Adem, A. (1992) Putative mechanisms of action of tacrine in Alzheimer's disease. 
Acta. Neurol Scand. 85, 69-74.
Anand-Srivastava, M.B. (1992) Enhanced expression of inhibitory guanine nucleotide 
regulatory protein in spontaneously hypertensive rats. Biochem, J. 288, 79-85.
Araujo, D.M., Lapchak, P.A., Robitaille, Y., Gauthier, S. & Quiron, R. (1988) Differential 
alterations of various cholinergic markers in cortical and subcortical regions of hum an brain in 
Alzheimer's disease. J. Neurochem. 50, 1914-1923.
Araujo, D.M., Lapchak, P.A., Meaney, M.J., Collier, B. & Quiron, R. (1990) Effects of aging on 
nicotinic and muscarinic autoreceptor function in the rat brain: Relationship to presynaptic 
cholinergic markers and binding sites. }. Neuroscience, 10,3069-3078.
Araujo, D.M. & Cotman, C.W. (1992) P-Amyloid stimulates glial cells in  vitro to produce 
growth factors that accumulate in senile plaques in Alzheimer’s disease.
Brain Research. 569, 141-145.
t
Arendt, T., Allen, Y., Marchbanks, R.M., Schugens, M.M., Sinden, J., Lantos, P.L. & Gray, J.A. 
(1989) Cholinergic system and memory in the rat: Effects of chronic ethanol, embryonic basal 
forebrain transplants and excitotoxic lesions of cholinergic basal forebrain projection system. 
Neuroscience. 33,435-462.
Asano, T., Semba, R., Kamiya, N., Ogasawara, N  & Kato, K. (1988) GQ, a GTP-binding 
protein: Immunochemical and immunohistochemical localisation in the rat.
J. Neurochem. 50,1164-1169.
176
Asano, T., Morishita, R., Sano, M. & Kato, K. (1989) The GTP-binding proteins G0  and G ^/ of 
neural cloned cells and their changes during differentiation. J. Neurochem. 53,1195-1198.
Asano, T., Morishita, R. & Kato, K. (1992) Two forms of GQ type G proteins: Identification and 
distribution in various rat tissues and cloned cells. }. Neurochem. 58,2176-2181.
Asano, T., Shinohara, H., Morishita, R. & Kato, K. (1990) Immunochemical and 
immunohistochemical localization of the G protein Gjj in rat central nervous tissues.
J. Biochem. 108, 988-994.
Asano, T., Semba, R., Ogasawara, N. & Kato, K. (1987) Highly sensitive immunoassay for 
the a  subunit of the GTP-binding protein Go and its regional distribution in bovine brain.
J. NeurochemAB, 1617-1623.
Atkinson, B.N. & Minneman, K.P. (1991) Multiple adrenergic receptor subtypes controlling 
cyclic AMP formation: Comparison of brain slices and primary neuronal and glial cultures.
J. NeurochemAB, 587-595.
Attali, A. & Vogel, Z. (1989) Long-term opiate exposure leads to reduction of the ori-1 subunit 
of GTP-binding proteins. J. Neurochem.53,1636-1639.
Avissar, S., Schreiber, G., Danon, A. & Belmaker R.H. (1988) Lithium inhibits adrenergic 
and cholinergic increases in GTP binding in rat cortex. Nature. 331,440-442.
Avissar, S., M urphy, D.L. & Schreiber, G. (1991) Magnesium reversal of lithium  inhibition of 
^-adrenergic and muscarinic receptor coupling to G proteins.
Biochemical Pharmacology. 41, 171-175.
Ayyagari, V. & Harrell, L. (1992) Cholinergic denervation alters [^Hlphorbol-12,13- 
dibutyrate binding to rat hippocampal membranes. Brain Resear ch.587, 343-347.
177
Bakalyar, H.A. & Reed, R.R. (1990) Identification of a specialised adenylyl cyclase that 
m ay mediate odorant detection. Science. 250, 1403-1406.
Bancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., 
Grundke-Iqbal, I., Iqbal, K. & Wisniewski, H.M. (1989) Accumulation of abnormally 
phosphorylated t  precedes the formation of neurofibrillary tangles in Alzheimer's disease. 
Brain Research. 477, 90-99.
Bancher, C., Grundke-Iqbal, I., Iqbal, K., Fried, V.A., Smith, H.T. & Wisniewski, H.M.
(1991) Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology 
of Alzheimer disease. Brain Research. 539, 11-18.
Barton, A.J.L., Pearson, R.C.A., Najlerahim, A. & Harrison, P.J. (1993) Pre- and postmortem 
influences on brain RNA. J. Neurochem. 61,1-11.
Baumgold, J. (1992) Muscarinic receptor-mediated stimulation of adenylyl cyclase.
TiPS. 13,339-340.
Beach, T.G., Walker, R. & Me Geer, E.G. (1989) Patterns of gliosis in Alzheimer's disease and 
aging cerebrum. GUA. 2,420-436.
Beal, M.F., Mazurek, M.F., Svendsen, C.N., Bird, E.D. &Martin, J.B. (1986) W idespread 
reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's 
disease. Ann. Neurol. 20 , 489-495.
Beal, M.F., Swartz, K.J., Finn, S.F., Mazurek, M.F. & Kowall, N.W. (1991) Neurochemical 
characterisation of excitotoxin lesions in the cerebral cortex. J. Neuroscience. 11,147-158.
Begin-Heick, N. (1990) Quantification of the a  and (3 subunits of the transducing elements (Gg 
and Gp of adenylate cyclase in adipocyte membranes from lean and obese (ob/ob) mice. 
Biochem. J. 268, 83-89.
178
Bern, W.T., Yeung, S.J., Belcheva, M., Barg, J. and Coscia, C.J. (1991) Age-dependent changes 
in the subcellular distribution of rat brain p-opioid receptors and GTP binding regulatory 
proteins. J. Neurochem. 57,1470-1477.
Ben-Arie, N., Gileadi, C. & Schramm, M. (1988) Interaction of the (3-adrenergic receptor 
with Gs following delipidation. Specific lipid requirements for Gs activation and GTPase 
function. Eur. J. Biochem. 176, 649-654.
Benowitz, L.I., Perrone-Bizzozero, N.I., Finklestein, S.P. and Bird, E.D. (1989) Localisation 
of the growth-associated phosphoprotein GAP-43 (B-50, FI) in the hum an cerebral cortex.
J. Neuroscience. 9,990-995.
Bergamaschi, S., Govoni, S., Battaini, F., Trabucchi, M., Del Monaco,S. & Parenti, M. (1992) 
G protein modulation of co-conotoxin binding sites in neuroblastoma X glioma NG 108-15 
hybrid cells. J. Neurochem. 59,536-543.
Bergstrom, L., Farlind, A., Nilsson, L., Alafuzoff, I., Fowler, C.J., Winblad, B. and Cowburn, 
R.F. (1991) Regional distribution of somatostatin receptor binding and m odulation of 
adenylyl cyclase activity in Alzheimer's disease brain. J. Neurol, Sci. 105, 225-233.
Berridge, M.J., Downes, C.P. & hanley, M.R. (1982) Lithium amplifies agonist-dependent 
phosphatidylinositol responses in brain and salivary glands. Boichem. J. 206, 587-595.
Berti-Mattera, L.N., Dougals, J.G., Mattera, R. and Goraya, T.Y. (1992) Identification of G 
protein subtypes in peripheral nerve and cultured schwann cells. J. Neurochem. 59,1729-1735.
Bimbaumer, L., Abramowitz, J. and Brown A.M. (1990) Receptor-effector coupling by G 
proteins. Biochim et Biophys Acta. 1031, 163-224.
Bizzarri, C., Di Girolamo, M., D'Orazio, M.C. & Corda, D. (1990) Evidence that a guanine 
nucleotide-binding protein linked to a muscarinic receptor inhibits directly phospholipase C. 
Proc. Natl. Acad, Sci. USA. 87, 4889-4893.
179
Bonner, T.I. (1992) Domains of muscarinic acetylcholine receptors that confer specificity of G 
protein coupling. TiPS. 13, 48-50.
Bonner, T.I. ((1989) The molecular basis of muscarinic receptor diversity. Ti NS. 1 2 ,148-151.
Bouvier, M., Szatkowski, M., Amato, A. & Attwell, D. (1992) The glial cell glutam ate 
uptake carrier countertransports pH-changing anions. Nature. 360,471-474.
Bowling, A.C., Mutisya, E.M., Walker, L.C., Price, D.L., Cork, L.C. & Beal, M.F. (1993) Age- 
dependent impairment of mitochondrial function in primate brain.
J. Neurochem. 60, 1964-1967.
Braak, H. & Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. 
Neuropathol. 82, 239-259.
Brabet, P., Dumuis, A., Sebben, M., Pantaloni, C., Bockaert, J. & Homburger, V. (1988) 
Immunocytochemical localisation of the guanine nucleotide-binding protein GQ in prim ary 
cultures of neuronal and glial cells. }. Neuroscience. 8,701-708.
Brandt, D.R. & Ross, E.M. (1986) Catecholamine-stimulated GTPase cycle.
}. Biol. Chem. 261, 1656-1664.
Bray, P., Carter, A., Simons, C., Guo, V., Puckett, C. Kamholz, J., Spiegel, A. & Nirenberg, M. 
(1986) Human cDNA clones for four species of G ag signal transduction protein.
Proc. Natl. Acad. Sci. U.S.A. 83, 8893-8897.
Brion, J.P. (1990) Molecular pathology of Alzheimer amyloid and neurofibrillary tangles. 
Neurosciences. 2, 89-100.
180
Bristow, M.R., Ginsburg, R., Minobe, W., Cubicciotti, R.S., Sageman, W.S., Lurie, K., 
Billingham, M.E., Harrison, D.C. & Stinson, E.D. (1982) Decreased catecholamine 
sensitivity and p-adrenergic receptor density in failing hum an hearts. N. Eng. J. Med. 307, 
205-211.
Bristow, M.R., Ginsburg, R., Umans, V., Fowler, M., Minobe, W., Rasmussen, R., Zera, P., 
Menlove, R., Shah, P., Jamieson, S. & Stinson, E.B. (1986) p j- and P2 - Andrenergic-receptor 
subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both 
receptor subtypes to muscle contraction and selective P |- receptor down-regulation in heart 
failure.Circulation Research. 59, 297-309.
Browne, S.E., Horsburgh, K., Dewar, D. & McCulloch, J. (1991) D-[^H]-Aspartate binding 
does not local glutamate-releasing neurones in the retino-fugal projection: An 
autoradiographic comparison with [^H]-cyclohexyladenosine binding.
Mol. Neuropharm. 1, 129-133.
Bartfai, T. (1979) Preparation of metal chelate complexes and the design of steady-state 
kinetic experiments involving metal nucleotide complexes.
Advances in Cyclic Nucleotide Research, 10, 219-246.
Bushfield, M., Murphy, G.J., Lavan, B.E., Parker, P.J., Hruby, V.J., Milligan, G. &
Houslay, M.D. (1990a) Hormonal regulation of G^2 a-subunit phosphorylation in intact 
hepatocytes. Biochem. J. 268, 449-457.
Bushfield, M., Griffiths, S.L., Murphy, G.J., Pyne, N.J., Knowler, J.T., Milligan, G.,
Parker, P.J., Mollner, S. and Houslay, M.D. (1990b) Diabetes-induced alterations in  the 
expression,functioning and phosphorylation state of the inhibitory guanine nucleotide 
regulatory protein Gj-2 hepatocytes. Biochem. J. 271, 365-372.
181
Bushfield, M., Lavan, B.E. & Houslay, M.D. (1991) Okadaic acid indentifies a 
phosphorylation/dephosphorylation cycle controlling the inhibitory guanine-binding 
regulatory protein Gj2. Biochem. J. 274, 317-321.
Buxbaum, J.D., Gandy, S.E., Cicchetti, P., Ehrlich, M.E., Czernik, A.J., Fracasso, R.P., 
Ramabhadran, T.V., Unterbeck, A.J. & Greengard, P. (1990) Processing of Alzheimer p/A 4 
amyloid precursor protein: Modulation by agents that regulate protein phosphorylation.
Proc. Natl Acad Sci U.S.A. 87, 6003-6006.
Buxbaum, J.D., Oishi, M., Chen, H.I., Pinkas-Kramarski, R., Jaffe, E.A., Gandy, S.E. & 
Greengard, P. (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion 
of the Alzheimer p/A 4 amyloid protein precursor.
Proc. Natl. Acad. Sci. USA.89, 10075-10078.
Caldwell K.K., Boyajian, C.L. & Cooper, D.M.F. (1992) The effects of Ca^+ and calmodulin 
on adenylyl cyclase activity in plasma membranes derived from neural and non-neural cells. 
Cell Calcium. 13, 107-121.
Camps, M., Carozzi, A., Schnabel, P., Scheer, A., Parker, P.J. & Gierschik, P. (1992) Isozyme- 
selective stimulation of phospholipase C-P2 by G protein Py-subunits. Nature. 360,684-686.
Candy, J.M., Klinowski, J., Perry, R.H., Perry, E.K., Fairbum, A., Oakley, A.E.,
Carpenter, T.A., Atack, J.R., Blessed, G. & Edwardson, J.A. (1986) Aluminosilicates and 
senile plaque formation in Alzheimer's disease. The Lancet 1, 354-356.
Candy, J.M., Court, J.A., Perry, R.H. & Smith, C.J. (19 84) Carbachol-stimulated 
phosphatidylinositol hydrolysis in the cerebral cortex after freezing and post mortem delay. 
Brit. J. Pharmacology.83, 356P.
Cantiello, H.F., Patenaude, C.R., Codina, J., Birnbaumer, L. & Ausiello, D.A. (1990) G at-3  
regulates epithelial N a+ channels by activation of phospholipase A2  and lipoxygenase 
pathways. J. Biol. Chem. 265, 21624-21628.
182
Carlier, M.F. & Pantaloni, D. (1981) Kinetic analysis of guanosine 5'-triphosphate 
hydrolysis associated with tubulin polymerisation. Biochem.20, 1918-1924.
Carr, C., Loney, C., Unson, C., Knowler, J. & Milligan, G. (1990) Chronic exposure of rat 
glioma C6 cells to cholera toxin induces loss of the a-subunit of the stimulatory guanine 
nucleotide-binding protein (Gg). Eur. J. Pharmacol 188, 203-209.
Casey, P.J., Fong, H.K.W., Simon, M.I. & Gilman, A.G. (1990) Gz, a guanine nucleotide- 
binding protein with unique biochemical properties. J. Biol. Chem. 265, 2383-2390.
Cassel, D. & Selinger, Z. (1976) Catecholamine-stimulated GTPase activity in turkey 
erythrocyte membranes Biochima et Biophysica Acta. 452, 538-551.
Cataldo, A.M. & Nixon, R.A. (1990) Enzymatically active iysosomal protesases are 
associated with amyloid deposits in Alzheimer brain.
Proc. Natl. Acad. Sci. USA. 87, 3861-3865.
Cerione, R.A. (1991) Reconstitution of receptor/GTP-binding protein interactions.
Biochimica et Biophysica Acta. 1071, 473-501.
Chafi, A.H., Hauw, J.J., Rancurel, G., Berry, J.P. & Galle, C. (1991) Absence of alum inium  in 
Alzheimer's disease brain tissue: electron microprobe and ion microprobe studies.
Neuroscience Letters. 123, 61-64.
Chan-Palay, V., (1987) Somatostatin immunoreactive neurons in the hum an hippocam pus and 
cortex shown by imm unogold/silver intensification on vibratome sections: coexistence with 
neuropeptide Y neurons, and effects in Alzheimer-type dementia.
J. Comp. Neurol. 260, 201-223.
183
Chalmers, D.T., Dewar, D., Graham, D.I., Brooks, D.N. & McCulloch, J. (1990) Differential 
alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. 
Proc. Natl. Acad. Sci. USA. 87, 1352-1356.
Chartier-Harlin, M.C., Crawford, F. Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, 
A., Rossor, M., Roques, P., Hardy, J. & Mullan M. (1991) Early-onset Alzheimer's disease 
caused by mutations at codon 717 of the (5-amyloid precursor protein gene.
Nature. 353, 844-845.
Chee, M.S., Satchwell, S.C., Preddie, E., Weston, K.M. & Barrell, B.G. (1990) Hum an 
cytomegalovirus encodes three G protein-coupled receptor homologues. Nature. 344, 774-777.
Childers, S.R. (1991) Opioid receptor-coupled second messenger systems.
Life Sciences. 48, 1991-2003.
Chu, D.C.M., Penney, J.B. & Young, A.B. (1987) Corical GABAg and GABA^ receptors in 
Alzheimer’s disease: A quantitative autoradiographic study. Neurology. 37,1454-1459.
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y. Seubert, P., Vigo-Pelfrey, C., 
Lieberburg, I. & Selkoe, D.J. (1992) Mutation of the (5-amyloid precursor protein in familial 
Alzheimer's disease increases (5-protein production. Nature. 360, 672-674.
Clapham, D.E. & Neer, E.J. (1993) New roles for G-protein PY-dimers in transmembrane 
signalling. Nature. 365, 403-406.
Cockcroft, S. (1992a) G-protein-regulated phospholipase C, D and A2 -mediated signalling in 
neutrophils. Biochimica et Biophysica Acta. 1113, 135-160.
184
Cockcroft, S. & Thomas, M.H. (1992b) Inositol-lipid-specific phospholipase C isoenzymes 
and their differential regulation by receptors. Biochem. J. 288, 1-14.
Codina, J., Hildebrandt, J.D. & Bimbaumer, L. (1984) Effects of guanine nucleotides and Mg on 
hum an erythrocyte Nj and N g, the regulatory components of adenylyl cyclase.
J. Biol. Chem. 259, 11408-11418.
Cohen-Armon, M. & Sokolovsky, M. (1991) Depolarisation-induced changes in the 
muscarininc receptor in rat brain and heart are mediated by pertussis-toxin-sensitive G- 
proteins. J. Biol. Chem. 266, 2595-2605.
Cooper, D.M.F. & Brooker, G. (1993) Ca -inhibited adenylyl cyclase in cardiac tissue.
TiPS. 14,34-36.
Colin, S.F., Chang, H.C., Mollner, S., Pfeuffer, T., Reed, R.R., Duman, R.S. & Nestler, E.J. 
(1991) Chronic lithium regulates the expression of adenylate cyclase and G^-protein in a  
subunit in rat cerebral cortex. Proc. Natl. Acad. Sci. USA. 88, 10634-10637.
Cole, G. Dobkins, K.R., Hansen, L.A., Terry, R.D. & Saitoh, T. (1988) Decreased levels of 
protein kinase C in Alzheimer brain. Brain Research. 452, 165-174.
Conklin, B.R., Chabre, O., Wong, Y.H., Federman, A.D. & Bourne, H.R. (1992) Mutational 
activiation and coupling to receptors and phospholipase C. J. Biol. Chem. 267,31-34.
Connor, D.J. & Harrell, L.E. (1989) Chronic septal lesions cause upregulation of cholinergic 
but not noradrenergic hippocampal phosphoinositide hydrolysis.
Brain Reasearch. 488, 387-389.
185
Cooper, D.M.F., Boyajian, C.L., Goldsmith, P.K., Unson, C.G. &Spiegel, A. (1990)
Differential expression of low molecular weight form of Gg-a  in neostriatum and cerebellum: 
correlation with expression of calmodulin-independent adenylyl cyclase.
Brain Research. 523, 143-146.
Cortes, R., Probst, A. & Palacios, J.M. (1988) Decreased densities of dopamine D1 receptors in 
the putam en and hippocampus in senile dementia of the Alzheirmer type.
Brain Research. 475, 164-167.
Court, J.A., Keith, A.B., Kerwin, J.M. and Perry, E.K. (1990) Fimbria-fornix lesions in aged 
rats cause increased carbachol-stimulated phosphoinositide hydrolysis in the hippocampus, 
but no change in muscarinic receptor binding. Brain Research. 532, 333-335.
Cowburn, R.F., Hardy, J.A., Briggs, R.S. & Roberts, P.J. (1989) Characterisation, density and 
distribution of kainate receptors in normal and Alzheimer's diseased hum an brain.
J. Neurochem. 52,140-147.
Cowburn, R.F., O'Neill, C., Ravid, R., Alafuzoff, I., Winblad, B. & Fowler, C.J. j (1992a) 
Adenylyl cyclase activity in postmortem human brain: Evidence of altered G protein 
mediation in Alzheimer's disease. J. Neurochem. 58,1409-1419.
Cowburn, R.F., O'Neill, C., Ravid, R., Winblad, B. & Fowler, C.J.| (1992b) Preservation of G -  
protein inhibited adenylyl cyclase activity in the brains of patients w ith Alzheimer's 
d isease.Neuroscience Letters. 141,16-20.
Cross, A.J., Crow, T.J., Perry, E.K., Perry, R.H., Blessed, G., & Tomlinson, B.E. (1981) Reduced 
dopamine-beta-hydroxylase activity in Alzheimer's disease. Br. Med. J. 282, 93-94.
Cross, A.J., Crow, T.J., Ferrier, I.N., Johnson, J.A., Bloom, S.R. & Corsellis, J.A.N. (1984a) 
Serotonin receptor changes in dementia of the Alzheimer type. J. Neurochem. 43, 1574-1581.
186
Cross, A.J., Crow, T.J., Ferrier, I.N., Johnson, J.A. & Markakis, D. (1984b) Striatal dopamine 
receptors in Alzheimer-type dementia. Neuroscience. Letters 52,1-6.
Cross, A.J., Slater, P., Perry, E.K. & Perry, H. (1988) An autoradiographic analysis of 
serotonin receptors in hum an temporal cortex: Changes in Alzheimer-type dementia. 
Neurochem. Int. 13, 89-96.
Crow, T.J., Cross, A.J., Cooper, S.J. et al. (1984) Neurotransmitter receptors and monoamine 
metabolites in the brains of patients with Alzheimer-type dementia and depression, and 
suicides. Neuropharm. 23,1561-1569.
Crutcher, K.A., Brothers, L. & Davis, J.N. (1981) Sympathetic noradrenergic sprouting in 
response to central cholinergic denervation: A histochemical study of neuronal sprouting in 
the rat hippocampal formation. Brain Research. 210,115-128.
D'Amato, R.J., Zweig, R.M., Whitehouse, P.J., Wenk, G.L., Singer, H.S., Mayeux, R.., Price, 
D.L. & Snyder, S.H. (1987) Aminergic systems in Alzheimer's disease and Parkinson's 
disease. Ann. Neurol. 22,229-236.
Danielsson, E., Eckernas, S.A., Westland-Danielsson, A., Nordstrom, O., Bartfai, T.,
Gottfries, C.G. & Wallin, A. (1988) VIP-sensitive adenylate cyclase, guanylate cyclase, 
muscarinic receptors, choline acetyltransferase and acetylcholinesterase, in brain tissue 
afflicted by Alzheimer's disease/senile dementia of the Alzheimer type.
Neurobiology of Aging. 9, 153-162.
Davies, C.A., Mann, D.M.A., Sumpter, P.Q. & Yates, P.O. (1987) A quantitative 
morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex 
in patients with Alzheimer's disease. J. Neurological Sciences. 78,151-164.
187
Davies, C.A., Morroll, D.R., Prinja, D., Mann, D.M.A. & Gibbs, A. (1990) A quantitative 
assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal
and temporal cortex of patients with Alzheimer's disease.
J. Neurological Sciences. 96, 59-73.
Dawson, V.L. & Wamsley, J.K. (1990) Hippocampal muscarinic supersensitivity after AF64A 
medial septal lesion excludes M | receptors. Brain Research. 25,311-317.
DeArmond, S.J., Fajardo, M., Naughton, S. & Eng. L.F. (1983) Degradation of glial fibrillary 
acidic protein by a calcium dependent proteinase: an electroblot study.
Brain Research. 262, 275-282.
Decker, M.W. (1987) The effects of aging on hippocampal and cortical projections of the
forebrain cholinergic system. Brain Research Rev. 12, 423-438.
De Keyser, J., Dierckx, R., Vanderheyden, P., Ebinger, G. & Vauquelin, G. (1988) Dj 
dopamine receptors in human putament, frontal cortex and calf retina: differences in gaunine 
nucleotide regulation of agonist binding and adenylate cyclase stimulation.
Brain Research. 443, 77-84.
De Keyser, J., Walraevens, H., De Backer, J.P., Ebinger, G. & Vauqelin, G. (1989b) D2 
dopamine receptors in the human brain: heterogeneity based on differences in guanine 
nucleotide effect on agonist binding, and their presence on corticostriatal nerve terminals. 
Brain Research. 484, 36-42.
De keyser, J., De Backer, J.P., Ebinger, G. & Vauqelin, G. (1989a) Coupling of D^ dopamine 
receptors to the quanine nucleotide binding protein Gs is deficient in Huntington's disease. 
Brain Research. 496, 327-330.
188
De keyser, J., Ebinger, G. & Vauqelin, G. (1990) Dj dopamine receptor abnormality in frontal 
cortex points to a functional alteration of cortical cell membranes in Alzheimer's disease. 
Arch. Neurol. 47, 761-763.
Dewar, D & McCulloch, J. (1994) Abmormalities in non-cholinergic neurotransmitter systems 
in Alzheimer's disease. In : Dementia p. 159-184. Ed. A.Bums & R.Levy.
Chapm an & Hall Medical London.
De Vos, H., Vauqelin, G., De keyser, J., De Backer, J.P. & Van Liefde, I. (1992) Regional 
distribution of a ^ -  and - adrenoceptor subtypes in postmortem hum an brain.
J. Neurochem. 58,1555-1560.
Dewar, D., Graham, D.I. & McCulloch, J. (1990a) 5 HT2 receptors in dementia of the 
Alzheimer type: a quantitative autoradiographic study of frontal cortex and hippocampus.
J. Neural Transm. 2,129-137.
Dewar, D., Horsburgh, K., Graham, D.I., Brooks, D.N. & McCulloch, J. (1990b) Selective 
alterations of high affinity [^H] forskolin binding sites in Alzheimer’s disease: a 
quantitative autoradiographic study. Brain Research. 511, 241-248.
Dewar, D., Chalmers, D.T., Graham, D.I. & McCulloch, J. (1991) Glutamate metabotropic 
and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the 
hippocam pus. Brain Reaserch. 553, 58-64.
Dixon, R.A.F., Sigal, I.S., Rands, E., Register, R.B., Candelore, M.R., Blake, A.D. & Strader, 
C.D. (1987) Ligand binding to the P-adrenergic receptor involves its rhodopsin-like core. 
Nature. 326, 73-77.
189
Dodd, P.R., Hambley, J.W., Cowburn, R.F. & Hardy, J.A. (1988) A comparison of 
methodologies for the study of fuctional transmitter neurochemistry in hum an brain.
J. Neurochem. 50, 1333-1345.
Dokas, L.A. & Ting, S.M. (1993) A comparison of the regulatory properties of striatal and 
cortical adenylate cyclase. Neurobiology of Aging. 14, 65-72.
Drewes, G., Lichtenberg-Kraag, B., Doring, F., Mandelkow, E.M., Biernat, J., Goris, J., Doree, 
M & Mandelkow, E. (1992) Mitogen activated protein (MAP) kinase transforms tau protein 
into an Alzheimer-like state. EMBO Journal. 11,2131-2138.
Drinnan, S.L., Hope, B.T., Snutch, T.P. & Vincent, S.R. (1991) Golf in the basal ganglia. 
Molecular and Cellular Neuroscience. 2,66-71.
Duffy, P.E., Rapport, M & Graf, L. (1980) Glial fibrillary acidic protein and Alzheimer-type 
senile dementia. Neurology. 30, 778-782.
Eagger, S.A., Levy, R. & Sahakian, B.J. (1991) Tacrine in Alzheimer's disease.
The Lancet. 337, 989-992
Ebersolt, C., Perez, M. & Bockaert, J. (1981) Neuronal, glial and meningeal localisations of 
neurotransmitter-sensitive adenylate cyclases in cerebral cortex of mice.
Brain Research. 213, 139-150.
Eriksson, P.S., Carlsson, B., Isaksson, G.P., Hansson, E. & Ronnback, L. (1992) Altered amounts 
of G-protein mRNA and cAMP accumulation after long-term opiod receptor stimulation of 
neurons in primary culture from the rat cerebral cortex.
Molecular Brain Research. 14, 317-325.
190
Farooqui, A.A. & Horrocks, L.A. (1991) Excitatory amino acid receptors, neural membrane 
phospholipid metabolism and neurological disorders. Brain Research. 16,171-191.
Federman, A.D., Conklin, B.R., Schrader, K.A., Reed, R.R. & Bourne, H.R. (1992) Hormonal 
stimulation of adenylyl cyclase through Gj- protein (fy subunits. Nature. 356,159-161.
Feinstein, P.G., Schrader, K.A., Bakalyar, H.A., Tang, W.J., Krupinski, J., Gilman, A.G. & 
Reed, R.R. (1991) Molecular cloning and characterisation of a Ca^+ /calmodulin-insensitive 
adenylyl cyclase from rat brain. Proc. Natl. Acad. Sci. USA. 88,10173-10177.
Feldman, A.M., Cates, A.E., Veazey W.B., Hershberger, R.E., Bristow, M.R., Baughman, 
K.L., Baumgartner, W.A. & Van Dop, C. (1988) Increase of the 40,000-mol w t pertussis toxin 
substrate (G protein) in the failing hum an heart. J. Clin. Invest. 82, 189-197.
Ferguson, K.M., Higashijima, T., Smigel M.D. & Gilman, A.G. (1986) The influence of bound 
GDP on the kinetics of guanine nucleotide binding to G proteins. J. Biol. Chem. 261, 7393-7399.
Ferrier, I.N., Cross, A.J., Johnson, J.A., Roberts, G.W., Crow, T.J., Corsellis, J.A.N., Lee, Y.C., 
O’Shaughnessy, D., Adrian, T.E., McGregor, G.P., Baracese-Hamilton, A.J. & Bloom, S.R. 
(1983) Neuropeptides in Alzheimer type dementia. J. Neurol. Sci. 62,159-170.
Fisher, S.K., McEwen, E., Kunkle, C., Thompson, A.K. & Slowiejko, D. (1993) Contribution of 
G protein activation to fluoride stimulation of phosphoinositide hydrolysis in hum an 
neuroblastoma cells. J. Neurochem. 60,1800-1805.
Florez, J.C., Nelson, R.B. & Routtenberg, A. (1991) Contrasting patterns of protein 
phosphorylation in human normal and Alzheimer brain.: Focus on protein kinase C and 
protein FI/GAP-43. Experimental Neurology. 112, 264-272.
191
Flynn, D.D., Weinstein, D.A. & Mash, D.C. (1991) Loss of high affinity agonist binding to 
muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic 
replacement therapies. Ann. Neurol. 29, 256-262.
Fong, H.K.W., Yoshimoto, K.K., Eversole-Cire, P. & Simon, M.I. (1988) Identification of a 
GTP-binding protein a  subunit that lacks an apparent ADP-ribosylation site for pertussis 
toxin. Proc. Natl. Acad. Sci. USA. 85,3066-3070.
Fonnum. F. (1975) A rapid radiochemical method for the determination of choline 
acetyl transferase. J. Neurochem. 24, 407-409.
Fowler, M.B., Laser, J.A., Flopkins, G.L., Minobe, W. & Bristow, M.R. (1986) Assessment of 
the p-adrenergic receptor pathway in the intact failing hum an heart: progressive receptor 
down-regulation and subsensitivity to agonist response. Circulation, 74,1290-1302.
Francis, P.T., Pangalos, M.N. & Bowen, D.M. (1992) Animal and drug modelling for 
Alzheimer synaptic pathology. Progress in Neurology. 39, 517-545.
Francis, P.T., Sims, N.R., Procter, A.W. & Bowen, D.M. (1993) Cortical pyramidal neurone 
loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: 
Investigative and therapeutic perspectives. J. Neurochem. 60,1589-1604.
Franklin, P.H. & Hoss, W. (1984) Opiates stimulate low GTPase in brain.
J. Neurochem. 43, 1132-1135.
Freund, T.F. & Antal, M (1988) GABA-containing neurons in the septum  control inhibitory 
interneurons in the hippocampus. Nature. 336,170-173.
Fukada, Y., Takao, T., Ohguro, H., Yoshizawa, T., Akino, T & Shimonishi, Y. (1990) 
Farnesylated y-subunit of photoreceptor G protein indispensable for GTP-binding.
Nature. 346, 658-660.
192
Fukamauchi, F., Hough, C. & Chuang, D.M. (1991) Expression and agonist-induced down- 
regulation of mRNAs of m2 - and m3-muscarinic acetylcholine receptors in cultured cerebellar 
granule cells./. Neurochem. 56, 716-719.
Fung, B.K.K. (1983) Characterisation of transducin from bovine retinal rod outer segments.
J. Biol Chem. 258, 10495-10502.
Gallego, C., Gupta, S.K., Winitz, S., Eisfelder, B.J. & Johnson, G.L. (1992) Myristoylation of 
the Got|2  polypeptied, a G protein a  subunit, is required for its signalling and transformation 
functions. Proc. Natl. Acad. Sci. USA. 89,9695-9699.
Gandy, S., Czemik , A.J.& Greengard, P. (1988) Phosphorylation of Alzheimer disease 
amyloid precursor peptide by protein kinase C and Ca^+/calm odulin-dependent protein 
kinase II. Neurobiology. 85, 6218-6221.
Gao, B. & Gilman, A.G. (1991) Cloning and expression of a widely distributed (type IV) 
adenylyl cyclase. Proc. Natl. Acad. Sci. USA. 88,10178-10182.
Gawler, D., Milligan, G., Spiegel, A.M., Unson, C.G. & Houslay, M.D. (1987) Abolition of the 
expression of inhibitory guanine nucloetide regulatory protein Gj activity in diabetes.
Nature. 327, 229-232.
Geddes, J.W., Monachan, D.T., Cotman, C.W., Lott, I.T., Kim, R.C. & Chang Chui, H. (1985) 
Plasticity of hippocampal circuitry in Alzheimer's disease. Science. 230, 1179-1181.
Geddes, J.W., Anderson, K.J. & Cotman, C.W. (1986) Senile plaques as aberrant sprout- 
stimulating structures. Exp. Neurol. 94,767-776.
Geddes, J.W., Brunner, L., Cotman, C.W. & Buzsaki, G. (1992) Alterations in [^HJKainate and 
N-M ethyl-D-Aspartate-Sensitive L-[^H]-Glutamate Binding in the Rat Hippocam pal 
Formation following Fimbria-Fomix Lesions. Exp. Neurol. 115, 271-281.
193
Gehlert, D.R. (1986) Regional modulation of [^H] forskolin binding in the rat brain by 
guanylyl-5'-imidodiphosphate and sodium fluoride: Comparison with the distribution of 
guanine nucleotide binding sites. J. of Pharmacol and Exp.Therapeutics. 239, 952-959.
Ghodsi-Hovsepian, S., Messer Jr, W.S. & Hoss, W. (1990) Differential coupling between 
muscarinic receptors and G-proteins in regions of the rat brain.
Biochemical Pharmacology. 39, 1385-1391.
Gilman, A.G. (1987) G proteins: Transducers of receptor-generated signals.
Ann. Rev. Biochem. 56, 615-649.
Ginn, S.R. & Peterson, G.M. (1992) Studies related to the use of colchicine as a neurotoxin in 
the septohippocampal cholinergic system. Brain Research. 590, 144-152.
Girault, J.A., Raisman-Vozari, R., Agid, Y. & Greengard, P. (1989) Striatal phosphoproteins 
in Parkinson disease and progressive supranuclear palsy.
Proc. Natl. Acad. Sci. USA. 86, 2493-2497.
Glatt, C.E. & Snyder, S.H. (1993) Cloning and expression of an adenylyl cyclase localised to 
the corpus striatum. Nature. 361,536-538.
Glenner,, G.G. & Wong, C.W. (1984) Alzheimer's disease: initial report of the purification 
and characterisation of a novel cerebrovascular amyloid protein.
Biochem. Biophys. Res. Commun. 120, 885-890.
Goate, A., Chartier-Harlin, M.C., Mullan, M. Brown, J., Crawford, F., Fidani, L., Giuffra, L., 
Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., Roques, P., Talbot, C., 
Pericak-Vance, M., Roses, A., Williamson, R., Rossor, M., Owen, M. & Hardy, J. (1991) 
Segregation of a missense mutation in the amyloid precursor protein gene with familial 
Alzheimer's disease. Nature. 349, 704-706.
194
Godchaux, W. & Zimmerman, W.F. (1979) Membrane -dependent guanine nucleotide binding 
and GTPase activities of soluble protein from bovine rod cell outer-segments.
}. Biol. Chem. 254, 7874-7884.
Goedert, M., Spillantini, M.G., Cairns, N.J. & Crowther, R.A. (1992) Tau proteins of 
Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. 
Neuron. 8,159-168.
Goldgaber, D., Lerman, M.I., McBride, O.W., Saffoitti, U. & Gajdusek, D.C. (1987) 
Characterisation and chromosomal localisation of a cDNA encoding brain amyloid of 
Alzheimer's disease. Science. 235, 877-880.
Gottfries, C.G. (1990) Disturbance of the 5-hydroxytryptamine metabolism in brains from 
patients with Alzheimer's dementia. J. Neurol. Transm. 30, 33-43.
Gottfries, C.G. (1992) Review of treatment strategies. Acta. Neurol. Scand. 85,63-68.
Granneman, J.G., Haverstick, D.M. & Chaudhry, A. (1990) Relationship between Gsa  
messenger ribonucleic acid splice variants and the molecular forms of Gga protein in rat brown 
adipose tissue. Endocrinology. 127, 1596-1601.
Granneman, J.G. & Bannon, M.J. (1991) Splicing pattern of Gga mRNA in hum an and rat brain. 
J. Neurochem. 57, 1019-1923.
Gray, J.A., Sinden, J.D. & hodges, H. (1990) Cognitive function: neural degeneration and 
transplantation. Neurosciences. 2,133-142.
Graziano, M.P., Freissmuth, M. & Gilman, A.G. (1989) Expression of Gga in escherichia coli. 
Purification and properties of two forms of the protein. J. Biol. Chem. 264, 409-418.
195
Greenamyre, J.T., Penney, J.B., Young, A.B., D'Amato, C.J., Hicks, S.P. & Shoulson, I. (1985) 
Alterations in ^-glutamate binding in Alzheimer's and Huntington's disease.
Science. 227, 1496-1499.
Greenamyre, J.T., Higgins, D.S. & Young, A.B. (1990) Sodium-dependent D -aspartate 
'binding' is not a measure of presynaptic uptake sites in an autoradiographic assay.
Brain. Research 511, 310-318.
Guy, P.M., Koland, J.G. Cerione, R.A. (1990) The influence of bound GDP on the kinetics of 
Guanine nucloetide binding to G-proteins. Biochemistry 2 9 ,6954-6964.
Grundke-Iqbal, I., Iqbal, K. Quinlan, M., Tung, Y.C., Zaidi, M. & Wisniewski, H.M. (1986) 
Microtubule-associated protein tau. J. Biol. Chem. 261,6084-6089.
Haass, C., Schlossmacher, M.G., Hung, A.Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B.L., 
Lieberburg, I., Koo, E.H., Schenk, D., Teplow, D.B. & Selkoe, D.J. (1992a) Amyloid P-peptide 
is produced by cultured cells during normal metabolism. Nature. 359,322-325.
Haass, C., Koo, E.H., Mellon, A., Hung, A.Y. & Selkoe, D.J. (1992b) Targeting of cell-surface 
P-amyloid precursor protein to iysosomes: alternative processing into amyloid-bearing 
fragments. Nature. 357, 500-503.
Hadcock, J.R., Ros, M., Watkins, D.C. & Malbon, C.C. (1990) Cross-regulation between G- 
protein-mediated pathways. J. Biol. Chem. 265, 14784-14790.
Hadcock, J.R., & Malbon, C.C. (1993) Agonist regulation of gene expression of adrenergic 
receptors and G proteins. J. Neurochem. 60,1-9.
196
Haga, K. & Haga T. (1992) Activation by g protein Py subunits of agonist- or light-dependent 
phosphorylation of muscarinic acetylcholine receptors and rhodopsin.
J. Biol. Chem. 267, 2222-2227.
Haglid, K.G., Wang, S., Hamberger, A., Lehmann A. & Moller, C.J. (1991) Neuronal and 
glial marker proteins in the evaluation of the protective action of MK 801.
J. Neurochem. 56,1957-1961.
Hamm, H.E., Deretic, D., Arendt, A., Hargrave, P.A., Koenig, B. & Hofmann, K.P. (1988)
Site of G protein binding to rhodopsin mapped with synthetic peptides for the a  subunit. 
Science. 241, 832-835.
Hanger, D.P. Brion, J.P., Gallo, J.M., Cairns, N.J., Luther, P.J. & Anderton, B.H. (1991) Tau in 
Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphoiylated. 
Biochem. J. 275, 99-104.
Harrison, P.J., Barton, A.J.L., Najlerahim, A., McDonald, B. & Pearson, R.C.A. (1991) 
Increased muscarinic receptor messenger RNA in Alzheimer s dosease temporal cortex 
dem onstrated by in situ hybridisation histochemistry. Molecular Brain Research. 9,15-21.
Hatta, S., Marcus, M.M. & Rasenick, M.M. (1986) Exchange of guanine nucleotide between 
GTP-binding proteins that regulate neuronal adenylate cyclase.
Proc. Natl. Acad. Sci.USA. 83, 5439-5443.
Hausdorff, W.P., Pitcher, J.A., Luttrell, D.K., Linder, M.E. Kurose, H., Parsons, S.J., Caron, 
M.G. & Lefkowitz, R.J. (1992) Tyrosine phosphorylation of G protein a  subunits by pp60c_src. 
Proc. Natl. Acad. Sci. USA. 89, 5720-5724.
Henderson, V.W. & Finch, C.E. (1989) The neurobiology of Alzheimer's disease.
J. Neurosurg. 70, 335-353.
197
Hershberger, R.E. Feldman, A.M. & Bristow, M.R. (1991) A-j-Adenosine receptor inhibition 
of adenylate cyclase in failing and nonfailing human ventricular myocardium.
Circulation. 83,1343-1351.
Herve, D., Levi-Strauss, M., Marey-Semper, I., Verney, C., Tassin, J.P. Glowinski, J & Girault, 
J.A.(1993) GQj£ and Gg in rat basal ganglia: Possible involvement of GQj£ in the coupling of 
dopamine D | receptor with adenylyl cyclase. J. Neuroscience. 13, 2237-2248.
Hescheler, J., Rosenthal, W., Trautwein, W. & Schultz, G. (1987) The GTP-binding protein GQ 
regulates neuronal calcium channels. Nature. 325,445-447.
Hildebrandt, J.D., Hanoune, J. & Bimbaumer, L. (1982) Guanine nucleotide inhibition of eye' 
S49 mouse lymphoma cell membrane adenylyl cyclase. J. Biol. Chem. 257,14723-14725.
Hilf, G. & Jakobs, K.H. (1989) Activation of cardiac G-proteins by muscarinic acetylcholine 
receptors regulation by Mg^+ and N ations. Eur. J. Pharmacol. 172, 155-163.
Holz, G.G., Kream, R.M. Spiegel, A. & Dunlap, K. (1989) G proteins couple a-adrenergic and 
GABAjj receptors to inhibition of peptide secretion from peripheral sensory neurons.
J. Neuroscience.9, 657-666.
Horsburgh, K., Dewar, D., Graham, D.I. & McCulloch J. (1991) Autoradiographic imaging of 
[^H] phorbol 12 ,13-dibutyrate binding to protein kinase C in Alzheimer's disease.
J. Neurochem. 56, 1121-1129.
Horsburgh, K., Inglis, F.M. & McCulloch, J. (1993) Focal increases in [^H] forskolin and [^H] 
phorbol 12 ,13-dibutyrate binding in the rat brain following lesions of the medial septum. 
Neuroscience Letts. 151, 166-169.
Hoss, W., Franklin, P.H. & Ghodsi-Hovsepian, S. (1988) Characterisation of low GTPase 
avtivity in rat brain: Comparison of opiod and muscarinic receptor stimulation.
Journal of Pharmaceutical Sciences. 77, 353-358.
198
Hausdorff, W. P., Caron, M.G., & Lofkowitz, R.J. (1990) Turning off the signal: desensitisation 
of the P-adrenergic receptor function. FESEB J. 4 2888-2889
Hubbard, B.M. & Anderson, J.M. (1985) Age-related variations in the neuron content of the 
cerebral cortex in senile dementia of Alzheimer type. Neuropathology and Applied 
Neurobiology. 11,369-382.
Hyman, B.T., Kromer, L.J. & Van Hoesen, G.W. (1987) Reinnervation of the hippocampal 
perforant pathway zone in Alzheimer's disease. Ann. Neurol. 21, 259-267.
Iimoto, D.S., Masliah, E., De Teresa, R., Terry, R.D. & Saitoh, T. (1989) Aberrant casein 
kinase II in Alzheimer’s disease. Brain Research. 507, 273-280.
Ikeda, S.I., Allsop, D. & Glenner, G.G. (1989) Morphology and distribution of plaque and 
related deposits in the brains of Alzheimer's disease and control cases.
An immunohistochemical study using amyloid P-protein antibody.
Laboratory Investigation. 60, 113-122.
Inoue, I., Fishman, P.H. & Rebois, R.V. (1990) Differential activation of the stimulatory and 
inhibitory guanine nucleotide-binding proteins by fluoroaluminate in cells and in membranes. 
}. Biol. Chem. 18, 10645-10651.
Iraizoz, I., De Lacalle. S. & Gonzalo, L.M. (1991) Cell loss and nuclear hypertrophy in 
topographical subdivisions of the nucleus basalis of meynert in A lzheim er's disease. 
Neuroscience. 41, 33-40.
Itano, Y., Murayama, T., Kiamura, Y. & Nomura, Y. (1991) Glutamate inhibits adenylate 
cyclase activity in dispersed rat hippocampal cells directly via an N-M ethyl-D-Aspartate­
like metabotropic receptor. J. Neurochem. 59,822-828.
199
Itoh, H., Toyama, R., Kozasa, T., Tsukamoto, T., Matsuoka, M. & Kaziro, Y. (1988) Presence 
of three distinct molecular species of G  ^protein a  subunit. Structure of rat cDNAs and hum an 
genomic DNA. J. Biol. Chem. 263, 6656-6664.
Jelsema, C.L. & Axelrod, J. (1987) Stimulation of phospholipase A2  activity in bovine rod 
outer segments by the Py subunits of transducin and its inhibition by the a  subunit.
Proc. Natl. Acad. Sci. USA. 84, 3623-3627.
Jones, D.T. & Reed, R.R. (1987) Molecular cloning of fice GTP-binding proteins cDNA species 
from rat olfactory neuroepithelium. J. Biol. Chem. 262,14241-14249.
Jones, D.T & Reed, R.R. (1989) G0j£i An olfactory neuron specific-G protein involved in 
odorant signal transduction. Science, 244, 790-795.
Jones, D.T., Masters, S.B., Bourne, H.R. & Reed, R.R. (1990) Biochemical characterisation of 
three stimulatory GTP-binding proteins. The large and small forms of Gg and the olfactory- 
specific G-protein, G0if. J. Biol. Chem. 265, 2671-2676.
Jones, T.L.Z., Simonds, W.F., Merendino, J.J., Brann, M.R. & Spiegel, A.M. J  (1990b) 
Myristoylation of an inhibitory GTP-binding protein a  subunit is essential for its membrane 
attachment. Proc. Natl. Acad. Sci. USA. 87, 568-572.
Joyce, J.N., Gibbs, R.B., Cotman, C.W. & Marshall, J.F. (1989) Regulation of muscarinic 
receptors in hippocampus following cholinergic denervation and reinnervation by septal and 
striatal transplants. J. Neuroscience. 9, 2776-2791.
Joyce. J.N., Lexow, N., Kim, S.J., Artymyshyn, R., Senzon, S., Lawerence, D., Cassanova, M.F., 
Kleinman, J.E., Bird, E.D. & Winokur, A. (1991) Distribution of beta-adrenergic receptor 
subtypes in hum an post-mortem brain: Alterations in limbic regions of schizophrenics. 
Synapse, 10, 228-246.
200
Kalaria, R.N. (1989) Characterisation of [^ IJH E A T  binding to a^-receptors in hum an 
brain: assessment in aging and Alzheimer's disease. Brain Research. 501, 287-294.
Kalaria, R.N., Andorn, A.C., Tabaton, M., Whitehouse, P.J., Harik, S.I. & Unnerstall, J.R. 
(1989) Adrenergic receptors in aging and Alzheimer's disease: Increased (^-receptors in 
prefrontal cortex and hippocampus. }. Neurochem. 53, 1772-1781.
Kalaria, R.N. & Andorn, A.C. (1991) Adrenergic receptors in aging and Alzheimer's disease:
O 1
Decreased o^-receptors demonstrated by [ H]p-aminoclonidine binding in prefrontal cortex . 
Neurobiology of Aging. 12,131-136.
Kammesheidt, A., Boyce, F.M., Spanoyannis, A.F., Cummings, B.J., Ortegon, M., Cotman, C., 
Vaught, J.L. & Neve, R.L. (1992) Deposition of (3/A4 immunoreactivity and neuronal 
pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer 
amyloid precursor in the brain. Proc. Natl Acad. Sci. USA. 89,10857-10861.
Kanaho, Y., Katada, T., Hoyle, K., Crooke, S.T. & Stadel, J.M. (1989) Immunochemical 
comparison of pertussis toxin substrates in brain and peripheral tissues.
Cellular Signalling. 1,553-560.
Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, M., Masters, C.L., Grzeschik, C.H., 
M ulthaup, G., Beyreuther, C. & Muller-hill, B. (1987) The precursor of Alzheimer's disease 
amyloid A4 protein resembles a cell surface receptor. Nature. 325, 733-736.
Katada, T., Bokoch, G.M., Smigel, M.D., Ui, M. & Gilman A.G. (1984a) The inhibitory 
guanine nucleotide-binding regulatory component of adenylate cyclase.
Subunit dissociation and the inhibition of adenylate cyclase in S49 lymphoma eye' and wild 
type membranes. J. Biol. Chem. 259,3586-3595.
201
Katada, T., Northup, J.K., Bokoch, G.M., Ui, M. & Gilman, A.G. (1984b) The inhibitory 
guanine nucleotide-binding regulatory component of adenylate cyclase.
Subunit dissociation and gunaine nucleotide-dependent hormonal inhibition.
}. Biol. Chem. 259, 3578-3585.
Katada, T., Oinuma, M & Ui, M. (1986) Two guanine nucleotide-binding proteins in rat brain 
serving as the specific substrate of islet-activating protein, pertussis toxin.
Interaction of the a-subunit with Py-subunits in development of their biological activities.
J. Biol. Chem. 261,8182-8191.
Katada, T., Kusakabe, K., Oinuma, M. & Ui, M. (1987) A novel mechanism for the inhibition 
of adenylate cyclase via inhibitory GTP-binding proteins. Calmodulin-dependent inhibition 
of the cyclase catalyst by the Py-subunits of GTP-binding proteins.
J. Biol. Chem. 25,11897-11900.
Katsushika, S., Chem, L., Kawabe, J.I., Nilakantan, R., Halnon, N.J., Homey, C.J. &
Ishikawa, Y. (1992) Cloning and characterisation of a sixth adenylyl cyclase isoform: Types 
V and VI constitute a subgroup within the mammalian adenylyl cyclase family.
Proc. Natl. Acad. Sci. USA. 89, 8774-8778.
Katz, A., Wu, D & Simon, M.I. (1992) Subunits py of heterotrimeric G protein activate p2 
isoform of phospholipase C. Nature. 360,686-689.
Kellar, K.J., Whitehouse, P.J., Martino-Barrows, A.M., Marcus, K. & Price, D.L. (1987) 
Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex.
Brain Research. 436, 62-68.
Khachaturian, Z.S. (1985) Diagnosis of Alzheimer's disease.Arc/i. Neurol. 42, 1097-1104.
Kimball, S.R., Vary, T.C. & Jefferson, L.S. (1992) Age-dependent decrease in the am ount of 
eukaryotic initiation factor 2 in various rat tissues. Biochem. J. 286, 263-268.
202
Kish, S.J., Young, L.T., Li, P.P., Siu, K.P., Robitaille, Y., Ball, M.J., Schut, L. & W arsh, J.J. 
(1993) Elevated stimulatory and reduced inhibitory G protein a  subunits in cerebellar cortex 
of patients with dominantly inherited olivopontocerebellar atrophy.
J. Neurochem. 60,1816-1820.
Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S. & Ito, H. (1988) Novel precursor of 
Alzheimer's disease amyloid protein shows protease inhibitory activity.
Nature. 331,530-532.
Kleuss, C., Hescheler, J., Ewel, C., Rosenthal, W., Schultz, G. & Wittig, B. (1991) Assignment 
of G-protein subtypes to specific receptors inducing inhibition of calcium currents.
Nature, 353, 43-47.
Kleuss, C., Scherubl, H., Hescheler, J., Schultz, G. & Wittig, B. (1992) Different (3-subunits 
determine G-protein interaction with transmembrane receptors. Nature. 358,424-426.
Kobilka, B.K., Kobilka, T.S. Daniel, K., Regan, J.W., Caron, M.G. & Lefkowitz, R.J. (1988) 
Chimeric o^-, P2" adrenergic receptors: Delineation of domains involved in effector coupling 
and ligand binding specificity. Science. 240,1310-1316.
Koh, J.Y., Yang, L.L. & Cotman, C.W. (1990) (3-amyloid protein increases the vulnerability of 
cultured cortical neurons to excitotoxic damage. Brain Research, 533, 315-320.
Koo, E.H., Sisodia, S.S. Archer, D.R., Martin, L.J., Weidmann, A., Beyreuther, K., Fischer, P., 
Maters, C.L. & Price, D.L. (1990) Precursor of amyloid protein in Alzheimer disease 
undergoes fast anterograde axonal transport. Proc. Natl. Acad. Sci. USA. 87, 1561-1565.
Kosik, K.S., Orecchio, L.D., Bakalis, S. & Neve, R.L. (1989) Developmentally regulated 
expression of specific tau sequences. Neuron. 2,1389-1397.
Kowall, N.W. & Beal, M.F. (1991) Glutamate-, glutaminase-, and taurine-immunoreactive 
neurones develop neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 29, 162-167.
203
Kozasa, T., Itoh, H., Tsukamoto, T. & Kaziro, Y. (1988) Isolation and characterisation of the 
hum an Gga  gene. Proc. Natl. Acad. Sci. USA. 85, 2081-2085.
Kozlowski, M.R., Spanoyannis, A., Manly, S.P., Fidel, S.A. & Neve, R.L. (1992) The 
neurotoxic carboxy-terminal fragment of the Alzheimer amyloid precursor binds specifically 
to a neuronal cell surface molecule: pH dependence of the neurotoxicity and the binding.
J.Neuroscience. 12, 1679-1687.
Krantic, S., Robitaille, Y. & Quirion, R. (1992) Deficits in the somatostatin SS| receptor sub- 
type in frontal and temporal cortices in Alzheimer's disease. Brain Research. 573, 299-304.
Kowall, N. W. & Beal, M.F. (1988) Cortical somatostatin, neuropeptide Y, and NADPH- 
diaphorase neurons: normal anatomy and alterations in Alzheimer’s disease. Ann Neurol.
23,105-114.
Kuhn, H. (1980) Light- and GTP-regulated interaction of GTPase and other proteins with 
bovine photoreceptor membranes. Nature. 283,587-589.
Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature. 227, 680-685.
Landis, C.A., Masters, S.B., Spada, A., Pace, A.M., Bourne, H.R. & Vallar, L. (1989) GTPase 
inhibiting mutations activate the a  chain of Gg and stimulate adenylyl cyclase in huam n 
pituitary tumours. Nature. 340, 692-696.
Lapchak, P.A. & Hefti, F. (1991) Effect of recombinant hum an nerve growth factor on 
presynaptic cholinergic function in rat hippocampal slices following partial 
septohippocampal lesions: Measures of [^H]acetylcholine synthesis, [^HJacetylcholine 
release and choline acetyltransferase activity. Neuroscience. 42, 639-649.
204
Lapchak, P.A., Jenden, D.J. & Hefti, F.l (1991b) Compensatory elevation of acetylcholine 
synthesis in vivo by cholinergic neurons surviving partial lesions of the septohippocampal 
pathway. J. Neuroscience. 11, 2821-2828.
Landsberg, J.P., McDonald, B. & Watt, F. (1992) Absence of aluminium in neuritic plaque cores 
in Alzheimer's disease. Nature. 360, 65-68.
Lang, J. & Costa, T. (1989) Chronic exposure of NG 108-15 cells to opiate agonists does not 
alter the amount of the guanine nucleotide-binding proteins Gj and GQ.
J. Neurochem. 53,1500-1506.
Largent, B.L., Jones,D.T., Reed, R.R., Pearson, C.A. & Snyder, S.H. (1988) G protein mRNA 
m apped in rat brain by in situ hybridisation. Proc, Natl. Acad. Sci. USA.85, 2864-2868.
Leake, A., Perry, E.K., Perry, R.H. et al. (1991) Neocortical concentrations of neuropeptides 
in senile dementia of the Alzheimer and Lewy body type: comparison with Parkinson's 
disease and severity correlations. Biol. Psychiatry. 29, 357-364.
Lefkowitz, R.J. & Caron, M.G. (1988) Adrenergic receptors. Models for the study of receptors 
coupled to guanine nucleotide regulatory proteins.
J. Biol. Chem.263, 4993-4996.
Levey, A.I., Kitt, C.A., Simonds, W.F., Price,D.L. & Brann, M.R. (1991) Identification and 
localisation of muscarinic acetylcholine receptor proteins in brain with subtype-specific 
antibodies. J. Neuroscience 11, 3218-3226.
205
Levine, M.A., Ahn, T.G., Klupt, S.F., Kaufman, K.D., Smallwood, P.M., Bourne, H.R., 
Sullivan, K.A. & Van Dop, C. (1988) Genetic deficiency of the a  subunit of the guanine 
nucleotide-binding protein Gg as the molecular basis for Albright hereditary 
osteodystrophy .Proc. Natl. Acad. Sci. USA. 85, 617-621.
Liebman, P.A., Parker, K.R. & Dratz, E.A. (1987) The molecular mechanism of visual 
excitation and its relation to the structure and composition of the rod outer segment.
Ann. Rev. Physiol. 49, 765-791.
Linder, M.E., Ewalds, D.A., Miller, R.J. & Gilman, A.G. (1990) Purification and 
characterisation of Go a  and three types of Gja  after expression in Escherichia coli.
J. Biol. Chem. 265, 8243-8251.
London, E.D., Waller, S.B., Ellis, A.T. & Ingram, D.K. (1985) Effects of intermittent feeding 
on neurochemical markers in aging rat brain. Neurobiol. Aging. 6,100-104.
Lowry, O.H., Roseburgh, N.J., Farr, A.L. & Randall, R.J. (1951) Protein measurements with 
the folin phenol reagent. J. Biol. Chem. 193, 165-175.
Lu, Q. & Wood, J.G. (1993) Functional studies of Alzheimer's disease tau protein.
J. Neuroscience. 13, 508-515.
Lyons, J., Landis, C.A. Harsh, G., Vallar, L., Grunewald, K., Feichtinger, H., Duh, Q.Y., 
Clark, O.H., Kawasaki, E., Bourne, H.R. & McCormick, F. (1990) Two G protein oncogenes in 
hum an endocrine tumours. Science. 249, 655-659.
McKenzie, F.R., Kelly, E.C.H., Unson, C.G., Spiegel, A.M. & Milligan, G. (1988) Antibodies 
which recognise the C-terminus of the inhibitory guanine-nucleotide-binding protein (G-) 
dem onstrate that opioid peptides and foetal-calf serum stimulate the high-affinity GTPase 
activity of two spearate pertussis-toxin substrates. Biochem. J. 248, 653-659.
206
McKinney, M. & Coyle, J.T. (1982) Regulation of neocortical muscarinic receptors: Effects of 
drug treatment and lesions. J. Neuroscience. 2,97-105.
McLaughlin, M., Ross, B.M., Milligan, G., McCulloch, J. & Knowler, J.T. (1991) Robustness of 
G proteins in Alzheimer's disease: An immunoblot study. J. Neurochem. 57,9-14.
Mangels, L.A., Neubig, R.R. Hamm, H.E. & Gnegy, M.E. (1992) Calmodulin binding 
distinguishes between fty subunits of activated G proteins and transducin.
Biochem. J. 283, 683-690.
M arte l, J.C., Alagar, R., Robitaille, Y. & Quirion, R. (1990) Neuropeptide Y receptor binding 
sites in hum an brain. Possible alteration in Alzheimer's disease.
Brain Research. 519, 228-235.
Mash, D.C., Flynn, D.D. & Potter, L.T. (1985) Loss of M2 muscarine receptors in the cerebral 
cortex in Alzheimer's disease and experimental cholinergic denervation.
Science. 228,1115-1117
Masliah, E., Terry, R.D., Mallroy, M., Alford, A. & Hansen, L.A. (1990A) Diffuse plaques do 
not accentuate synapse loss in Alzheimer's disease. Am.J Pathol. 137,1293-1297.
Masliah, E., Terry, R.D., Alford, M & DeTeresa, R. (1990B) Quantitative 
immunohistochemistry of synaptophsin in hum an neocortex: An alternative method to 
estimate density of presynaptic terminals in paraffin sections.
J. Histochem Cytochem. 38, 837-844.
Masliah, E., Cole, G., Shimohama, S., Hansen, L., De Teresa, R., Terry, R.D. & Saitoh, T. 
(1990C) Differential involvement of protein kinase C isozymes in Alzheimer's disease.
J. Neuroscience. 10 2113-2124
207
Masliah, E., Terry, R.D. Alford, M., DeTeresa, R. & Hansen, L.A. (1991a) Cortical and 
subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease.
Am. J. Pathol 138, 235-246.
Masliah, E., Mallroy, M., Hansen, L., Alford, M., Albright, T., DeTeresa, R., Terry, R., 
Baudier, J. & Saitoh, T. (1991b) Patterns of aberrant sprouting in Alzheimer’s disease. 
Neuron. 6, 729-739.
Masliah, E., Mallroy, M., Hansen, L., Alford, M., DeTeresa, R., Terry, R., Baudier, J. &
Saitoh, T.(1992) Localisation of amyloid precursor protein in GAP43-immunoreactive 
aberrant sprouting neurites in Alzheimer's disease. Brain Research. 574,312-316.
Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., Me Donald, B.L. & Bayreuther, K. 
(1985) Amyloid plaque core protein in Alzheimer's disease and Down syndrome.
Proc. Natl. Acad. Sci. USA. 82, 4245-4249.
Masters, S.B., Miller, R.T., Chi, M.H., Chang, F.H., Beiderman, B., Lopez, N.G. & Bourne, 
H.R. (1989) Mutations in the GTP-binding site of Gga alter stimulation of adenylyl cyclase.
J. Biol. Chem. 264, 15467-15474.
Mathewson, A.J. & Berry, M. (1985) Observations on the astrocyte response to a cerebral stab 
wound in adult rats. Brain Research. 327,61-69.
Milligan, G., Spiegel, A.M., Unson, C.G. & Saggerson, E.D. (1987) Chemically induced 
i hypothyroidism produces elevated amounts of the a  subunit of the inhibitory guanine 
nucleotide binding protein (Gj) and thep subunit common to all G-proteins.
Biochem. J. 247, 223-227
l
Matsuoka, M., Itoh, H., Kozasa, T. & Kaziro, Y. (1988) Sequence analysis of cDNA and 
genomic DNA for a putative pertussis toxin-insensitive guanine nucleotide-binding regulatory 
protein a  subunit. Proc. Natl. Acad. Sci. USA. 85,5384-5388.
208
Matsuoka, M., Itoh, H. & Kaziro, Y., (1990) Characterisation of the hum an gene for Gxa , a 
pertussis toxin-insensitive regulatory GTP-binding protein. J. Biol. Chem. 265, 13215-13220.
Mattera, R., Graziano, M.P., Yatani, A., Zhou, Z., Graf, R., Codina, J., Bimbaumer, L.,
Gilman, A.G & Brown, A.M. (1989) Splice variants of the a  subunit of the G protein and Gg 
activate both adenylyl cyclase and calcium channels. Science, 243,804-807.
Mattson, M.P. Engle, M.G. & Rychlik, B. (1991) Effects of elevated intracellular calcium 
levels on the cytoskeleton and tau in cultured human cortical neurons. Molecular and 
Chemical Neuropathology. 15, 117-142.
Mattson, M.P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I. & Rydel, R.E. (1992) (3- 
Amyloid peptides destabilise calcium homeostasis and render hum an cortical neurons 
vulnerable to excitotoxicty./. Neuroscience. 12 , 376-389.
Mattson, M.P., Lovell, M.A., Ehmann, W.D. & Markesbery, W.R. (1993) Comparison of the 
effect of elevated intracellular aluminium and calcium levels on neuronal survival and tau 
im m unoreactivity .Brain Research. 602, 21-31.
Mullaney, I. & Milligan, G. (1990) Identification of two distinict isoforms of the guanine 
nucleotide binding proteins GQ in neuroblastoma X glioma hybrid cells: independent regulation 
during cyclic AMP—induced differentiation. J. Neurochem. 55,1890-1898.
Mazurek, M.F. & Beal, M.F. (1991) Cholecystokinin and somatostatin in Alzheimer's disease 
postmortem cerebral cortex. Neurology. 41, 716-719.
Meana, J.J., Barturen, F., Garro, M.A., Garcia-Sevilla, J.A., Fontan, A. & Zarranz, J.J. (1992) 
Decreased density of presynaptic o^-adrenoceptors in postmortem brains of patients with 
Alzheimer's disease./. Neurochem. 58, 1896-1904.
209
Meldrum, B & Garthwaite, J. (1991) Excitatory amino acid neurotoxicty and 
neurodegenerative disease. TiPS. 54-62.
Mengod, G., Palacios, J.M., Probst, A. & Harris, B. (1988) Regional distribution of the 
expression of a hum an stimulatory GTP-binding protein a-subunit in the hum an brain studied 
by in situ hybridisation. Molecular Brain Research. 4, 23-29.
Milligan, G.!(1993a) Mechanisms of multifunctional signalling by G protein-linked receptors. 
TiPS. 14, 239-244.
Milligan, G. (1993b) Regional distribution and quantitiative measurment of the 
phosphoinositidase C-linked guanine nucleotide binding proteins G ^ a  and Gqtx in rat brain. 
J. Neurochem. 61, 845-851.
Milligan, G. & Klee, W.A. (1985) The inhibitory guanine nucleotide-binding protein (Nj) 
purified from bovine brain is a high affinity GTPase. J. Biol. Chem. 260, 2057-2061.
Milligan, G. & Unson, C.G. (1989) Persistent activation of the a  subunit of Gs promotes its 
removal from the plasma membrane. Biochem. J. 260, 837-841.
Mollner, S., Simmoteit, R., Palm, D. Pfeuffer, T. (1991) Monoclonal antibodies against 
various froms of the adenylyl cyclase catalytic subunit and associated proteins.
J. Biochem. 195, 281-286.
Moriarty, T. M., Padrell, E., Carty, D.J., Omri, G., Landau, E.M. & Iyengar, R., (1990) G0  
protein as signal transducer in the pertussis toxin-sensitive phosphatidylinositol pathway. 
Nature. 343, 79-82.
Mullaney, I., Magee, A.I., Unson, C.G. & Milligan, G. (1988) Differential regulation of 
amounts of the guanine-nucleotide-binding proteins Gj and GQ in neuroblastoma X glioma 
hybrid cells in response to dibutyryl cyclic AMP. Biochem. J. 256, 649-656.
210
Mullaney, I., Dodd, M.W., Buckley, N. & Milligan, G. (1993) Agonist activation of 
transfected hum an M l muscarinic acetylcholine receptors in CHO cells results in down-
regulation of both the receptor and the a  subunit of the G-protein Ga .Hi
Biochem. J. 289, 125-131.
Mumby, S.M., Heukeroth, R.O., Gordon, J.I. & Gilman, A.G. (1990) G-protein a-subunit 
expression, myristoylation, and membrane association in COS cells.
Proc. Natl. Acad. Sci. USA. 87, 728-732.
M urphy, P.M. & McDermott D. (1992) The guanine nucleotide-binding protein Gg activates a 
novel calcium transporter in Xenopus oocytes. J. Biol. Chem. 267, 883-888.
Nagahara, A.H. & McGaugh, J.L. (1992) Muscimol infused into the medial septal area 
impairs long-term memory but not short-term memory in inhibitory avoidance water maze 
place learning and rewarded alternation tasks. Brain Research. 591, 54-61.
Nestler, E.J., Erdos, J.J., Terwilliger, R., Duman, R.S. & Tallman, J.F. (1989) Regulation of G 
protein by chronic morphine in the rat locus coeruleus. Brain Research. 476, 230-239.
Nestler, E.J., Terwilliger, R.Z., Walker, J.R., Sevarino, K.A. & Duman, R.S. (1990) Chronic 
cocaine treatment decreases levels of the G protein subunits Gja  and Goa in discrete regions of 
rat brain. }. Neurochem. 55, 1079-1082.
Neve, R.L., Harris, P., Kosik, K.S., Kurnit, D.M. & Donlon, T.A. (1986) Identification of 
cDNA clones for the hum an microtubule-assodated protein tau and chromosomal localisation 
of the genes for tau and microtubule-associated protein 2. Mol. Brain Res. 1, 271-280.
Nicol, S.E., Senogles, S.E., Caruso, T.P., Hudziak, J.J., McSwigan, J.D. & Frey, W.H. (1981) 
Postmortem stability of dopamine-sensitive adenylate cyclase, guanylate cyclase, ATPase, 
and GTPase in rat striatum. J. Neurochem. 37, 1535-1539.
211
Nicoletti, F., Wroblewski, J.T., Eva, A.C., Fadda, E. & Costa, E., (1987) Lesions of putative 
glutamatergic pathways potentiate the increase of inositol phospholipid hydrolysis elicited 
by excitatory amino acids. Brain Research. 436, 103-112.
Ninomiya, H., Fukunaga, R., Taniguchi, T., Fujiwara, M., Shimohama, S & Kameyama, M.
(1990) [^H]N-[l-(2-Thienyl)cyclohexyl]-3,4-Piperidine ([^H]TCP) Binding in hum an frontal 
cortex: Decreases in Alzheimer-type dementia. J. Neurochem. 54,526-532.
Nishimoto, I., Okamoto, T., Matsuura, Y., Takahashl, S., Okamoto, T., M urayama, Y. & 
Ogata, E. (1993) Alzheimer amyloid protein precursor complexes with brain GTP-binding 
protein GQ. Nature. 362,75-79.
Nitsch, R.M., Slack, B.E., W urtman, R.J. & Growdon, J.H. (1992) Release of Alzheimer 
amyloid precursor drivatives stimulated by activation of muscarinic acetylcholine receptors. 
Science, 258,304-307.
Nordberg, A., Alafuzoff, I. & Winblad, B. (1992) Nicotinic and muscarinic subtypes in the 
hum an brain: Changes with aging and dementia. J. Neuroscience Research. 31, 103-111.
Northup, J.K., Smigel, M.D., Sternweis, P.C. & Gilman, A.G. (1983) The subunits of the 
stimulatory regulatory component of adenylate cyclase. J. Biol. Chem. 258,11369-11376.
Ohm, T.G., Bohl, J. & Lemmer, B. (1991) Reduced basal and stimulated (isoprenaline, 
Gpp(NH)p, forskolin) adenylate cyclase activity in Alzheimer's disease correlated with 
histopathological changes. Brain Research. 540, 229-236.
212
O’Neill, C., Fowler, C.J., Wiehager, B., Cowburn, R.F., Alafuzoff, I. & W inblad, B. (1991a) 
Coupling of hum an brain cerebral cortical c^-adrenoceptors to GTP-binding proteins in 
Alzheim er's disease.Bram Research. 563, 39-43.
O'Neill, C., Cowburn, R.F., Wiehager, B., Alaufozz, I., Winblad, B. & Fowler, J.F. (1991b) 
Preservation of 5-hydroxytryptamine j  ^  receptor-G protein interactions in the cerebral cortex 
of patients with Alzheimer’s disease. Neuroscience Letters. 133, 15-19.
Osawa, S., Dhanasekaran, N., Woon, C.W. & Johnson, G.L. (1990) G alpha i-G alpha s 
chimeras define the function of alpha chain domains in control of G protein activation and 
beta gamma subunit complex interactions. Cell. 63 697-706.
Overstreet, D.H., Speth, R.C., Hruska, R.E., Dumont, E.Y. & Yamamura, H.I. (1980) Failure 
of spetal lesions to alter muscarinic cholinergic or benzodiazepine binding sites in 
hippocam pus of rat brain .Brain Research. 195, 203-207.
Oyama, F., Shimada, H., Oyama, R., Titani, K. & Ihara, Y. (1992) A novel correlation 
between the levels of (5-amyloid protein precursor and x transcripts in the aged hum an brain.
J. Neurochem. 59, 1117-1125.
Ozawa, H., & Rasenick, M.M. (1991) Chronic electroconvulsive treatment augments coupling 
of the GTP-binding protein Gg to the catalytic moiety of adenylyl cyclase in a m anner similar 
to that seen with chronic antidepressant drugs. J. Neurochem. 56, 330-338,
Palacios, G., Garda-Ladona, J. & Codina, M. (1991) Ultrastructural study of cholinergic 
neurons in the medial septal nucleus and vertical limb of the diagonal band of broca in the 
basal forebrain of the rate. Journal of Chemical Neuroanatomy. 4, 205-221.
Palmer, A.M., Wilcock, G.K. Esiri, M.M., Frands, P.T. & Bowen, D.M. (1987) Monoaminergic 
innervation of the frontal and temporal lobes in Alzheimer’s disease. Brain Research. 401, 
231-238.
213
Palmer, A.M. & Gershon, S. (1990) Is the neuronal basis of Alzheimer's disease cholinergic or 
glutamatergic? FASEB /. 4,2745-2752.
Parks, K.M., Sugar, J.E., Haroutunian, V., Bierer, L., Perl, D. & Wallace, W.C. (1991) 
Reduced in vitro phosphorylation of synapsin I (site 1) in Alzheimer's disease postmortem 
tissues. Molecular Brain Research. 9, 125-134.
Pascaul, J., Fontan, A., Zarranz, J.J., Berciano, J., Florez, J. & Pazos, A. (1991) High-affinity 
choline uptake carrier in Alzheimer's disease: implications for the cholinergic hypothesis of 
dementia. Brain Research. 552, 170-174.
Pascaul, J., Grijalba, B., Garcia-Sevilla, J.A., Zarranz, J.J. & Pazos, A. (1992) Loss of high- 
affinity 012-adrenoceptors in Alzheimer's disease: an autoradiographic study in frontal cortex 
and hippocampus. Neuroscience Letts. 142, 36-40.
Pearce, B.D. & Potter, L.T. (1991) Coupling of m l muscarinic receptors to G protein in 
Alzheimer disease. Alzheimer Disease and Associated Disorders. 5, 163-172.
Pearson, R.C.A. & Powell, T.P.S. (1989) The neuroanatomy of Alzheimer's disease. Reviews 
in the Neurosciences. 2 , 101-122.
Peralta, E.G., Ashkenazi, A., Winslow, J.W., Ramachandran, J. & Capon, D.J. (1988) 
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. 
Nature, 334,434-437.
Perl, D.P. & Brody, A.R. (1990) Alzheimer's disease: X-ray spectrometric evidence of 
alum inum  accumulation in neurofibrillary tangle-bearing neurons. Science. 208,297-299.
214
Perry, R.H., Dockray, G.J., Dimaline, R., Perry, E.K., Blessed, G. & Tomlinson, B.E. (1981) 
Neuropeptides in Alzheimer's disease, depression and schizophrenia. A post mortem 
analysis of vasoactive intestinal polypeptide and cholecystokinin in cerebral cortex. /.
Neurol. Sci. 51, 465-472.
Perry, E.K., Perry, R.H. & Tomlinson, B.E. (1982) The influence of agonal status on some 
neurochemical activities of postmortem hum an brain tissue. Neuroscience Letts. 29, 303-307.
Perry, E.K. (1986) The cholinergic hypothesis - ten years on.
British Medical Bulletin. 42, 63-69.
Piggott, M.A., Perry, E.K., Sahagal, A. & Perry, R.H. (1992) Examination of param eters
O
influencing [ HJMK-801 binding in postmortem human cortex. J. Neurochem. 58,1001-1008.
Poat, J.A., Cripps, H.E. & Iversen, L.L. (1988) Differences between high-affinity forskolin 
binding sites in dopamine-rich and other regions of rat brain.
Proc. Natl. Acad. Sci. USA. 85, 3216-3220.
Poirier, J., Davignon, J., Bouthillier, D., Kogan, S., Bertrand, P & Gauthier, S. (1993) 
Apolipoprotein E polymorphism and Alzheimer's disease. The Lancet. 342, 697-699.
Ponte, P., Gonzalez-DeWhitt, P., Schilling, J., Miller, J., Hsu, D., Greenberg, B., Davis, K., 
Wallace, W., Lieberburg, I., Fuller, F. & Cordell, B. (1988) A new A4 amyloid mRNA 
contains a domain homologous to serine proteinase inhibitors. Nature. 331,525-527.
Probst, A., Cortes, R., Ulrich, J. & Palacios, J.M. (1988) Differential modification of 
muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: an 
autoradiographic study. Brain Research. 450, 190-201.
Procter, A.W., Palmer, A.M., Francis, P.T., Lowe, S.L., Neary, D., M urphy, E., Doshi, R. & 
Bowen, D.M. (1988) Evidence of glutamatergic denervation and possible abnormal 
metabolism in Alzheimer's disease. J. Neurochem. 50,790-802.
215
Procter, A.W., Wong, E.H.F., Stratmann, G.C., Lowe, S.L. & Bowen, D.M. (1989) Reduced 
glycine stimulation of [^H]MK-801 binding in Alzheimer's disease.
J. Neurochem. 53, 698-704.
Pronin, A.N. & Gautam, N. (1992) Interaction between G-protein P and y  subunit types is 
selective. Proc. Natl, Acad. Sci. USA. 89, 6220-6224.
Quigley Jr., B.J. & Kowall, N.W. (1991) Subtance p-like immunoreactive neurons are 
depleted in Alzheimer's disease cerebral cortex. Neuroscience. 41,41-60.
Rail, T.W., Sutherland, E.W. & Wosilait, W.D. (1956) The relationship of epinephrine and 
glucagon to liver phosphorylase. Reactivation of liver phophorylase in slices and in extracts. 
}. Biol. Chem. 218, 483-495.
Rossor, M & Iverson, L.L., (1986) Non-cholinergic neurotransmitter abnormalities in 
Alzheimer's disease. Br. Med. Bull. 42 70-74.
Rasenick, M.M. & Wang, N. (1988) Exchange of guanine nucleotides between tubulin and GTP- 
binding proteins that regulate adenylate cyclase: Cytoskeletal modification of neuronal 
signal transduction. J. Neurochem. 51, 300-311.
Raulli, R.E., Arendash, G & Crew, F.T. (1989) Effects of nBM lesions on muscarinic- 
stim ulation of phosphoinositide hydrolysis. Neurobiology of Aging. 10 , 191-197.
Ravindra, R. & Aronstam, R.S. (1990) Influence of anti-tubulin antibodies on muscarinic 
receptor modulation of G protein GTPase activity in rat striatum. Biochemical 
Pharmacology. 40,457-463.
Ravindra, R. & Aronstam, R.S. (1991) Colchicine inhibits acetylcholine receptor stimulation 
of G protein GTPase activity in rat striatum. Pharmacology & Toxicology. 69, 259-262.
216
Rinne, J.O., Lonnberg, P., Marjamaki, P. & Rinne, U.K. (1989) Brain muscarinic receptor 
subtypes are differently affected in Alzheimer’s disease and Parkinson's disease. Brain 
Research. 483, 402-406.
Rius, R.A., Streaty, R.A., Peng Loh, Y. & Klee, W.A. (1991) Developmental expression of G 
proteins that differentially modulate adenylyl cyclase activity in mouse brain. FEBS 
LETTERS. 288, 51-54.
Robishaw, J.D., Smigel, M.D. & Gilman, A.G. (1986) Molecular basis for two forms of the G 
protein that stimulates adenylate cyclase. J. Biol. Chem. 261, 9587-9590.
Rodbell, M., Birnbaumer, L., Pohl, S.L. & Krans, H.M.J. (1971) The glucagon-sensitive adenyl 
cyclase system in plasma membranes of rat liver. V. An obligatory role of guanyl nucleotides 
in glucagon action. J. Biol. Chem. 246,1877-1882.
Ross, B.M., Knowler, J.T. & McCulloch, J. (1992) On the stability of messenger RNA and 
ribosomal RNA in the brains of control human subjects and patients with Alzheimer's disease. 
J. Neurochem. 58,1810-1819.
Ross, B.M. (1992) A study of G protein coupled signal transduction in Alzheimer’s disease. 
PhD thesis, Wellcome Surgical Institute, University of Glasgow.
Rugg, E.L., Dunbar, J.S., Latimer, M. & Winn, P. (1992) Excitotoxic lesions of the 
pedunculopontine tegmental nucleus of the rat. I. Comparison of the effects of various 
excitotoxins, with particular reference to the loss of immunohistochemically identified 
cholinergic neurons. Brain Research. 589,181-193.
Saitoh, T., Masliah, E., Jin, L.W., Cole, G.M., Wieloch, T. & Shapiro, I.P. (1991) Biology of 
Disease. Protein kinases and phosphorylation in neurologic disorders and cell death. 
Laboratory Investigation. 64, 596-616.
217
Sakurada, T., Alufuzoff, I., Winblad, B. & Nordberg, A. (1990) Substance P-like 
immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in 
Alzheimers's disease and multi-infarct dementia. Brain Research. 521, 329-332.
Sauvage, C., Rumigny, J.F. & Maitre, M. (1991) Purification and characterisation of g 
proteins from hum an brain: modification of GTpase activity upon phosphorylation.
Molecular and Cellular Biochemistry. 107, 65-77.
Scarth, B.J., Jhamandas, K., Boegman, R.J., Beninger, R.J. & Reynolds, J.N. (1989) Cortical 
muscarinic receptor function following quinolinic acid-induced lesion of the nucleus basalis 
magnocellularis. Experimental Neurology. 103, 158-164.
Scheff, S.W., DeKosky S.T. & Price, D.A. (1990) Quantitative assessment of cortical synaptic 
density in Alzheimer's disease. Neurobiology of Aging. 11, 29-37.
Schellenberg, G.D., Bird, T.D., Wijsman, E.M., Orr, H.T., Anderson, L., Nemens, E., White, 
J.A. Bonnycastle, L., Weber, J.L., Alonso, M.E., Potter, H., Heston, L.L. & Martin, G.M. (1992) 
Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14.
Science. 258,668-671.
Schnabel, J. (1993) New Alzheimer's therapy suggested. A small trial hints that an anti­
inflammatory drug slows Alzheimer's disease, thereby supporting the idea that 
inflammation contributes to the pathology. Science. 260,1719-1720.
Schoepp, D.D. & Conn, P.J. (1993) Metabotropic glutamate receptors in brain function and 
pathology. TiPS. 14, 13-20.
Selkoe, D.J. (1989) Biochemistry of altered brain proteins in Alzheimer’s disease.
Ann. Rev. Neurosci. 12,463-490.
218
Seubert, P., Oltersdorf, T., Lee, M.G., Barbour, R., Blomquist, C., Davis, D.L. Bryant, K., Fritz, 
L.C., Galasko, D., Thai, L.J., Lieberburg, I. & Schenk, D.B. (1993) Secretion of p-amyloid 
precursor protein cleaved at the amino terminus of the p-amyloid peptide. Nature. 361,260- 
263.
Shapiro, I,P., Masliah, E. & Saitoh, T. (1991) Altered protein tyrosine phosphorylation in 
Alzheimer's disease. J. Neurochem. 56,1154-1162.
Shimohama, S., Taniguchi, T., Fujiwara, M. & Kameyama, M. (1986B) Biochemical 
characterisation of a-adrenergic receptors in human brain and changes in Alzheimer-type 
dementia. J. Neurochem. 47,1294-1301.
Shimohama, S., Taniguchi, T., Fujiwara, M. & Kameyama, M. (1987) Changes in P- 
adrenergic receptor subtypes in Alzheimer-type dementia. J. Neurochem. 48, 1215-1221.
Shimohama, S., Ninomiya, H., Saitoh, T., Terry, R.D. Fukunaga, R., Taniguchi, T., Fujiwara, 
M.,Kimura, J. & Kameyama, M. (1990) Changes in signal transduction in Alzheimer's 
disease./. Neural. Transm. 30, 69-78.
Shimohama, S., Homma, Y., Suenaga, T., Fujimoto, S., Taniguchi, T., Araki, W., Yamaoka,
Y., Takenawa, T., & Kimura, J. (1991) Aberrant accumulation of phospholipase C-delta in 
Alzheimer brains. Am. J. Pathol. 139,737-743.
Shimohama, S., Fujimoto, S., Taniguchi, T. & Kimura, J. (1992) Phosphatldylinositol- 
specific phospholipase C activity in the postmortem hum an brain: no alteration in 
Alzheimer’s disease. Brain Research. 579, 347-349.
Shin, R.W., Bramblett, G.T., Lee, V.M.Y. & Trojanowski. (1993) Alzheimer disease A68  
proteins injected into rat brain induce codeposits of p-amyloid, ubiquitin, and a l-  
antichymotrypsin. Proc. Natl. Acad. Sci. USA. 90, 6825-6828.
219
Shpetner, H.S. & Vallee, R.B. (1992) Dynamin is a GTPase stimulated to high levels of 
activity by microtubules. Nature. 355,733-735.
Sidhu, A., Sullivan, M., Kohout, T., Balen, P. & Fishman, P.H. (1991) D | dopamine receptors 
can interact with both stimulatory and inhibitory guanine nucleotide binding proteins.
J. Neurochem. 57, 1445-1451.
Simon, M. I., Strathmann, M.P. & Gautam, N. (1991) Diversity of G proteins in signal 
transduction. Science. 252, 802-808.
Simonds, W,F., Goldsmith, P.K., Woodard, C.J., Unson, C.G. & Spiegel, A.M. (1989) Receptor 
and effector interactions of Gg Functional studies with antibodies to the a s carboxyl-terminal 
decapeptide. FEBS LETTERS. 249, 189-194.
Salomon, Y. Londos, C. & Rodbell, M., (1974) A highly sensitive adenylate cyclase assay. 
Analytical Biochem., 58, 541-548.
Smith, C.J., Perry, E.K. & Birdsall, N.J.M. (1989) M odulatory effects of 
guanylylimidodiphosphate and Mg2+ on [3H]oxotremorine-M binding in normal and 
Alzheimer’s disease parietal cortex: an index of muscarinic receptor-G-protein coupling. 
Biochemical Society Transactions. 17, 202-203.
Sisodia, S.S., Koo, E.K., Beyreuther, K., Underbeck, A. & Price, D.L. (1990) Evidence that p- 
amyloid protein is not derived by normal processing, Science, 248, 492-495.
Slotkin, T.A., Seidler, F.J., Crain, B.J., Bell, J.M., Bissette, G. & Nemeroff, C.B. (1990) 
Regulatory changes in presynaptic cholinergic fuction assessed in rapid autopsy material from 
patients with Alzheimer disease: Implications for etiology and therapy.
Proc. Natl. Acad. Sci. USA. 87, 2452-2455.
220
Smith, C.J., Court, J.A., Keith, A.B. & Perry, E.K. (1989) Increases in muscarinic stimulated 
hydrolysis of inositol phospholipids in rat hippocampus following cholinergic 
deafferentation are not parallelled by alterations in cholinergic receptor density.
Brain Research. 485, 317-324.
Smith, C.D., Carney, J.M., Starke-Reed, P.E., Oliver, C.N., Stadtman, E.R., Floyd, R.A.
& Markesbery, W.R. (1991) Excess brain protein oxidation and enzyme dysfunction in normal 
aging and in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 88,10540-10543.
Smith, C.J., Perry, E.K., Fairbairn, A.F. & Birdsall, N.J.M. (1987) Guanine nucleotide 
modulation of muscarinic cholinergic receptor binding in postmortem hum an brain - a 
preliminary study in Alzheimer's disease. Neuroscience. 82, 227-232
Smith, G. (1988) Animal models of Alzheimer's disease: experimental cholinergic 
denervation. Brain Research Rev. 13,103-118.
Smrcka, A.V., Helper, J.R., Brown, K.O. & Stemweis, P.C. (1991) Regulation of 
polyphosphoinositide-specific phospholipase C activity by purified Gq 
Science. 251,804-807.
Soderberg, M., Edlund, C., Kristensson, K. & Dallner, G. (1990) Lipid compositions of 
different regions of the hum an brain during aging. J. Neurochem. 54,415-423.
Sommer, B., & Seeburg, P.H. (1992) Glutamate receptor channels: novel properties and new 
clones. Trends Pharmacol Sci, 13, 291-296.
Soderberg, M., Edlund, C., Alafuzoff, L., Kristensson, K. & Dallner, G. (1992) Lipid 
composition in different regions of the brain in Alzheimer's disease/senile dementia of 
Alzheimer's type. J. Neurochem. 59, 1646-1653.
221
Sofic, E., Frolich, L., Riederer, P., Jellinger, K., Heckers, S., Beckmann, H., Deinzer, E., 
Pantucek, F.,Hebenstreit, G. & Ransmayr, G. (1991) Biochemical membrane constituents and 
activities of alkaline and acid phosphatase and cathepsin in cortical and subcortical brain 
areas in dementia of the Alzheimer type. Dementia. 2 ,39-44.
Sparks, D.L. (1989) Aging and Alzheimer's disease. Altered cortical serotergic binding. 
Arch. Neurol, 46, 138-140.
Spiegel, A.M. & Aurbach, G.D. (1974) Binding of 5-guanylyl-imidodiphosphate to turkey 
erythrocyte membranes and effects on p-adrenergic-activated adenylate cyclase.
J. Biol. Chem. 249, 7630-7636.
Spiegel, A.M., Backlund Jr., P.S., Butrynski, J. E., Jones, T.L.Z. & Simonds, W.F. (1991) The G 
protein connection: molecular basis of membrane association. TIBS. 16,338-341.
Strathmann, M., Wilkie, T.M. & Simon, M.I. (1989) Diversity of the G-protein family: 
sequences from five additional a  subunits in the mouse. Proc. Natl. Acad. Sci. USA. 86,7407- 
7409.
Stemweis, P.C. (1986) The purified a  subunits of GQ and Gj from bovine brain require Py for 
association with phospholipid vesicles. J. Biol. Chem. 261, 631-637.
Sternweis, P.C. & Robishaw, J.D. (1984) Isolation of two proteins w ith high affinity for 
guanine nucleotides from membranes of bovine brain. J. Biol Chem. 259,13806-13813.
St. George-Hyslop, P.H., Tanzi, R.E., Polinsky, R.J., Haines, J.L., Nee, L., Watkins, P.C., 
Myers, R.H., Feldman, R.G., Pollen, D., Drachman, D., Growdon, J., Bruni, A., Foncin, J.F., 
Salmon, D., Frommelt, P.,Amaducci, L., Sorbi, S., Placentini, S., Stewart, G.D., Hobbs,W.J., 
Conneally, P.M. & Gusella, J.F. (1987) The genetic defect causing familial Alzheimer's 
disease m aps on chromosome 2 1 . Science. 235,885-890.
222
Stokes, C.E. & Hawthorne, J.N. (1987) Reduced phosphoinositide concentrations in anterior 
temporal cortex of Alzheimer-diseased brains. J. Neurochem. 48, 1018-1021.
Strader, C.D., Dixon, R.A.F., Cheung, A.H., Candelore, M.R., Blake, A.D. & Sigal, I. S.
(1987) Mutations that uncouple the P-adrenergic receptor from Gg and increase agonist 
affinity. J. Biol. Chem. 262, 16439-16443.
Strassheim, D., Milligan, G. & Houslay, M.D. (1990) Diabetes abolishes the GTP-dependent, 
but not the receptor-dependent inhibitory function of the inhibitory guanine-nucleotide- 
binding regulatory protein (Gp on adipocyte adenylate cyclase activity.
Biochem. J. 266, 521-526.
Strathmann, M., Wilkie, T.M. & Simon, M.I. (1990) Alternative splicing produces transcripts 
encoding two forms of the a  subunit of GTP-binding protein G0  Proc. Natl. Acad. Sci. USA. 87, 
6477-6481.
Striplin, C.D. & Kalivas, P.W. (1992) Correlation between behavioral sensitisation to 
cocaine and G protein ADP-ribosylation in the ventral tegmental area. Brain Research. 579, 
181-186.
Strittmatter, S.M., Valenzuela, D., Kennedy, T.E., Neer, E.J. & Fishman, M.C. (1990) GQ is a 
major growth cone protein subject to regulation by GAP^43. Nature. 344, 836-841.
Strittmatter, S.M., Valenzuela, D., Sudo, Y., Linder, M.E. & Fishman, M.C. (1991) An 
intracellular guanine nucleotide release protein for GQ. GAP-43 stimulates isolated a  subunits 
by a novel mechanism. f. Biol Chem. 266, 22465-22471.
Strittmatter, S.M., Cannon, S.C., Ross, E.M., Higashuima, T. & Fishman, M.C. (1993) GAP-43 
augments G protein-coupled receptor transduction in Xenopus laevis oocytes.
Proc. Natl. Acad. Sci.USA. 90, 5327-5331.
223
Sugiyama, K., Brunori, A. & Mayer, M.L. (1989) Glial uptake of excitatory amino acids 
influences neuronal survival in cultures of mouse hippocampus. Neuroscience. 32, 779-791.
Sullivan, K.A., Miller, R.T., Masters, S.B., Beiderman, B., Heideman, W. & Bourne, H.R.
(1987) Identification of receptor contact site involved in receptor-G protein coupling.
Nature. 330, 758-760.
Summers, R.J. & McMartin, L.R. (1993) Adrenoceptors and their second messenger systems.
J. Neurochem. 60,10-23.
Sutherland, E.W. & Cori, C.F. (1951) Effect of hyperglycemic-glycogenolytic factor and 
epinephrine on liver phosphorylase. J. Biol. Chem. 188, 531-543.
Syapin, P.J., Ritchie, T., Noble, L. & Noble E.P. (1987) Postmortem changes in rat brain: 
Studies on membrane-bound enzymes and receptors. J. Neurochem. 48, 1285-1290.
Takenaka, K., Kanaho, Y., Nagata, K., Sakai, N., Yamada, H & Nozawa, Y. (1991)
*¥)Ischemia of rat brain decreases pertussis toxin-catalysed [a P]ADP ribosylation of GTP- 
binding proteins (G^ and GQ) in membranes.
J. Cerebral Blood Flow and Metabolism. 11, 155-160.
Tamer, A.E1., Corey, J., Wulfert, E. & Hanin, I. (1992) Reversible cholinergic changes induced 
by AF64A in rat hippocampus and possible septal compensatory effect. Neuropharmacology. 
31,397-402.
Tang, W.J. & Gilman, A.G. (1991) Type-specific regulation of adenylyl cyclase by G protein 
PY subunits. Science. 254,1500-1503.
Tang, W.J., Krupinski, J. & Gilman, A.G. (1991) Expression and characterisation of 
calmodulin-activated (Type I) adenylylcyclase. J. Biol. Chem. 266, 8595-8603.
224
Tanzi, R.E., Gusella, J.F., Watkins, P.C., Bruns, G.a.P., St George-Hyslop, P., Van Keuran, 
M.L., Patterson, D., Pagan, S., Kurnit, D.M. & Neve, R.I. (1987) Amyloid (3 protein gene: 
cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus.
Science. 235, 880-884.
Tanzi, R.E., McClatchey, A.I., Lampert, E.D., Villa-Komaroff, L., Gusella, J.F. & Neve, R.L.
(1988) Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated 
with Alzheimer's disease. Nature. 331, 528-530.
Tanzi, R.E. & Hyman, B.T. (1991) Alzheimer's mutation. Nature. 350, 564.
Taussig, R., Quarmby, L.M. & Gilman, A.G. (1993b) Regulation of purified type I and type II 
adenylylcyclases by G protein py subunits. J. Biol. Chem. 268, 9-12.
Taussig, R., Iniguez-Lluhi, J.A & Gilman, A.G. (1993a) Inhibition of adenylyl cyclase by Gja  
Science. 261, 218-221.
Taylor, S.J., Chae, H.Z., Rhee, S.G. & Exton, J.H. (1991) Activation of the p i isozyme of 
phospholipase C by a  subunits of the Gq class of G proteins. Nature. 350,516-518.
Terry, R.D., Hansen, L.A., DeTeresa, R., Davies, P., Tobias, H. & Katzman, R. (1987) Senile 
dementia of the Alzheimer type without neocortical neurofibrillary tangles.
J. Neuropathol. Exp. Neurolo. 46, 262-268.
Terry, R.D., Peck, A., DeTeresa, R., Schechter, R., Horoupian, D.S. (1981) Some morphometric 
aspects of the brain in senile dementia of the alzheimer type. Ann. Neurol. 10,184-192.
Towbin, H., Staehelin, T. & Gordon, J. (1979) Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: Procedure and some applications.
Proc. Natl. Acad. Sci. USA. 76,4350-4354.
225
Tsukamoto, T., Toyama, R., Itoh, H., Kozasa, T., Matsuoka, M. & Kaziro, Y. (1991) Structure 
of the hum an gene and two rat cDNAs encoding the a  chain of GTP-binding regulatory protein 
Gq: T w o  different mRNAs are generated by alternative splicing.
Proc. Natl. Acad. Sci. USA. 88 , 2974-2978.
Ueda, H., Misawa, H., Katada, T., Ui, M., Takagi, H & Satoh, M. (1990) Fuctional 
reconstitution of purified Gj and G0  with |i-opioid receptors in guineas pig striatal membranes 
pretreated with micromolar concentrations of N-ethylmaleimide.
J. Neurochem. 54, 841-848.
Vallar, L., Soada, A. & Giannattasio, G. (1987) Altered Gg and adenylate cyclase activity in 
hum an GH-secreting pituitary adenomas. Nature. 330, 566-568.
VanDongen, A.M.J., Codina, J., Olate, J., Mattera, R., Joho, R., Bimbaumer, L. & Brown, A.M.
(1988) Newly identified brain potassium channels gated by the guanine nucleotide binding 
protein GQ Science. 242, 1433-1437.
Van Nostrand, W.E., Wagner, S.L., Suzuki, M., Choi, B.H. Farrow, J.S., Geddes, J.W., Cotman, 
C.W. & Cunningham, D.D. (1989) Protease nexin-II, a potent antichymotrypsin, shows 
identity to amyloid P-protein precursor. Nature. 341, 546-549.
Vannucchi, M.G. & Goldman-Rakic, P.S. (1991) Age-dependent decrease in the affinity of 
muscarinic M l receptors in neocortex of rhesus monkeys. Proc. Natl. Acad. Sci. USA. 8 8 , 
11475-11479.
Viget, X & Briley, M (1989) Muscarinic receptor plasticity in rats lesioned in the nucleus 
basalis of meynert. Neuropharmacology. 28, 727-732.
Vijayan, V.K., Geddes, J.W., Anderson, K.J., Chang-Chui, H., Ellis, W.G. & Cotman, C.W. 
(1991) Astrocyte hypertrophy in the Alzheimer's disease hippocampal formation. Exp. 
Neurol. 1 1 2 , 72-78.
226
Villalobos-Molina, Rv Joseph, J.A. & Roth, G.S. (1992) a^-Adrenergic stimulation of low Km 
GTPase in rat striata is diminished with age. Brain Research. 590, 303-304.
Vogels, O.J.M, Broere, C.A.J., Ter Laak, H.J., Ten Donkelaar, H.J., Nieuwenhuys, R & Schulte, 
B.P.M. (1990) Cell loss and shrinkage in the nucleus basalis meynert complex in Alzheimer's 
disease.Neurobiology of Aging. 11,3-13.
Vogt, B.A., Crino, P.B. & Volicer, L. (1991) Laminar alterations in 7-aminobutyric acid^ , 
muscarinic, and p adrenoceptors and neuron degeneration in cingulate cortex in Alzheimer's 
disease. J. Neurochem. 57, 282-290.
Walseth, T.F., Zhang, H.J., Olson, L.K., Schroeder, W.A. & Robertson, R.P. (1989) Increase in 
Gg and cyclic AMP generation in HIT cells. Evidence that the 45-kDa a-subunit of Gs has 
greater functional activity than the 52-kDa a-subunit. J. Biol. Chem. 264, 21106-21111.
Wang, G.P., Khatoon, S., Iqbal, K. & Grundke-Iqbal, I. (1991) Brain ubiquitin is markedly 
elevated in Alzheimer disease. Brain Research. 566, 146-151.
Wang, H.Y., Watkins, D.C. & Malbon, C.C. (1992) Antisense oligodeoxynucleotides to Gg 
protein a-subunit sequence accelerate differentiation of fibroblasts to adipocytes. Nature.
358,334-337.
Wang, S.Z., Zhu, S.Z., Mash, D.C. & El-Fakahany, E. (1992) Comparison of the 
concentration of messenger RNA encoding four muscarinic receptor subtypes in control and 
Alzheimer brains. Molecular Brain Research. 16, 64-70.
Watkins, D.C., Johnson, G.L. & Malbon, C.C. (1992) Regulation of the differentiation of 
teratocarcinoma cells into primitive endoderm by G a^- Science. 258, 1373-1375.
227
Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, J.M., Masters, C.L. & Beyreuther, 
K. (1989) Identification, biogenesis, and localisation of precursors of Alzheimer's disease A4 
amyloid protein. Cell. 57,115-126.
Weinstein, L.S., Gejman, P.V., Friedman, E., Kadowaki, T., Collins, R.M., Gershon, E.S.
& Spiegel, A.M. (1990) Mutations of the Gg a-subunit gene in albright hereditary 
osteodystrophy detected by denaturing gradient gel electrophoresis.
Proc.Natl. Acad.Sci. USA. 87, 8287-8290.
Wenk, G.L. & Olton, D.S. (1984) Recovery of neocortical choline acetyltransferase activity 
following ibotenic acid injection into the nucleus basalis of Meynert in rats. Brain Research. 
293,184-186.
Wheeler, G.L. & Bitensky, M.W. (1977) A light-activated GTPase in vertebrate 
photoreceptors: Regulation of light-activated cyclic GMP phosphodiesterase.
Proc. Natl. Acad. Sci. USA. 74, 4238-4242.
Whitehouse, P.J., Lynch, D & Kuhar, M.J. (1984) Effects of postmortem delay and 
temperature on neurotransmittter receptor binding in a rat model of the hum an autopsy 
process. }. Neurochem. 43, 553-559.
Whitford, C., Candy, J., Edwardson, J. & Perry, R. (1988) Cortical somatostatinergic system 
not affected in Alzheimer's and Parkinson's diseases. J. Neurological Sci. 8 6 , 13-18.
Wilkie, T.M., Scherle, P.A., Strathmann, M.P., Slepak, V.Z. & Simon, M.I. (1991)
Characterisation of G-protein a  subunits in the Ga class: Expression in m urine tissues and in4
stromal and hematopoietic cell lines. Proc. Natl. Acad.Sci. USA. 8 8 , 10049-10053.
Wilson, K.M., Gilchrist, S. & Minneman, K.P. (1990) Comparison of -adrenergic receptor- 
stimulated inositol phosphate formation in primary neuronal and glial cultures.
J. Neurochem. 55, 691-697.
228
Wood, H. & de Belleroche, J. (1990) Excitotoxin lesion of nucleus basalis causes a specific 
decrease in GQ mRNA in cerebral cortex. Sensitivity to MK-801. FEBS LETTERS. 274,63-67.
Wischik, C.M., Novak, M., Thorgersen, H.C., Edwards, P.C., Runswick, M.J., Jakes, R., 
Walker, J.E., Milstein, C., Roth, M. & Klug, A. (1988b) Isolation of a fragment of tau derived 
from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. 
USA. 85,4506-4510.
Worley, P.F., Baraban, J.M., Van Dop, C., Neer, E.J. & Snyder, S.H. (1986A) GQ, a guanine 
nucleotide-binding protein: Immunohistochemical localisation in rat brain resembles 
distribution of second messenger systems. Proc. Natl. Acad. Sci. USA. 83, 4561-4565.
Worley, P.F., Baraban, J.M. & Snyder, S.H. (1986B) Heterogeneous localisation of protein 
kinase C in rat brain: Autoradiographic analysis of phorbol ester receptor binding. J. 
Neuroscience. 6,199-207.
Wong, Y,H., Federman, A., Pace, A.M., Zachary, I., Evans, T., Pouyssegur, J. & Bourne, H.R.
(1991) Mutant a  subunits of G ^  inhibit cyclic AMP accumulation. Nature. 351, 63-65.
Xia, Z., Refsdal, C.D., Merchant, K.M., Dorsa, D.M. & Storm, D.R. (1991) Distribution of 
mRNA for the calmodulin-sensitive adenylate cyclase in rat brain: Expression in areas 
associated with learning and memory. Neuron. 6, 431-443.
Xia, Z., Choi, E.J., Wang, F., Blazynski, C. & Storm, D.R. (1993) Type I calmodulin-sensitive 
adenylyl cyclase is neural specific. J. Neurochem. 60, 305-311.
Yamagami, K., Joseph, J.A. & Roth, G.S. (1992) Decrement of muscarinic receptor-stimulated




Yamaguchi, H., Nakazato, Y., Hirai, S., Shoji, M. & Harigaya, Y. (1989) Electron 
micrograph of diffuse plaques. Initial stage of senile plaque formation in the Alzheimer 
brain. Am. J. Pathol. 135,593-597.
Yamaguchi, H., Ishiguro, Kv Shoji, M., Yamazaki, T., Nakazato, Y., Ihara, Y. & Hirai, S. 
(1990b) Amyloid p/A4 protein precursor is bound to neurofibrillary tangles in Alzheimer-type 
dementia. Brain Research. 537, 318-322.
Yanker, B.A., Dawes, L.R., Fisher, S., Villa-Komaroff, L., Oster-Granite, M.L. & Neve, R.L.
(1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's 
disease. Science. 243, 417-420.
Yanker, B.A., Caceres, A. & Duffy, L.K. (1990) Nerve growth factor potentiates the 
neurotoxicity of P amyloid. Proc. Natl. Acad.Sci. USA. 87, 9020-9023.
Yatani, A., Codina, J., Imoto, Y., Reeves, J.P., Bimbaumer, L & Brown, A.M. (1987) A G 
protein directly regulates mammalian cardiac calcium channels. Science. 238,1288-1292.
Yoshimura, M., & Cooper, D.M.F. (1993) Type-specific stimulation of adenylyl cyclase by 
protein kinase C. J. Biol. Chem. 268, 4604-4607.
Young, L.T., Kish, S.J., Li, P.P. & Warsh., J.J. (1988) Decreased brain [^H]inositol 1,4,5- 
trisphosphate binding in Alzheimer's disease. Neurosci. Lett. 94, 198-202.
Young, L.T., Li, P.P., Kish, S.J., Siu, K.P. & Warsh, J.J. (1991) Postmortem cerebral cortex Gg 
a-subunit levels are elevated in bipolar affective disorder. Brain Research. 553, 323-326.
230
Yovell, Y., Kandel, E.R., Dudai, Y. & Abrams, T.W. (1992) A quantitative study of the 
C dr /calm odulin sensitivity of adenylyl cyclase in Aplysia, drosophila, and rat.
J. Neurochem. 59, 1736-1744.
Zawia, N., Arendash, G.W. & Wecker, L. (1992) Basal forebrain cholinergic neurons in aged 
rat brain are more susceptible to ibotenate-induced degeneration than neurons in young adult 
brain. Brain Research. 589, 333-337.
Zhang, H., Stemberger, N.H., Rubinstein, L.J., Herman, M.M., Binder, L.J. & Sternberger, L.A.
(1989) Abnormal processing of multiple proteins in Alzheimer disease.
Proc. N atl Acad. Sci. USA. 86, 8045-8049.
231
ADDENDUM
Golde, T.E., Estus, S., Younkin, L.H. (1992) Processing of the amyloid protein precursor to 
potentially amyloidogenic derivatives. Science. 255, 728-30.
Good, P.F. & Perl, D.P., (1993) Aluminium in Alzheimer's ? Nature, 362,418
Herve, D., Levi-Strauss, M., Marey-Semper, I., Vemey, C., Tassin, J.P., Glowinski, J. & 
Girault, J.A. (1993) GQj£ and Gg in rat basal ganglia: Possible involvement of G0if in the 
coupling of dopamine D | receptor with adenylyl cyclase. J. Neuroscience. 13,2237-2248.
Hertz, L. (1989) Is Alzheimer's disease an anterograde degeneration, originating in the 
brainstem, and disrupting metabolic and functional interactions between neurons and glial 
cells? Brain Reasearch. 14,335-353.
Innis, R.B., Nestler, E.J. & Aghajanian, G.K. (1988) Evidence for G protein mediation of 
serotonin- and GABAp- induced hyperpolaristaion of rat dorsal raphe neurons.Brazn 
Research. 459, 27-36.
McKenzie, F.R. & Milligan, G. (1990) Delta-opiod receptor-mediated inhibition of 
adenylate cyclase is transduced specifically by the guanine-nucleotide-binding protein Gi2. 
Biochent J. 267, 391-398.
Masters, S.B., Stroud, R.M., & Bourne, H.R. (1986) Family of G-protein alpha chains: 
amphophatic analysis and predicted structure of functional domains. Protein Eng. 1,47-54.
Rocca, W.A., Hofman, A., Brayne, C. Breteler, M.M.B., Clarke, M., Copeland, .R,M., 
Dartigues, J., Engedal, K. Hagnell, O. Heeeren, T.J., Jonker, C., Lindesay, J., Lobo, A.,Mann, 
A.H., Molsa,P.K., Morgan, K., O’Connor, D.W., Druox, A.S., Sulkavan, R., Kay, D.W.K., & 
Amaducci, L. (1991) Frequency and distribution of Alzheimer's disease in Europe: A 
collabarative study of 1980-1990 findings. Ann Neurol 30, 381-390.
PUBLICATIONS
McLaughlin, M.; Ross, B.M.; Milligan, G.; Knowler,J.T.; McCulloch,J.; (1990)
Immunoblot analysis of G-proteins in Alzheimers diseased and control brains;
Br. J. Pharm 99, 269P.
McLaughlin, M.; Ross,B.M.; Milligan, G.; McCulloch J.; Knowler, J.T.; (1991)
Robustness of G-proteins in Alzheimers disease: an immunoblot study;
/ Neurochem, 57, 9-14.
Ross, B.M.; McLaughlin, M.; Milligan, G.; Knowler, J.T.; McCulloch J.;(1993)
The effect of Alzheimer’s disease on the activities of adenylate cyclase and GTPase 
Annals of Neurology, 32, 269P
Ross, B.M.; McLaughlin, M.; Milligan, G.; Knowler, J.T.; McCulloch J.;(1993)
A lteration in the activities of adenylate cyclase and the high affinity GTPase in 
Alzheimer's diseased brains. Brain Research, 622, 35-42.
GLASGOW
UNIVERSITY
LIBRARY
